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The World Health Organization predicts that the worldwide incidence of diabetes will 
increase from 171 million in 2000 to 366 million in 2030, driving projections for the global 
glucose monitoring market to over USD 12 billion by 2025. This requires a technological 
revolution to take place: so far, no technology able to monitor glucose in the body non-
invasively has been developed, leaving patients affected by diabetes to handle invasive, 
needle-based devices (often associated with significant user resistance, originating 
primarily in the pain and discomfort during usage). In this context, there is a clear need 
for innovative, non-invasive and pain-free technologies to enter the market. This would 
eliminate patient resistance towards more frequent sampling and, hence, considerably 
improve a diabetic’s control over glycaemia; and, in time, help shift emphasis from 
diabetes treatment to its prevention, resulting in considerable financial savings for the 
healthcare system.  
In this thesis, a new path-selective, non-invasive, transdermal glucose monitoring system, 
based on a miniaturized pixel array platform, is introduced. The system samples glucose 
from the interstitial fluid (ISF) via electroosmotic extraction through individual, 
privileged, follicular pathways in the skin, accessible via the pixels of the array. A proof 
of principle - using mammalian skin ex vivo, as well as in-vivo tests on human volunteers 
- is demonstrated for specific and ‘quantized’ glucose extraction/detection via follicular 
pathways, and across the hypo- to hyper-glycaemic range in humans. Furthermore, the 
quantification of follicular and non-follicular glucose extraction fluxes is clearly shown, 
indicating that quantitative, calibration-free (i.e. needle free) glucose detection is 
achievable with this method. In vivo continuous monitoring of ISF-borne glucose with the 
pixel array was able to track blood sugar in healthy human subjects for a period of up to 
6 hours, and, importantly, without inducing skin irritation. A pilot study on a small cohort 
(n = 10) of healthy human volunteers subjected to an oral glucose tolerance test provided 
the data for a preliminary Clarke Error Grid: glucose was tracked over 6 hours within 
acceptable limits, i.e., with all data falling within zones A and B of the grid. 
The progression of the work required several generations of pixel array prototypes, which 
evolved from using thin film technologies (which included  Chemical Vapour Deposition 
(CVD) graphene and vacuum techniques for electrode definition), to scalable, cost-
effective techniques, such as screen printing of functional (e.g. graphene and Ag/AgCl) 
inks. Several pixel device layouts were also investigated in view of decreasing glucose 
response time and increasing collection efficiency. The studies also highlighted some 
XV 
 
limitations of the current technological implementation (primarily related to electrode 
biofouling, and the extraction process affecting the detection) that will need to be 
addressed to advance the technology to commercialization. Finally, the work in this thesis 
also provided insight into the possibility of multiplexed detection of multiple analytes that 




Research project aims and objectives 
The overall goal of this project is to provide people suffering from diabetes with a non-
invasive device with which blood glucose levels can be monitored and management of the 
disease improved.  In turn, attainment of this objective would significantly reduce the risk 
of developing the common co-morbidities of diabetes and thereby substantially improve 
quality-of-life. The project has focussed on an innovative transdermal technology, based 
on reverse iontophoresis coupled with (bio)electrochemical glucose detection, that is both 
highly sensitive and selective.  
The specific aims of the project were: 
1. To design and fabricate several generations of multiplexed, pixel array prototypes 
capable of randomly accessing existing preferential glucose pathways across the 
skin and performing the dual function of glucose extraction-detection.  
2. To electrochemically characterise the realised prototypes. 
3. To validate the hypothesis of preferential, follicular, electro-osmotic glucose 
extraction both ex-vivo (using porcine skin) and in-vivo (in human volunteers). 
4. To verify sensor and performance in a pilot trial in a cohort of 10 healthy 
volunteers.  
The overall structure of the thesis is as follows: 
Chapter 1: Introduction to diabetes and glucose sensing 
This chapter presents a synopsis of diabetes mellitus, biosensors, glucose 
biosensors, glucose-sensing technologies/mechanisms, existing challenges in the 
field of glucose sensing, graphene-based transducers and wearable sensors, 
analytical and fabrication techniques used in this work.  
 
Chapter 2: Concept, sensor design and prototype fabrication 
This chapter describes the concept of the proposed non-invasive biosensor whose 
functionalities rely on a miniaturised pixel array platform able to exploit 
preferential pathways located in the skin allowing the extraction of glucose 
directly from the interstitial fluid, via reverse iontophoresis (RI). The materials 
used for detection and extraction were electrochemically characterised, together  




Chapter 3: Non-invasive, transdermal, path-selective and specific glucose monitoring via 
a graphene-based platform 
The content of this chapter has been published in the following article: Lipani, L., 
Dupont, B.G., Doungmene, F., Marken, F., Tyrrell, R.M., Guy, R.H. and Ilie, A., 
2018. Non-invasive, transdermal, path-selective and specific glucose monitoring 
via a graphene-based platform. Nature nanotechnology, 13(6), pp.504-511. 
Here the focus is on the validation of the glucose follicular extraction hypothesis, 
using an ex-vivo model, with subsequent calculation of the electro-osmotic flux 
of glucose.  An in-depth characterisation (using physical characterisation and 
electrochemical techniques) of the two generations of sensor prototypes was 
attained together with benchmark calibrations and assessments of the influence of 
common interferant species (using proportionate concentrations to mimic the in 
vivo detection scenario). Furthermore, the first demonstration of the 
functionalities and tracking capabilities of the sensor towards the interstitial fluid-
borne glucose was achieved in-vivo on a healthy volunteer. 
 
Chapter 4: Device further optimizations and in vivo study 
The objectives of this chapter were to implement the design of the second 
generation prototype improving both glucose extraction from the skin and 
diffusion through the collection reservoir, to validate the follicular glucose 
extraction hypothesis in-vivo and to verify the functionalities and performance of 
the sensor in a small group of healthy human volunteers. Besides, the ageing effect 
on the sensors, due to the operations of the system, was evaluated. 
 
Chapter 5: Conclusions and Perspectives 
This chapter provides a general conclusion of the above studies and 












Diabetes mellitus represents a worldwide health problem estimated to affect 415 million 
people in 2015, and this figure has been predicted to rise over 642 million in the next 25 
years [1]. Even though there is no clear evidence to establish the cause of diabetes, lifestyle 
changes (as a result of economic development) and increased urbanisation of society have 
been related to its rapid growth. Diets contain more processed food, and the amount of 
physical activity has reduced, thus broadening the overweight population [2]. In addition, 
certain ethnic groups show an increased risk of contracting the disease, thus relating it to 
a possible genetic predispositions [3]. 
The disease describes a group of metabolic disorders characterised by abnormal glycaemic 
fluctuations outside the normal physiological range of 70 – 120 mg/dL (4.4 – 8 mM). 
These blood glucose (BG) oscillations can lead to a series of disabling and life-threatening 
adverse events; therefore, patients need to manage the condition adequately. It follows 
that a diabetic individual will require periodic blood glucose monitoring to evaluate the 
glycaemic status and bring it back to near-normal levels with the correct therapeutic 
response [4].  
As a result, sensors for the self-monitoring of blood glucose (SMBG), especially 
fingerstick biosensors [5], were introduced in the market, allowing people with diabetes 
to discontinuously measure the capillary blood glucose by piercing the skin with a sterile 
lancet and collecting a droplet of blood into the monitor device. Despite its widespread 
use, finger pricks show numerous disadvantages; for instance: the stress caused by the 
responsibility of self-care, the anxieties of regular and repeated painful finger pricking, 
possible errors related to the analysis or the misuse from the operator, poor disease 
management especially at a young age, religious beliefs, cost [6]. Additionally, glucose 
self-monitoring devices only provide isolated values which do not reflect day and night 
variations. These factors severely compromise patients compliance, only 46% of patients 
with type 1 diabetes, and 39% of patients with type 2 diabetes have been reported to track 
their glucose levels carefully, reducing the occurrence of adverse effects [7].  
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Until recent years, the lack of continuous glucose monitoring systems (CGMSs) meant 
that finger-pricking remained the best procedure in clinical practice. However, CGMSs 
are presently gaining spotlight in the medical community, reversing the trend and rapidly 
creating a new glucose monitoring devices market. Simultaneously, recent progress in 
micro- and nano-sensor production is leading to new technologies with a wide range of 
benefits in terms of portability, specificity, sensitivity, linear dynamic range, detection 
limit, lower overall price, and, most important for the patient,  a lack of associated painful 
sensations and user-friendliness. Industries, start-ups and universities have made 
developed new glucose monitoring sensors and a plethora of new technologies is currently 
under study; however, to date, only invasive devices have achieved an ongoing market 
presence.  
Technologies for glucose detection can be divided into two major groups: non-invasive 
(NI) and minimally invasive (MI). While the former relies only on some form of radiation, 
the latter operates in two phases: extracting fluids from the body (e.g., interstitial fluid, 
tears) and then quantifying glucose levels via an enzymatic reaction; that said, MI 
technologies can still operate without any related pain sensation. 
Building on this concept, the work described in this thesis has focused on the design of a 
wearable, minimally invasive glucose sensor that is suitable for miniaturisation by micro- 
and nanotechnology. Therefore, the project aims primarily to benefit individuals suffering 
from Type 1 and Type 2 diabetes, prediabetics; the approach may also be appealing to a 
broader audience of users who may wish to keep track of significant analytes, for example, 











1.2 Diabetes Mellitus 
1.2.1 Introduction 
WHO defines diabetes mellitus as: “a metabolic disorder of multiple aetiologies 
characterised by chronic hyperglycaemia with disturbance of carbohydrate, fat and protein 
metabolism resulting from defects in insulin secretion, insulin action or both” [8].  
Metabolism indicates the sum of biological processes that either produce or consume 
energy (catabolism and anabolism). Consequently, the disturbance of these mechanisms 
creates a metabolic disorder causing indirect adverse effects. 
The metabolism of glucose, the principal energy source for all living organisms, is 
regulated by two hormones, insulin and glucagon. The former was the first protein for 
which the amino acid sequence was defined (studied by Sanger’s group in Cambridge in 
1955); it is composed of two peptidic chains (for a total of 51 amino acids) linked by 
disulphide bonds [9]. Insulin is secreted by the β-cells of the pancreas, and its most crucial 
role is enhancing the transport of glucose into cells, reducing overall the glycaemic levels. 
The unused portion of glucose is stored as glycogen or converted into fat. On the other 
hand, glucagon is a 29 amino acid protein, the pancreatic α-cells produce it as a response 
to low plasma glucose levels (fasting state), it leads the release of glucose from glycogen, 
and it promotes the gluconeogenesis, thus restoring the euglycemia. In this strictly 
regulated process, the secretion of one hormone reciprocally suppresses the production of 
the other. β-cells also secrete C-peptide, serving as a linker between the two chains of the 
proinsulin molecule, and amylin, a hormone involved in both the delay of the gastric 
emptying and inhibition of insulin secretion [10]. Therefore, it is clear that problems in 
the production or in the utilisation of insulin, such as in people who have diabetes, disrupt 









1.2.2 Types of glucose metabolic disorders 
Metabolic disorders disturbing the euglycemia are classified in the following conditions:  
type 1 and 2 diabetes, gestational diabetes and impaired glucose tolerance.  
Type 1 diabetes (T1D) is associated with the destruction of Langerhans islets hosting 
pancreatic β-cells; consequently, the production of insulin is impaired. This condition 
affects 5-10% of the diabetic population [11], and insulin injections are vital for survival. 
It can be separated into two categories:  
- Type 1A or immune-mediated is characterised by the early presence of antibodies 
against glutamic acid, β-cells or insulin; it is predominant in neonatal and young 
people under the age of 25 [12].  
- Type 1B or idiopathic is not immunological; it is an unusual phenotypic form of 
type 1 diabetes, characterised by a nearly complete insulin deficiency. 
 
Type 2 diabetes (T2D) is the most common form of glucose metabolic disorders; also 
referred to as non-insulin-dependent, it can remain asymptomatic over a long period 
before its diagnosis, thus complicating its rational management. The pathology is 
associated to either a reduced capacity of the cells to recognise the insulin hormone 
(insulin resistance) or an impairment in its production, and most generally, both. Several 
factors govern the development of the Type 2 condition, including genetic factors, 
ethnicity, [13] obesity, little or no physical activity, an ageing population, poor diet and, 
in general, an unhealthy lifestyle [13]. Nonetheless, if treated early, Type 2 diabetics can 
reverse this condition through exercise, and a healthier diet and lifestyle10. 
Gestational diabetes (GDM) is a condition which can appear during the 3rd trimester of 
pregnancy [14] when increased hormone levels partially decrease the function of insulin; 
thus,  β-cells compensate increasing the production of insulin. The disease predisposes, in 
combination with other risk factors, both the mother and the child towards higher risks for 
the development of T2D, but in most cases, it disappears after the child is born. It affects 
about 14% of pregnancies in the US [15]. 
Impaired Glucose Tolerance (IGT) and Impaired Fasting Glycaemia (IFG) represent the 
so-called prediabetic type 2 conditions and are reversible if diagnosed at an early stage. 
WHO defined IGT and IFG as conditions with a generally elevated BG concentration that 
is lower than that of diabetes but higher than the healthy level [14]. A more detailed 
description of the glucose concentration thresholds for diabetes, IGT and IFG are 
presented in Table 1. 
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Other types of diabetes such as: (1) drug- or chemical-induced (caused by medication 
such as antibiotics or immune system suppression therapy), triggered by the toxicological 
effects of these chemical species on the pancreas [13], (2) virus-induced, for example, 
following a viral infection by coxsackievirus B4 [16], cytomegalovirus, adenovirus, 
rubella virus [17] and also the mumpsvirus , (3) related to both genetic defects of the β-
cells or in insulin action, (4) related to pancreatic injuries, including pancreatitis, trauma, 
infection, pancreatectomy, and pancreatic carcinoma, (5) or endocrinopathie`s-induced, 
generally due to an overproduction of hormones (e.g., growth hormone, cortisol, 
glucagon, epinephrine) that antagonize insulin action [13]. 
 
1.2.3 Diagnosis of diabetes mellitus 
Symptoms of diabetes correlate with hyperglycaemic events which are defined as: 
polydipsia (extreme thirst), polyuria (large production and/or passage of urine), sudden 
weight loss, blurred vision, extreme fatigue and recurrent skin infections caused by yeast, 
virus and bacteria. Three tests are typically used to diagnose diabetes mellitus:  
- Fasting plasma glucose (FPG) involves 8-hour fasting followed by the 
measurement of the basal BG concentration [18]. 
- The oral glucose tolerance test (OGTT) involves the administration of a glucose 
solution (the equivalent of 75 g anhydrous glucose dissolved in water) and 
assessment of glycaemia after 2 hours [18]. 
- The analysis of HbA1c, i.e. glycated haemoglobin, a diagnostic test for diabetes 
accepted by the WHO [18]. HbA1c is expressed as a fraction of total haemoglobin 
and it is proportional to glycaemic levels, indicating the average level of BG over 
a time period (subject to certain individual limitations related to age, genetic 
disease, use of medications, etc. [19]). An HbA1c of 48 mmol/mol (6.5%) is 
recommended as a threshold value for diagnosing diabetes. 
 
The WHO has determined a range of blood glucose values used to confirm the diagnosis 






Table 1.1: Blood glucose concentration values used for the diagnosis of diabetes mellitus and 
prediabetics conditions according to WHO[14]. 
Glucose concentration, mM (mg dl-1) 











≥7.0 (≥ 126) 
≥11.1(≥200) 
IGT 
Fasting (if measured) 
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1.2.4 Treatment and management of diabetes 
According to the type, disease progression and physical condition of the patient, diabetes 
treatments are diversified. For example, the treatment of early-stage T2D needs only a 
special diet and appropriate physical activity; however, if allowed to progress, it requires 
treatments combining different medications aiming to reduce hyperglycaemic status; in 
the worst case, it may also require insulin injections. Such medicines are classified as: (1) 
Insulin Secretagogues, including sulfonylurea and non-sulfonylurea drugs, which 
stimulate insulin secretion  by closing potassium channels on the surface of pancreatic 
beta cells; (2) Biguanides, for instance metformin, which primarily act by decreasing 
hepatic glucose output; (3) Thiazolidinediones increase the sensitivity to insulin in 
peripheral tissues; (4) Alpha-Glucosidase Inhibitors, acting at the brush border level, 
inactivate the enzymes involved in the digestion of complex carbohydrates, slowing 
absorption, thus reducing BG; (5) Incretin Mimetics and Incretin Enhancers. Incretin 
hormones have various effects including the stimulation of insulin production, reduction 
of glucagon secretion, decelerating gastric emptying, and reducing appetite; (6) Amylin 
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Analogues, such as Pramlintide which is indicated for use in patients with T1D [17]. Type 
1 diabetes cannot be managed by diet or physical activity alone, and requires strict and 
specific insulin therapy.  
The diabetes control and complications trial research group showed how, in insulin-
dependent diabetics,  maintaining glycaemic levels close to the normal range reduced the 
following factors: the risk for the development , and the progression, of retinopathy, the 
occurrence of both microalbuminuria and albuminuria and that of clinical neuropathy [20]. 
Therefore, diabetic patients need to attain specific glycaemic targets to reduce the risk of 
developing life-threatening illness associated with the progress of the disease. The 
American Diabetes Association (ADA) has established several recommendations and 
targets that have to be patient-tailored according to several factors, such as duration of 
diabetes, age, comorbid conditions, cardiovascular and microvascular diseases, 
hypoglycaemia unawareness, and others [21]. For instance, ADA recommends as 
reasonable, for non-pregnant adults diabetics, a HbA1c < 7% goal,  specifying the 
glycaemic cut-off values of capillary plasma glucose of between 3.9 and 7.2 mM (70 and 
130 mg/dL) for pre-prandial measurements, or < 10 mM (180 mg/dL) for the post-prandial 
peak.[22]  Finally, the approach to individualisation of glycaemic targets depends on 
patients and disease factors; usually, a stringent HbA1c< 7% target is applied to newly 
diagnosed patients with long life expectancy, no vascular complications or other 
comorbidities, and low associated risk of hypoglycaemia and adverse effect from other 
drugs[23]. 
Even though ADA recommendations involve a tight BG control, patients do not generally 
adhere to a frequent glucose monitoring regime, thus making the achievement of BG 
targets quite difficult. An observational study conducted in real-life settings on over 
50.000 worldwide diabetics showed how a higher BG scanning frequency is associated 
with better glycaemic values, increasing the time spent in the euglycemic range and 
lowering of the HbA1c levels [24]. Consequently, providing patients with frequent 







1.3 Sensors and Biosensors 
A biosensor can be defined as a chemical sensor, or device, which can transform chemical 
information into analytical signals, incorporating a biological or biologically-derived 
recognition element integrated with a physicochemical transducer[25]. Therefore, a 
biosensor has three main components: (1) a biological recognition element which can 
differentiate between specific chemical species, (2) a transducer that transforms the 
biorecognition event into a detectable signal, and (3) a signal processing system which 
provides a readable form of the signal. Examples of the most commonly used biological 
entities in biosensing are enzymes, antibodies, receptors, nucleic acids, organelles, 
microorganisms and tissues[26]; also, biologically-derived (such as aptamers, engineered 
proteins, recombinant antibodies) and bio-mimic materials can be used as recognition 
systems. The major transducer classes are electrochemical, optical, piezoelectric, 
thermometric and magnetic[27]. However, electrochemical transducers represent the 
majority of the current biosensors because of their low cost, easy maintenance, good 
sensitivity and reproducibility. Generally, electrochemical systems involve the 
measurement of catalytic current (amperometric), potential or charge accumulation 
(potentiometric),  the altered conductive properties of a medium between electrodes 





1.3.1 Background on the glucose molecule 
D-glucose is an aldohexose with five different isomers (Figure 1.1). In aqueous solution, 
γ-glucose, the open-chain aldehyde structure, cyclizes forming a hemiacetal bond via acid-
catalysed hydrolysis (known as mutarotation), as a result, furanose or pyranose structures 
(respectively, five- and six-membered rings) are produced. Also, two cyclic glucose 
anomers, α and β, can be distinguished according to the cis-trans position of the hydroxyl 
group in C-1. The relative amounts of β-glucopyranose, α-glucopyranose, glucofuranose 










1.3.2 Electrochemical detection 
Electrochemical sensing requires an electrochemical cell which usually comprises a 
reference electrode (RE), a counter or auxiliary electrode (CE) a working electrode (WE) 
and an (often aqueous) solution containing the analytes and electrolytes. Since the 
detection process takes place at the electrode surface, clearly the electrode dimensions, 
material and surface modification play a crucial role in the sensor performance. 
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1.3.2.1 Reference electrodes 
Various electrodes are commonly used as a reference (Figure 1.2). The International 
Union of Pure and Applied Chemistry (IUPAC) accepts as a standard comparative system 
the hydrogen electrode (SHE)[29], which has an electrode potential E0(H+/H2) = 0 at any 
temperature. However, other reference electrodes are used due to their simplicity of 
operation (i.e., not requiring a constant flux of hydrogen gas) and fabrication.  
 
 
Figure 1.2| Reference electrode potentials relative to that of the standard hydrogen electrode.  
 
The most commonly used reference electrodes are the Ag/AgCl and the saturated calomel 
electrode (SCE).  A commercial Ag/AgCl electrode is made of silver wire, covered with 
a porous silver chloride layer, that is dipped in a KCl solution. This reference electrode 
has the following equilibrium: 
 
 
AgCl(s) + e-           Ag(s) + Cl-(aq) 
 
The SCE is made of liquid mercury, in contact with di-mercury (I) chloride (also named 
“calomel”), that is dipped in a saturated KCl solution. The redox equilibrium of the 










1.3.2.2 Counter electrode 
The purpose of the counter electrode is to complete the electrochemical circuit by applying 
a voltage difference to the working electrode, and thereby allowing current to flow. The 
CE is usually made of an inert material (it should not be involved in the redox reactions 
in the electrochemical cell under study), such as carbon or platinum, and its active area 
should preferably be larger than that of the working electrode to avoid influencing charge 
flow. 
 
1.3.2.3 Working electrode 
The working electrode is the fundamental element of the electrochemical cell, in which 
the redox reactions occur. The electrode material has to be stable in the electrolyte medium 
used, avoiding corrosion or fouling, and alteration of the electroactive surface area. 
Metallic (platinum, gold, silver) and carbon electrodes (graphite, glassy carbon, carbon 
paste, carbon nanomaterials) are commonly used. The choice of the material is influenced 
by several factors: surface stability and reproducibility (preferably with a uniform 
distribution of potential across the surface), level of background current in the potential 
region of interest (to increase sensitivity), availability, potential toxicity and cost[31]. In 
self-monitoring blood glucose (SMBG) strips the working electrode is constructed by 
screen-printing a carbon ink (mixing carbon particles and a polyester binder) or vapour 
depositing gold or palladium onto a plastic substrate; active reagents can be either 
deposited or admixed into the conducting material. The reproducibility of the electrode 
area is ensured either by the deposition and scribing process or by an additional insulating 
dielectric over-layer which partially covers the working electrode in a reproducible 
fraction. 
 
1.3.2.4 Supporting electrolytes 
In an electrochemical cell, supporting electrolytes comprise ionic chemical species which 
are not electroactive in the potential range of interest and enhance the conductivity of the 
medium[32]. The electrolyte also reduces the Ohmic drop (IR) in the cell, removes the 
contribution from electromigration effects and maintains a fixed ionic strength. 
Conventional electrolytes are aqueous solutions containing ions of potassium, sodium, 




1.3.3 Biological recognition elements in glucose biosensors 
Most of the commercially available glucose biosensors are based on enzymatic reactions 
coupled with amperometric detection that monitor the electric current generated by either 
direct or indirect transfer of electrons from the biological system to the electrode. 
Commonly, three enzymes are employed in glucose sensing: hexokinase, glucose-1-
dehydrogenase (GDH) or glucose oxidase (GOx). The hexokinase method has been used 
in spectrophotometric assays where the absorption of light at 340 nm wavelength is 
directly related to the quantity of glucose[33]; the relevant chemistry is summarised in 
Figure 1.3 (a). Self-monitoring blood glucose biosensors are instead based on GOx and 
GDH enzymes. GOx catalyses the oxidation of β-D-glucose into D-glucono-1,5-lactone 
and hydrogen peroxide (H2O2) in the presence of oxygen (O2). It is a dimeric protein where 
the two polypeptide chains are identical and linked by disulphide bonds; each subunit 
contains a tightly bound flavin adenine dinucleotide (FAD) prosthetic group which it is 
the actual catalytic centre of GOx enzyme; the relevant chemistry/electrochemistry is 
summarised in Figure 1.3 (b). The electric signal at the Pt electrode is proportional to the 
amount of glucose present in solution. The GDH family comprises GDH-
pyrroloquinolinequinone (PQQ)[34], GDH-NAD[35] and GDH-FAD[36]. Although the 
GDH based enzymatic reactions are independent from dissolved oxygen, this enzyme 
family also catalyses the oxidation of other sugars such as maltose, maltotetraose, 
maltotriose, and icodextrin[37]. As in the GOx family, the different prosthetic groups are 
the catalytic centres which act as electron acceptor. 
 
 
Figure 1.3| Hexokinase and Glucose Oxidase enzymatic reactions. 
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1.3.4 Glucose (bio)sensing 
The core event in glucose biosensing is the electron transfer (ET) from the enzyme 
cofactor (FAD, NAD, PQQ, etc.) to the sensing electrode, and three generations of  
glucose biosensor have been studied to achieve this objective (see Figure 1.4). 
 
 
Figure 1.4| Schematic illustration of three biosensor generations.  
 
1.3.4.1 First-generation glucose biosensors 
The first-generation of glucose biosensing was proposed by Clark and Lyons in 1962[38]. 
Here, glucose biosensing is achieved by oxidising the enzyme cofactor using oxygen and 
then electro-oxidising the hydrogen peroxide product at a platinum electrode. However, 
this strategy suffered from two problems: (1) the amperometric measurement of hydrogen 
peroxide necessitated a relatively high operation potential, and was therefore prone to 
interference from endogenous substances, such as uric and ascorbic acids, and exogenous 
compounds such as acetaminophen; (2) oxygen deficit occurred due to the restricted 
solubility of oxygen in biological fluids[39]. 
 
1.3.4.2 Second-generation glucose biosensors 
The use of a redox mediator overcame the limitations of the first-generation glucose 
biosensors. In fact, the electrochemical mediator replaced oxygen as the intermediate 
electron acceptor and carried electrons from the enzyme to the electroactive sites of the 
working electrode[39]. Therefore, the mediator is initially reduced, oxidising back the 
14 
 
enzyme-cofactor complex, and re-oxidised later at the electrode surface where it provides 
a measurable amperometric signal[40]. A broad range of electron mediators has been 
studied to improve sensing performance, such as ferricyanide, ferrocene, quinines, 
tetracyanoquinodimethane (TCNQ), tetrathiafulvalene (TTF), thionine, methylene blue 
and methyl viologen. For example, a ferrocene-derivative mediator was employed in 
combination with GDH-PQQ enzyme in the first glucose monitoring strips (Exactech by 
Medisense, Inc.)[41]. Further implementation of second-generation glucose biosensors 
facilitated the electron transfer between the enzyme catalytic centre and the electrode 
surface; for example, by using either an electron-conducting redox hydrogel to wire the 
enzyme to the electrode, or nanomaterials as electrical connectors, or via chemical 
modification of the enzyme with electron-relay groups[42]–[44]. 
 
1.3.4.3 Third-generation of glucose biosensors 
The third-generation glucose biosensors rely on direct electron transfer between the 
enzyme and electrode. However, since the active centre of an enzyme is embedded in the 
protein, the electron transfer distance between the catalytic centre and the electrode can 
be long; direct electron transfer is limited, therefore, to enzymes with ‘exposed’, 
peripheral redox-active centres. Furthermore, orientation of the biorecognition element on 
the electrode must be optimal as, according to Marcus theory[45], the electron transfer 
kinetics decrease exponentially with increasing donor-acceptor distance; indeed, in the 
case of proteins, the transfer rate drops by a factor of ca. 104 when the distance is increased 
from 8 to 17 Å[46]. The use of organic conducting materials is therefore crucial to 
accomplish direct electron transfer at the electrode surface; for example, TTF-TCNQ has 
been coupled with GDH-PQQ[47], [48] and polypyrrole with GOx[49], [50].  
 
1.3.4.4 Non-enzymatic glucose sensing 
Even though sensors based on GOx enzyme have proved to be stable and highly selective 
for glucose, compared to other enzymes, it is known that biological species may suffer 
thermal and chemical deformation during fabrication, use or storage; in fact, GOx activity 
decreases at temperature above 40oC, below pH 2 and above pH 8, as well as in the 
presence of ionic detergents such as sodium-n-dodecyl sulphate (at low pH) and 
hexadecyltrimethylammonium bromide (at high pH)[51]. Therefore, non-enzymatic 
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glucose sensors may appear attractive to overcome the enzyme stability and oxygen 
dependency disadvantages and to provide a simpler device structure suitable for mass 
production. Several strategies have been employed to achieve non-enzymatic glucose 
sensing such as direct glucose oxidation via metallic redox centres or detection via 
association with glucose.  Both approaches may use nanostructures to increase the 
electrocatalytic active site and to form nano-spaces surrounded by conducting structures. 
Direct glucose oxidation involves adsorption-desorption of the analyte on noble metals 
electrodes, such as Pt and Au, as depicted by the chemisorption model[52]; in this case, 
interaction of glucose C-1 with the electrode causes the dehydrogenation and adsorption 
onto the electrode surface, and glucose is successively electro-oxidised to glucono-δ-
lactone which then weakens the interaction with the electrode and leads to desorption. In 
this context, the presence of reactive hydroxide species (OHads), which are generated 
during the electrocatalysis process, influences the redox reaction of glucose. In fact, in the 
incipient hydrous oxide adatom mediator (IHOAM) model proposed by Burke[53], 
surface hydroxide radicals mediate the oxidation of reactants, leading to the application 
of other metals such as Ni, Cu and Co for the glucose electro-oxidation reaction. Also, 
materials involving boronic acid groups and molecularly imprinted polymers (MIPs), with 
amines, hydroxyl and carboxylic groups, have been studied for non-faradaic detection via 
association with glucose. Boronic acid comprises a central boron atom, two hydroxyl 
groups and an alkyl or aryl group in a trigonal planar structure that is sp2 hybridised. The 
vacant p-orbital permits the central boron atom to act as a Lewis acid, thus pairing with 
nearby nucleophiles releasing H+. The peculiarity of boronic acid can be attributed to its 
ability to form reversible diesters with 1,2-diols and 1,3-diols, and its strong affinity to 
polyols making it suitable for carbohydrate detection[54], [55]. The decoration of MIPs 
with different functional moieties is therefore used to create a mould that recognises and 




1.4 State-of-the-art in glucose monitoring technologies 
1.4.1 History of glucose sensing 
The origin of the word “Diabetes” can be attributed to Greek and it means siphon (related 
to the excessive urination in diabetic patients), while “Mellitus” comes from Latin and it 
means honey (due to the extensive presence of glucose in serum and urine). The presence 
of glucose in urine is named glycosuria and diabetes was first diagnosed in the 18th century 
thanks to the sweet taste of urine. Therefore, the first methodologies to determine glucose 
levels were applied to urine samples. In 1870, the French physiologist Claude Bernard[58] 
pointed out various glucose detection methods, such as polarimetry, observing the 
formation of CO2 due to glucose fermentation, using the Fehling solution (where copper 
is reduced in presence of reducing sugars)[59]. The latter reaction was used in the first 
marketed urine sugar testing tablets, Clinitest®, from Miles Laboratories in 1941[60]. 
However, BG levels were not assessed and hypoglycaemia could not be discriminated 
from normal physiological conditions (where no glucose excess in urine can be found). 
The first glucose meter was patented and mass-produced thirty years later under the name 
Ames Reflectance Meter (Miles Laboratories, now Bayer[40]) and relied on a colorimetric 
reaction on a strip with reflectance measurements used to determine the colour change as 
a function of glucose concentration. From the Children’s Hospital of Cincinnati, Clark 
and Lyons first proposed in 1962 the concept of the biosensor to measure glucose[38]. 
The idea consisted of measuring the glucose concentration using an enzyme-catalysed 
process whereby glucose oxidase converts glucose into gluconic acid and H2O2 which is 
subsequently oxidised by horseradish peroxidase and O2 is then finally detected at the 
electrode. The first commercially available clinical glucose analyser was introduced in 
1968 by Beckman Instruments (Fullerton, CA); this device was able to monitor the 
decreasing concentration of dissolved O2 (due to the glucose reaction with glucose 
oxidase) by electro-reducing O2 on a gold cathode[61]. In 1974, Yellow Springs 
Instruments (Ohio, USA) developed a different electrochemical biosensor, the glucose 
analyser YSI 23 A, the detection concept of which was based on the electrooxidation of 
the Gox product (H2O2) on a platinum electrode[62]. This model introduced two 
remarkable design principles: the reduction of glucose influx (by incorporation of an outer 
polycarbonate membrane and diluting the analyte solution) to avoid partial reactions with 
dissolved O2 (the concentration of which in water at 25
oC is only ~0.2 mM, compared to 
glucose levels as high as 30 mM in the undiluted blood of diabetics), and the incorporation 
of glucose oxidase into the polycarbonate membrane in contact with the Pt electrode 
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(which allowed prolongation of the operational life of the probe, and maintained a high 
linear range of detection).  Therefore, even though this was stationary device used only in 
hospitals, the technology formed the basis for a new generation of glucose monitoring 
devices, specifically the most widely-used finger-stick biosensors.  
 
1.4.2 Self-monitoring blood glucose (SMBG) 
SMBG sensors are the classic glucometers which require finger pricking with a lancet to 
assess glucose in the capillary blood. The first finger-pricking home glucose monitoring 
device was the Exactech® strip, developed by Genetics International, Inc. (Cambridge, 
MA, USA) in 1987[63], which used an integrated ferrocene-based electrochemical 
mediator as the electron acceptor. As these electrochemical strips required a much smaller 
blood volume, compared to the reflectance based glucose meter, and were easily 
integrated with an automatic detection system, they rapidly became a commercial success, 
acquiring up to 85% of the market[64]. These SMBG devices are usually composed of a 
plastic substrate material comprising the electrochemical cell with a working and a 
counter/reference electrode and a capillary chamber; the electrochemical cell also contains 
Gox, PQQ-GDH, FAD-GDH or NAD-GDH and a redox mediator. Examples of redox 
mediators are Fe(CN)6
3+/4+, ferrocene-derivative and Os2+/3+ (Table 1.2). 
 
 
Table 1.2: Characteristics of some electrochemical test-strips. 


































Despite the commercial success of SMBG, the finger pricking method suffers from many 
drawbacks: (1) changing the lancet in the device requires a certain amount of mechanical 
and visual capability which can be an issue for elderly patients; (2) the pain associated 
with finger pricking reduces patient compliance leading to a reduced number of glucose 
measurements and negatively impacting on achievement of glycaemia targets; (3) 
repetition over time of this methodology increases the risk of scarring and callous 
formation and loss of sensitivity/sensation- in the finger tips[65]. 
 
 
1.4.3 Continuous glucose monitoring systems (CGMSs) 
1999 saw the start of a new era in diabetes care with the approval of the first continuous 
glucose monitoring system, marketed by Medtronic MiniMed (Sylmar, CA, USA), which 
offered improved control of diabetes through the provision of real-time data. With these 
monitors, practitioners could make long term adjustments in, and thereby personalise, the 
drug treatment of each patient. The devices could also alert patients when glycaemia 
varied out of the acceptable physiological range, avoiding extreme hypo- and 
hyperglycaemia events which increase the risk of kidney disease, vision loss, stroke, 
amputations, etc. The technology involves insertion of a needle-type electrode into the 
subcutaneous tissue, allowing blood glucose levels to be checked indirectly via 
measurements made in the interstitial fluid[66] (although continuous blood glucose 
monitors have been proposed, they have not proven successful due to biofouling of the 
electrode surface by protein and coagulation factors and the associated risk of 
thromboembolism). CGMSs comprise three essential components: a sensor, a transmitter 
and a wireless receiver. From the subcutaneously implanted sensor, which uses an 
electrochemical technique just as a test strip in SMBGs, the electrical response is 
transmitted as a RF signal to the receiver that then processes the information to calculate 
the glucose concentration that is displayed on the monitor. These devices are able to make 
glucose measurements every one to five minutes and to function independently for three 
to seven days[67]. Table 1.3 summarises the main characteristics of the state-of-the-art 
CGMSs.  However, it is important to note that despite the apparent advantages, the new 
CGMSs are expensive and that older devices require calibration at least twice a day with 
the standard finger-pricking method[68]; in addition, there are problems related to poor 
self-monitoring technique, mishandling, discomfort associated with the insertion and 
removal of the sensor under the skin and skin irritation[69]. 
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1.4.4 Relationship between interstitial fluid and blood glucose levels  
The concentration of glucose in the interstitial fluid (ISF) is the measurement made by the 
CGMSs, discussed above, and of minimally-invasive such as the GlucoWatchTM, and its 
relationship with blood glucose level has been examined in some depth[74], [75]. While 
finger pricking accesses blood from the capillaries in the dermis, and glucose levels 
measured here have been correlated with systemic arterial blood concentrations[76], there 
are important distinctions to be made between the blood and the ISF. The total ISF volume 
is three-fold greater than that of plasma, and it represents the 45% of the human skin 
volume fraction (while only 5% is represented by the blood vessels)[77]; ISF therefore 
acts as a reservoir for numerous biomarkers such as proteins, exosomes, nucleic acids, 
ions and small molecules. As a result, ISF and plasma are considered as separate 
compartments for glucose (Figure 1.5). Glucose moves by passive diffusion, down its 
concentration gradient, from the capillary endothelium to the ISF where the amount of 
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glucose present is determined by the balance between this diffusion rate and the glucose 
uptake rate by the cells of the subcutaneous tissue. Thus, several factors may influence the 
glucose concentration in the ISF, including (1) the metabolic rate of nearby cells, (2) the 
presence of insulin, (3) local blood flow, and (4) the permeability of the capillaries which, 
in turn, is affected by numerous factors such as nerve stimulation[78]. Consequently, there 
is a lag-time before dynamic equilibrium is reached between plasma and ISF; on  average, 
this is about 10-20 minutes[79], but has been reported to range from 0 to 45 minutes[77]. 
However, during abrupt changes in glucose levels, the lag time is probably related to the 
variation of the glucose concentration in the different tissues[80]. 
 
 
Figure 1.5| Schematic plasma/ISF glucose dynamics.  
 
From the two-compartment model[81], [82] of glucose dynamics between the plasma and 





= 𝐾21𝑉1𝐺1 − (𝐾12 + 𝐾02)𝑉2𝐺2 
 
where G1 and G2 are the plasma and ISF glucose concentrations, respectively, V1 and V2 
are the corresponding plasma and ISF volumes, K12 and K21 are rate constants describing, 
respectively, glucose transfer from capillary blood to ISF and vice versa, and K02 is the 
rate constant characterising glucose uptake into the subcutaneous tissue. Using micro 
dialysis as an indirect method to access the ISF, it has been shown in healthy subjects that 
ISF glucose levels are nearly identical to those in the venous plasma during steady-




difference in pre- and postprandial glucose levels between the dermal ISF and the 
plasma[84]. However, it has been observed, when glycaemia is falling, that interstitial 
glucose does so in advance of plasma glucose[85], and attains lower values than the 
corresponding venous glucose concentrations[86]. It has also been reported that interstitial 
glucose tends to remain below the plasma level after insulin-induced hypoglycaemia[87]. 
This effect could be explained by a so-called “push-pull” phenomenon wherein glucose is 
pushed from the blood to the ISF, when glycemia increases and then, later on, is pulled 
from the ISF to the surrounding cells as glycaemic falls. However, this putative 
mechanism is still a matter of debate with many arguing that both an increased plasma 
glucose delivery, and a deficiency in glucose removal effect of insulin in the adipose ISF, 






1.5 Compendium of non-invasive glucose sensing technologies 
1.5.1 Introduction 
Intensive research has been directed at less invasive and user-friendly glucose detection 
technologies that can be classified as either minimally invasive (MI) or non-invasive (NI). 
MI devices require access to a physiological fluid (e.g., tears, saliva, interstitial fluid) in 
which glucose levels are usually measured via an enzymatic reaction. NI devices, on the 
other hand, rely on the application of some sort of radiation without having to extract or 
sample a bodily fluid. Technologies for glucose sensing can be further classified in four 
categories: electrochemical, optical, thermal and electric (Figure 1.6). Electrochemical 
detection is used in most invasive and MI devices, and has been discussed above. Optical 
detection involves use of different parts of the electromagnetic spectrum relying on the 
properties of light to reflect, absorb and scatter when passing through biological media. 
Thermal detection is achieved by monitoring physiologic indices associated with 
metabolic heat generation related to glucose. Finally, electric detection exploits the 




Figure 1.6| Glucose sensing methodologies and technologies.  
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1.5.2 Electric sensing 
1.5.2.1 Bioimpedance spectroscopy (BS) 
BS involves the application of a small, defined alternating current to evaluate changes in 
the resistance (and, hence, the conductivity) of red blood cell membranes induced by 
variation in glucose concentrations; these changes occur due to alterations in sodium and 
potassium ions levels [89]. Although relatively inexpensive, BS is sensitive to motion, 
temperature and variations in physiological conditions confounding, therefore, its ability 
to report specifically on the effect of glucose. 
 
1.5.2.2 Electromagnetic sensing (EMS) 
Electromagnetic sensing assesses the current, or voltage, deriving from the magnetic 
coupling between two inductors which surround an area of the body (usually earlobe)[90]. 
This coupling is dependent on both the dielectric properties of the media between the coils 
and concentration and type of analyte. In order to produce enough coupling, frequencies 
in the band between 2.4 MHz and 2.9 MHz have been used for glucose sensing in-
vivo[91], and a frequency of 7.7 GHz has also been suggested as a better option[92]. This 




1.5.3 Acoustic sensing 
1.5.3.1 Photoacoustic spectroscopy (PAS) 
Photoacoustic spectroscopy in non-invasive glucose sensing involves a pulsed or 
continuous photonic wave as a form of excitation; both methods rely on the absorption by 
glucose of a specific wavelength producing microscopic localised heating and, as a result, 
volumetric expansion of the medium which, in turn, generates an ultrasound wave that 
can be detected by an acoustic or pressure sensor[93]. The pulse frequency, which is in 
the lower range of Kilohertz, causes a fast adiabatic thermal expansion of the fluid 
containing glucose thereby generating a broad spectrum of acoustic frequencies[94]. On 
the other hand, continuous-wave mode induces tissue excitation that produces a single 
acoustic frequency, permitting an increased signal-to-noise ratio (SNR) in a lock-in 
detection configuration[95]. Due to the inadequate sensitivity of this technique for in-vivo 
glucose detection, use of two laser sources has been suggested[96] to boost the analytic 
signal. PAS can use a broad range of wavelengths, from ultraviolet to MIR, thus taking 
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advantage of the characteristic glucose absorption spectrum between 800-1200 cm-1 [97]. 
However, this technique still suffers significant disadvantages such as low SNR, long 
integration time and susceptibility to motion, pulsation, temperature variations and 
surrounding acoustic noise. 
 
1.5.3.1 Ultrasound 
This technology measures the propagation time of ultrasound waves through biologic 
fluids; the acoustic velocity through a medium is defined by its degree of compressibility, 
which depends on the density and strength of intermolecular bonding forces, and is 




1.5.4 Thermal sensing 
1.5.4.1 Metabolic heat conformation (MHC) 
Metabolic heat conformation technology measures the heat generated by the metabolic 
oxidation of glucose. Heat production can be externally emitted in the form of convection, 
radiation and evaporation all of which depend on the skin and ambient temperatures[99]. 
The MHC detector measures a number of parameters, including thermal generation, 
oxyhaemoglobin concentration and blood flow rate, usually at the fingertip, using multi-
wavelength spectroscopy. The recorded data are consequently evaluated statistically 
using, for example, regression, multivariate and discriminant analyses. Application of 
MHC is limited due to its susceptibility to environmental temperature variations and 
perspiration. 
 
1.5.4.1 Thermal emission spectroscopy (TES) 
Heat is naturally emitted by the human body in the far-infrared (8-14 µm)[100]. TES 
analyses the heat radiated from the body including that sensitive to the level of glucose 
which is detected at a wavelength of ~9.4 µm[101]. The small thermal energies involved 
in TES are compared with predicted values using the Planck distribution function; a 
measured reference level is then used to calculate the actual thermal absorption which is 
converted to a glucose concentration[101]. While TES shows good selectivity toward 
glucose (due to its well-defined absorption spectrum) and is non-invasive, this technique 




1.5.5 Optical sensing 
1.5.5.1 Raman spectroscopy 
Raman spectroscopy assesses the degree of scattering of monochromatic light after 
interaction with a target. The majority of the scattered light has the same wavelength as 
the incident light (elastic or Rayleigh scattering), while the much smaller remainder shows 
a wavelength shift (inelastic or Raman scattering). This Raman shift characterises the 
variation between the initial and final vibrational and rotational states of the chemical 
species under examination[102] and is independent of the incident light wavelength. 
Raman spectroscopy can be employed to detect specific absorption bands and to quantify 
the molecule of interest[93]. Characteristic vibration modes of glucose are associated with 
C-H stretching around 2900 cm-1, and C-O and C-C stretching between 800 and 1300    
cm-1 [103]. Regrettably, tissue autofluorescence, photobleaching, and interference from 
other compounds with similar Raman signals, significantly undermines the acquisition 
and identification of a specific glucose signal. 
 
1.5.5.2 Near-infrared spectroscopy (NIRS) 
Near-infrared spectroscopy involves the absorption and scattering of wavelengths in the 
range of 780-2500 nm reflecting bond rotations and vibrations in the examined 
molecule[104]. NIRS can operate in three different modes: (1) transmittance, where the 
sample is irradiated with polychromatic light and a diffraction grating then splits the 
transmitted radiation into its constituent parts that are then detected and analysed.; (2) 
reflectance, where the detector and diffraction grating are on the same side of the light 
source; and (3) interactance, which is similar to reflectance, in that it separates the field of 
view of the detector from the irradiated area using a light barrier between the reflected and 
incident beams[105]. Although, in this wavelength range, water absorbs little 
radiation[93], many biomolecules, such as proteins and other sugars, share similar 
absorption characteristics with glucose and robustly interfere with its detection; in-vivo 
sensing is also compromised by light scattering in the tissue[106]. 
 
1.5.5.3 Mid-infrared spectroscopy (MIRS) 
MIRS relies on the same absorption principles and system configuration of NIRS, but it 
assesses infrared spectra using wavelengths in the range of 120-30 THz (2.5 – 10 
µm)[107]. MIRS leads to superior absorption sharp spectral lines because the longer 
wavelengths are less scattered in tissue[108]. However, because of pronounced water 
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absorption in this region of the spectrum, glucose detection sensitivity is low even when 
a more powerful MIR source is used[109] with complementary technologies, such as 
photoacoustic spectroscopy[110]. 
 
1.5.5.4 Far-infrared spectroscopy (FIRS) 
Far-Infrared spectroscopy involves wavelengths in the range of 0.3-30 THz (1000-10 µm). 
Water absorption is even more pronounced significantly impeding the identification of 
molecules of interest in biological fluids. 
 
1.5.5.5 Time of flight (TOF) and Terahertz time-domain spectroscopy (THz-
TDS) 
With the advent of quantum-cascade lasers, FIR spectroscopy became more accessible for 
biomedical applications in the micrometre wavelength range using time-resolved 
techniques (also known as Terahertz time-domain spectroscopy). TOF employs single-
frequency laser pulses (on the order of picoseconds) to assess both the absorbed radiation 
and the time needed for photons to travel across the sample. The photons that reach the 
detector may have followed different paths: some propagate directly through the sample, 
others travel longer distances due to multiple internal reflections, and another fraction can 
undergo total scattering resulting in diffuse light. The analysis of the time of flight 
distribution, variation in pulse form, and amount of absorbed radiation identify the optical 
properties of the sample, including the level of glucose therein. Likewise, THz-TDS uses 
pulses in the time domain of a few hundred femtoseconds to calculate the phase 
information (travel time) of reflected and scattered radiation and absorption of the 
medium. The unique Gaussian or differentiated Gaussian pulse-shape obtained using this 
ultrafast-laser pump permits, in a single scan using a wide frequency sweep, measurement 
of the refractive index and the spectrum of the complex permittivity; furthermore, critical 
frequency-dependent parameters such as signal-to-noise ratio, bandwidth and dynamic 
range can be evaluated[111]. THz-TDS can operate in two modes: transmission mode 
(which does not provide useful data because of strong water absorption) and reflection. 
The latter is used between 0.1 and 1 THz and, although such radiation scarcely penetrates 
the skin, there are efforts underway to target and correlate changes in optical parameters 
related to the variation of glucose concentration[112]. Further progress requires key 
limitations, such as the need for prolonged measurement times and the minimal spatial 
and depth resolution, to be overcome. 
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1.5.5.6 Millimeter/micrometer waves sensing 
Millimeter radiation and microwaves contain lower energy than infrared and present a 
smaller amount of scattering in the tissue[113], thus, they are able to reach deeper tissue 
levels and to contact regions with adequate blood supply, possibly increasing the glucose 
sensing accuracy. These radiations can be used in different techniques[114]: (1) in 
reflection mode a one-port technique is used to measure the reflection parameter S11, 
which symbolises the amount of power reflected from the antenna, assessing the 
amplitude and phase variation in the reflected signal caused by permittivity variations 
related to glucose fluctuations; (2) The transmission mode uses a two-port methodology, 
essentially expanding the reflection mode providing a full set of S-parameters, thus 
permitting the calculation of the media complex propagation constant, the phase 
transition, and attenuation of the transmitted signal due to glucose level variations; (3) the 
resonant perturbation technique uses a near-field sensor (i.e. microstrip patch antennas 
and waveguides[115], [116], high-Q resonance[117], split-ring resonators[118] and 
dielectric resonator antennas[119]) with an incredibly high quality-factor Q, which is a 
dimensionless parameter describing how underdamped an oscillator or resonator is, 
aiming for the measurement of the changes in resonant frequencies, 3dB bandwidth and 
quality factor and relating them with dielectric properties of the media[120]; (4) 
conversely, radar method that works in the far-field by transmitting an electromagnetic 
wave to the target and detecting the reflected signal which contains information regarding 
the speed, location, size and composition of the object. Currently, scientists are working 
on signal processing and AI algorithms to correlate the signal to blood glucose 
concentrations[114]. However, all the mm- and µ-wave detection techniques suffer from 
poor selectivity and are sensitive to physiological parameter variations, including cardiac 
activity, breathing and sweating levels[121]. 
 
1.5.5.7 Optical coherence tomography (OCT) 
Optical coherence tomography is an imaging technology that exploits low coherence 
interferometry with coherent radiation[122] and is used to examine tissues of the body 
with a resolution in the micrometre range. OCT involves radiation of the skin with 
coherent light, with a wavelength between 800 and 1300 nm, and generation of a filtered 
interferometric signal of the acquired backscattered radiation. Increasing levels of glucose 
proportionally increase tissue refractive index and decrease its scattering coefficient 
offering an opportunity for monitoring. However, although this technique has a high 
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signal-to-noise ratio and permits relatively deep tissue penetration, it is sensitive to 
movement, temperature changes in the tissue, and skin inhomogeneity. 
 
1.5.5.8 Optical polarimetry (OP) 
Optical polarimetry detection methods are applicable to chiral molecules which are able 
to rotate the plane of polarised light by an angle proportional to their concentration. Other 
parameters, including temperature, optical path length and the wavelength of the laser 
beam, also contribute to the rotation of the light beam and, unfortunately, interference 
from other molecules and the elevated light scattering in the skin tissue makes this 
technique impracticable for glucose monitoring in the skin[123]. A better alternative may 





Sonophoresis technology enables to extract samples of the interstitial fluid, containing 
glucose which will be enzymatically detected, using low-frequency pressure waves to 
drive the process. This technique takes advantage of the cavitation phenomenon to 
increase the permeability of the skin[125]; cavitation is induced by the longitudinal nature 
of ultrasound waves, where the direction of propagation and oscillation are the same, and 
it generates a series of compression and expansion movements driving the gas and 
analytes extraction from the skin, including glucose[126]. However, despite the feasibility 
of this technique, research is focused on its use in drug delivery. 
 
 
1.5.7 Reverse iontophoresis (RI) 
Like sonophoresis, reverse iontophoresis is classified as “minimally invasive”; it relies on 
the collection of a small amount of interstitial fluid from the skin and measures the 
extracted glucose via an enzyme reaction coupled with electrochemical detection. RI 
applies a defined, small electric current between two electrodes positioned on the surface 
of the skin and induces the electromigration of ions, in both directions at the anode and 
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cathode.  Sodium ions are drawn primarily to the cathode, and because the skin supports 
a net negative charge under normal conditions, this generates an electroosmotic flow of 
water thereby significantly enhancing the transport of polar solutes dissolved therein 
including, of course, glucose[91]. RI has been a particularly well-studied technique for 
glucose monitoring and has demonstrated superior accuracy to the methods discussed 
above; however, RI is recognised to cause at least some degree of skin irritation due to the 








1.6 Wearable, non-invasive glucose sensors 
Considerable recent effort has been invested in the development of wearable medical and 
lifestyle sensors in[127]–[131]. Initially, wearable devices focused on measuring physical 
parameters related to mobility and vital signs such as steps, heart rate and calories burned; 
however, with the advent of new materials, advances in micro- and nanofabrication 
techniques and integrated electronics, research into devices able to monitor (bio)chemical 
parameters, i.e., biomarkers, has been rapidly increasing and many proof-of-concept 
studies are now being reported. Usual biofluid targets for wearable biosensors are tears, 
saliva, sweat and ISF, see Table 1.4. 
Wearable monitors may lead to insights into dynamic biochemical processes in body 
fluids supporting continuous and real-time detection of biomarkers associated with the 
health and performance of the user. Besides, wearable sensing devices can be fabricated 
to prevent painful blood sampling and, without inducing discomfort, to ensure both a 
direct contact with body tissues and the prompt access to sample biofluids. For instance, 
a wearable glucose sensor could drastically enhance diabetes management and alert the 











- Continuous access to the target biofluid 
 
- Short lag time and close tear–blood 
correlation 
 
- Can be used to detect protein biomarkers 
- Frequent device calibration 
 
- Eye irritation and 
variations in the tear 
production rate impair the 

























- Passive glucose 
collection 
 
- Intended for sport 
applications 
- Sensors designed solely for 
sport applications, physical 
exertion is necessary to 
generate sweat 
 
- Irregular sampling rates 
 
- Fluctuations in the sweat 



















increase the accuracy 
of glucose sensing 
- Power requirement to draw 
glucose out from the skin in 
iontophoretic devices 
 
- Disruption of the outer skin 
layer to access ISF in 
microneedles-based devices 
Oral cavity Saliva 
- Continuous access and prompt collection 
of the target biofluid 
 
-Possibility to detect bacteria 
- Frequent device calibration 
 
-Difficult to standardize 
measurements and reference 
baselines 
 
- Influenced by food intake 
and biofouling 
 






The first wearable device that tried to start a new era in the medical sensing field was the 
glucose monitor Glucowatch® Biographer which, unfortunately, exhibited a short 
commercial life.  Nowadays, plenty of novel wearable biosensing platforms have proven 
their capabilities in different applications, ranging from the detection of electrolytes (such 
as potassium, sodium or chlorides) to the monitoring of metabolites (for example, glucose 
or lactate) in a variety of biofluids via (bio)electrochemical detection. The literature in this 
field has proven the enormous potential for real-world applications, and examples of 
wearable, successful or quasi, glucose monitoring devices are summarised in Table 1.5. 
 
 



























Electrochemistry On hold [133] 










































1.6.1 Epidermal wearable biosensors and skin structure 
Skin-worn biosensing devices have received the greatest attention among the different 
types of wearable biosensors. These biosensors rely on access to ISF or sweat, with or 
without disrupting the stratum corneum (the outermost protective layer of the skin), 
permitting analytes sampling via minimally-invasive methods. Various technologies have 
been used in the signal transduction processes, the most common being optical and 
electrochemical. The format of such sensors has included smart patches and wristbands, 
smart watches, tattoos or textiles.  
Human skin consists of a succession of layers, ensuring its essential function as a barrier, 
including (from the most external layer to the internal one) the epidermis, dermis and 
hypodermis with typical thicknesses of 150 µm, 1 mm, and 0.1 to 5 cm, respectively (see 
Figure 1.7).  
 
 
Figure 1.7| Schematic of skin layers and structures. 
 
 
    Hypodermis 
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The epidermis can be sub-divided into two layers; the stratum corneum, the outermost 
layer of dead cells arranged a “brick and mortar” structure which acts as a physical barrier, 
and the viable epidermis, a multi-layered structure (basal epidermis, stratum spinosum, 
and the so-called granular layer) reflecting the progressive stages of epidermal cell 
(keratinocyte) differentiation. Moving up from the basal layer, cells pass from 
metabolically active to terminally-differentiated, fully-keratinised cells (corneocytes) 
which are flat, enucleated, and typically organised in a stack of ~20 layers, filled with 
keratin filaments and enclosed in a cornified envelope comprising insoluble loricrin, 
involucrin and covalently bound lipids.  The stratum basale of the viable epidermis 
contains the stem cells of the skin that differentiate into various epidermal cells; the 
stratum spinosum consists of polyhedral-shaped cells, while the stratum granulosum 
includes keratinocytes with high levels of keratohyalin granules and inter-locking 
desmosomes. 
Below the epidermis, the dermis presents as an aqueous, gel-like tissue. The dermis 
contains mostly collagen and elastin fibres, blood capillaries, lymphatic vessels and 
nerves. The dermal capillaries form the cutaneous microcirculation which provides 
nutrients to the skin, and plays a crucial role in thermoregulation. 
The skin also supports appendageal structures, including hair follicles, sweat glands 
(eccrine and apocrine), sebaceous glands and nails. Hair follicles are ubiquitous, except 
on the palms, soles and lips, and incorporate sebaceous glands which secrete sebum (a 
mixture of highly lipophilic substances).  Eccrine glands produce sweat and are involved 
in thermoregulation. Apocrine glands are located only in specific body sites and open into 
associated hair follicles. 
In the viable skin tissue, ISF bathes the cells and delivers nutrients by diffusion from the 
dermal microcirculation. The ISF therefore  offers a reliable source of many analytes, 
including metabolites (such as glucose, lactate, alcohol, cortisol), electrolytes (e.g., 
sodium, potassium, magnesium, phosphate, calcium, chloride) and other important 
molecules including, inter alia, proteins, nucleic acids, cytokines, neuropeptides[139]. 
Sweat is also a fluid that has been targeted for biosensing but this requires its secretion 
from the skin to be accessible; i.e., physical exercise, stress, thermal heating, iontophoretic 
or drug stimulation are required to provoke active sweating. While the biomarkers present 
in these biological fluids offer significant opportunities for in-situ, real-time and non-
invasive monitoring both of disease progression/management and of well-being and 
health, the accurate quantification of physiologically relevant analytes in ISF and sweat is 
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challenging due to multiple factors that are difficult to control.  These include skin surface 
pH and temperature variations, signal interference between analytes, low sampling 
volumes, and the unpredictability of analyte dilution (which may be affected, for example, 
by sweat rate and by analyte partitioning into the sweat)[140]. 
 
1.6.1.1 The GlucoWatch Biographer and current investigations 
The first FDA-approved, non-invasive glucose monitoring system was the GlucoWatch® 
Biographer (Cygnus, CA, USA) in 1999. This system combined reverse iontophoresis and 
electrochemical detection for glucose sensing. However, this device was only 
commercially available for a few years[141]. In principle, the GlucoWatch offered several 
advantages for people with diabetes including: fewer finger pricks, better patient 
compliance, close-to-continuous glucose monitoring, the practicality of a cost-effective 
wrist-worn device[142], and better control over changes in blood glucose 
concentration[143]. Unfortunately, several limitations impacted significantly on the 
commercial success of this device: (1) low sensitivity and accuracy especially during 
hypoglycaemic events, (2) the need for conventional, invasive finger pricks to calibrate 
the sensor due to intra- and inter-individual variability in RI extraction efficiency [144], 
(3) the sensor operated close to its limit of detection due to the large dilution of the 
extracted interstitial fluid into the volume of the collection gel (of about 400 µL) resulting 
in sub-micromolar glucose concentrations, (4) a long warm-up period, (5) skin irritation, 
and (6) skipped readings when the wearer was actively sweating.  
Other molecules, which can be accessed from the interstitial fluid by reverse 
iontophoresis, include biomarkers such as prostate-specific antigen (PSA), osteopontin 
and urea[145] (i.e., for prostate and ovarian cancer and kidney disease, respectively), 
amino acids related to various metabolic diseases (e.g., high levels of phenylalanine[146] 
(> 100 µM) and tyrosine identify phenylketonuria and tyrosinemia, respectively), and 
certain drugs, such as lithium[147], phenytoin[148] and valproate[149]. 
Other novel technologies for the non-invasive detection of glucose levels are being 
explored. For example, both the electro-osmotic extraction and sweat collection of glucose  
has been considered using a flexible tattoo platform able to assess glycaemia in healthy 
human subjects before and after meal[128]. Elsewhere, the enhanced collection of ISF 
glucose resulting from the iontophoretic delivery of positively-charged hyaluronic acid 
embedded in a wearable platform has been reported[150]. A further research initiative has 
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focused on the integration of iontophoretic sweat-generation, by delivering small doses of 
pilocarpine, coupled with different detection systems[151]. However, in this case, the 
efficiency of electro-osmotic glucose extraction by RI is not easy to control, resulting in 
variable volumes of sampled ISF and hence disparities in the measured glucose 
concentrations. 
 
1.6.1.2 Microneedle (MN) technologies 
The use of microneedles as a minimally invasive technology is currently attracting much 
interest in the area of vaccine and drug delivery and has also been considered for glucose 
sensing. Although microneedles were first proposed in 1976[152], their manufacture only 
became feasible in the 1990s following innovation in microfabrication techniques. Current 
production methods permit microneedle arrays to be made in various sizes, shapes and of 
diverse materials, including silicon, stainless steel, carbohydrates, and polymers[153], 
[154]. 
Microneedle-based glucose sensing relies on micrometre-scale hypodermic needles to 
access the interstitial fluid in the skin and are usually coupled with enzymatic 
electrochemical detection system. The technology is perceived as mainly risk-free, nearly 
pain-free compared to other more conventional needles, with increased user compliance 
and ease-of-operability for non-trained personnel[155], [156]. Microneedle biosensors 
require the necessary geometry and material composition to guarantee a mechanically 
robust structure able to both penetrate the skin successfully and to remain in place for the 
required time; this may also necessitate the design and use of a suitable applicator capable 
of providing a defined insertion force and velocity to ensure successful and reproducible 
skin penetration without mechanical failure or material fracture. However, while ISF flow 
may be driven by capillary forces into the microneedle lumen, this passive process may 
not be sufficient to maintain constant fluid extraction; in addition, there is also the risk of 
needle biofouling due to (e.g.) protein deposition. 
A recent example of a wearable MN-based biosensor device[157] integrated multiple 
components to assess glucose (in sweat), humidity, pH, temperature and mechanical strain 
with a polymeric microneedle metformin delivery system.  An array of sensors was 
patterned onto gold-doped graphene, to enhance the sensitivity of electrochemical 
detection. However, the proof-of-concept of this attractive close-loop-system idea for 
diabetes management was demonstrated only in diabetic mice where the quantity of drug 
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required to lower blood sugar is obviously very much less than that needed in humans; the 
feasibility of scale-up, without an impossibly large number of microneedles and, hence, 




1.6.2 Ocular wearable devices 
The tears represent an alternative biofluid in which to monitor physiological parameters 
and biomarkers. Tears are secreted by the lachrymal gland to protect the eye and comprise 
a variety of peptides, proteins, electrolytes, metabolites and lipids.   Glucose levels in tears 
are in a dynamic equilibrium with those in blood perfusing the lachrymal artery (except 
when the eye irritated, for example)[158]. Therefore, a contact lens-based device has been 
proposed as a tool with which to indirectly measure blood glycaemia via the tears[159]. 
Indeed, this technology has been pursued by Google, in partnership with Novartis, to 
develop a prototype that incorporated a miniaturised electrochemical transducer, a 
wireless control chip and an antenna on a soft contact lens platform[160]. A different 
approach, again with wireless data transmission, involves a miniature, spring-shaped 
electrochemical sensor, comprising a polysaccharide-based hydrogel matrix used to coat 
multiple coiled wire electrodes, which is placed in the inferior conjunctival fornix. This 
location provides constant access to the lachrymal fluid and the sensor has demonstrated 
good correlation between glucose concentrations in the tears and the blood in both an 









1.6.3 Oral-cavity wearable devices 
Another diagnostic biofluid under current attention in the scientific community is 
saliva[162]. Several biomarkers can also pass directly into the saliva from the bloodstream 
via paracellular or transcellular pathways across the oral mucosa. Saliva is mainly 
produced by the parotid gland and its composition includes enzymes, hormones, 
metabolites, proteins, ions and microorganisms[160]. While some of these biomarkers 
have been targeted in various clinical settings[164], the number of studies focused on the 
development of wearable oral cavity sensors is limited due, for example, to the potential 
for biofouling by food debris and the high protein content in saliva, as well as the low 
concentrations present of targeted analytes. With respect to glucose biosensing.,[165] a 
monolithic mouthguard platform, using an electrochemical transducer, based on GOx-
glucose biorecognition, and integrated with a wireless transmitter, has been investigated. 
Oral sensing platforms using RF sensors have also been examined to assess other sugars, 
alcohol, pH, electrolytes and temperature[166]; however, even though some testing has 
been done in man, the present level of validation, with respect to selectivity and accuracy, 
is insufficient to envisage any real-life applications in the near future.  There would also 
need to be a significant effort directed at safety, addressing issues such as local toxicity, 
biocompatibility, sterilization and operational stability to chemical and mechanical 
impediments to the diffusion of analyte to the sensor itself.  
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1.7 Graphene-based transducers and wearable sensors 
The experimental discovery of graphene in 2004 [167] has revolutionised material science 
in a wide range of research fields. Graphene is an atom-thin nanomaterial composed of 
carbon atoms arranged in a two-dimensional honeycomb structure, and it can serve as 
building block for other sp2 bonded materials. Due to its many excellent qualities, such as 
large surface area (2600 m2 g-1)[168] and Young’s modulus (1 TPa) [169], high electron 
mobility (350 000 cm2 V-1s-1)[170] and thermal conductivity (5300 W m-1 K-1) [171], 
graphene is considered a promising material for electronics and sensing; and related to 
this work, for the development of wearable and implantable biosensors for health 
monitoring. 
 
1.7.1 Graphene production 
So far, graphene production has been achieved utilizing various methods: 
1. Exfoliation techniques are based on the breaking of Van der Waals bonds holding 
together layers of graphene sheets, hence detaching them into separated graphene 
sheets. Mechanical exfoliation of highly oriented pyrolytic graphite was the first 
approach used to obtain graphene layers (also known as the Scotch-tape method); 
however, this methodology is not applicable for mass production. Another 
example of mechanical exfoliation process is ball milling where a grinding media 
is used to generate shear forces via impact and attrition resulting in the exfoliation 
of graphite and the formation of graphene flakes[172]. However, the processing 
time is in the range of 24 to 48 hours which is not suitable for large scale 
production and continuous processes. 
2. Liquid-phase exfoliation involves the dispersion of graphite in a solvent, its 
exfoliation taking place by low-frequency ultrasound, followed by purification of 
the final product. Even though further optimisation is required to avoid defects on 
the graphene edges and basal planes[173], the versatility of this technique for 
product synthesis and functionalization may attract attention because of the 
potential of this process for scale-up. 
3. Arc discharge technique involves the application of high voltages, usually in a 
high vacuum chamber, between graphite electrodes which are separated by a small 
distance.  The high electric field induces an instantaneous spark between the 
electrodes causing the generation of graphene flakes and other debris. 
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4. Laser-induced graphene (LIG) methodology has been reported to induce the 
formation of 3D-graphene from polyimide (PI) or naturally occurring materials by 
photothermal processes related to the laser irradiation causing localized high 
pressure and temperature. Carbon atoms in LIG are bonded in hexagonal, 
pentagonal and heptagonal rings, hence showing a substantial departure from the 
ideal hexagonal structure, potentially because of the fast transformation process 
to which the carbon-based substrate is subjected [174] and the lack of equilibration 
time to establish the hexagonal matrix. LIG has been paired with roll-to-roll and 
3D-printing in an effort to improve the scalability of the process. Overall, the 
possibility of using natural products in the fabrication of biodegradable graphene-
based devices makes this technique attractive as a means to reduce electronic 
waste [175]. 
5. Chemicals-based techniques involve the use of strong oxidant species, such as 
nitric, sulfuric, and hydrochloric acids, or permanganate and chlorate, to exfoliate 
graphite by chemical oxidation. This results in the generation of graphene oxide 
sheets which are then chemically, electrochemically or thermally reduced. These 
techniques are reported to have low production cost and high yield, making them 
potentially suitable for scale-up in industrial settings. However, reduced graphene 
oxide (rGO) is electronically very different from pristine graphene because of a 
high density of defects and dimensional differences which result in lower surface 
area and solubility, and, especially, in poor electronic conductivity [176]. 
Furthermore, there are concerns regarding batch-to-batch reproducibility of the 
oxidation and reduction processes which can cause high variability in the graphene 
chemical composition [177]. 
6. Among so-called bottom-up techniques, chemical vapour deposition (CVD) is a 
promising graphene fabrication method for industrial scale. Growth is achieved 
by activating a gaseous carbon hydrate and the subsequent chemical reaction on a 
metallic substrate with low solubility for carbon (such as copper, nickel, 
ruthenium, iridium, platinum), which acts as a catalyst, leading to the formation 
of a sheet of graphene. The graphene then needs to be removed from its metallic 
substrate and transferred onto insulating substrates for subsequent device 
fabrication: this requires wet transfer methodologies[178], processes that have 
been primarily developed in academic laboratories. Nevertheless, this technique 
has the potential to be used in mass-production, and several research teams have 
40 
 
demonstrated roll-to-roll CVD processes for graphene synthesis [179], and is 
particularly appealing for the transfer of graphene onto flexible substrates [180]. 
 
In order to simplify the manufacture of graphene in industrial processes, substantial effort 
needs to be dedicated to perfecting graphene synthesis, batch-to-batch consistency, 
storage, and reducing the overall cost of production. On the other hand, the possibility of 
manufacturing specialised graphene materials may facilitate implementation of specific 
graphene-based devices via synergy between production- and application-driven 




1.7.2 Graphene in wearable sensors 
Due to its elevated electron mobility, graphene presents new opportunities to out-perform 
established electronics; in addition to its atomic thickness and low sheet resistance, 
graphene is also attracting attention for the implementation and integration of both 
transparent and flexible electronics in upcoming devices associated with applications in 
the “internet-of-things”. Graphene-based biosensors have benefits such as broad working 
range, high sensitivity, and wide functionalization options. In the last decade, graphene 
has been integrated in a variety of sensing platforms detecting, for example, mechanical 
signals (including human motion, pulse, breath and heart rate) [181], electrophysiological 
signals such as ECG, EMG, EEG and EOG (respectively electrocardiogram, 
electromyogram, electroencephalogram and electrooculogram) [182], [183], and diverse 
(bio)chemical species including key analytes in different body fluids[184]. Although 
graphene-based devices have greatly enhanced the performance of sensors, the main 
challenge remains the realisation of fully integrated devices to replace the existing Si-
based platforms.  This is especially true for wearable devices for which the promise of 
real-time, continuous monitoring of relevant physiological parameters is highly desirable 






1.8 Thin film deposition and analytical techniques 
Throughout the thesis, a range of graphene-based device prototypes were developed. The 
first generation involved CVD graphene and compatible thin film deposition techniques 
for the realization of a dual device combining reverse iontophoresis extraction with 
electrochemical sensing. Several thin film deposition techniques have been used to 
fabricate various metal layers (such as Pt), or to deposit Ag and AgCl that define the 
electrochemical electrodes; catalytic nanoparticles have also been produced to enhance 
the sensitivity of the electrochemical sensors. 
 
 
1.8.1 Physical vapour deposition techniques 
The physical vapour deposition techniques used in this work are thermal and electron 
beam evaporation, as well as sputtering. These techniques aim to controllably transfer 
atoms onto substrates and produce, as a result, the growth of thin films; such methods are 
mostly used in the electronics industry where thin films of metallic or semiconducting 
materials are incorporated in many common devices (e.g., microprocessors are 
manufactured from silicon wafers using a process called photolithography which involves 
the deposition of different layers of various materials on the chip), in thin film solar panels 
as well as protective coating for food packaging or on gas turbine components. Physical 
vapour deposition methods use vacuum systems that enable the melting temperatures of 
evaporation materials to be lowered, eliminating the possibility of oxide formation and 
permitting more uniform film growth. 
 
1.8.1.1 Thermal evaporation  
In thermal evaporation, a high purity source is placed into a small container  (or ‘boat’) 
which is clamped between two electrodes in a high vacuum chamber. Resistive heating is 
generated by applying a defined electric current to the boat causing the melting and 
subsequent evaporation of the source which then deposits onto a substrate and grows into 
a thin film. Usually, tungsten boats are used in the process due to the high melting 
temperature and electric conductivity of this metal; tantalum and molybdenum can be also 
used for evaporation sources but require higher melting temperatures. 
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1.8.1.2 Electron beam evaporation  
Electron beam evaporation is a physical deposition technique similar to thermal 
evaporation. However, in this case, an electron gun is used to produce a stream of 
electrons.  This gun is usually a tungsten filament that is heated until it glows brightly, 
and the resulting electron stream is focused and accelerated toward the evaporation 
material located in a crucible. Upon impact, the electron stream kinetic energy is 
converted into heat which melts or sublimates the source, and the resulting vapour then 
coats the target substrate.  
 
1.8.1.3 Sputtering deposition  
Sputtering deposition relies on the kinetic ejection of material vapourised from the source 
(the so-called “target”); this involves physically knocking atoms from the “target” surface 
using energetic and inert ions (such as those generated in an argon plasma). Once the 
ejected atoms condense onto the substrate, a film is formed. This technique can employ 
either direct current or radio frequencies (the latter are commonly used to allow deposition 
of non-metallic target materials) to create an electric field which energises and ionises the 
atoms of inert gas and to direct the formed plasma toward the target connected to the 
negative bias of the power source.  
 
 
1.8.2 Electrochemical techniques and fundamental concepts 
In an electrochemical cell, charge is transported across the electronic conductor 
(electrode) and ionic conductor (electrolyte) interface. In the electrode, the movement of 
charge is associated with electron transport whereas, in the electrolyte, ions act as charge 
carriers. Classic electrode materials are metals (e.g., Au, Pt, Hg, amalgams), carbon 
(graphite) and semiconductors (such as indium-tin-oxide and Si). Typical electrolytes are 
aqueous or non-aqueous solutions containing ionic species, such as Na+, Cl-, H+.  
An electrochemical reaction implies the transfer of charge via an ion or electron[185]; the 
latter is termed a redox reaction which can occur either by applying an external voltage or 
via the natural release of chemical energy. In electrochemistry, the cathode is the 
negatively charged electrode, where reduction occurs, and the anode is the positively 
charged electrode at which oxidation takes place. When electrons are transferred at the 
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electrode-solution interface, the generated electric current is called the faradaic current, 
and the reaction conforms to Faraday’s law of electrolysis, which asserts the direct 
proportionality between quantities of reacted species and electrical charge passing through 
the working electrode according to: 
𝑄 = 𝑛 · 𝑧 · 𝐹 
where Q is the total electric charge passed through the electrode in coulombs, n is the 
number of moles of the substance liberated at an electrode in grams, z is the valence 
number of ions of the substance (electrons transferred per ion), and F = 96485.3329 C 
mol−1 is the Faraday constant. 
Non-faradaic processes are instead associated to adsorption and desorption phenomena at 
the electrode-solution interface, which acts as a capacitor and, according to the applied 
potential, accumulates ions at the electrode surface generating a charging or capacitive 
current: 
𝑄/𝐸 = 𝐶  
where Q is the charges stored in the capacitor, E is the voltage across the capacitor (in 
volts, V) and C the capacitance (in Farads, F). Usually, the capacitive current generated 
by the electrochemical double layer is negligible compared to the faradaic current. 
The next sections describe the fundamental electrochemical concepts and techniques used 
in this work. 
 
1.8.2.1 Cyclic Voltammetry (CV)  
Cyclic voltammetry is among the most widely used electrochemical techniques and 
involves measurement of the electric current flowing through the working electrode as a 
function of an applied triangular potential and generation of the voltammogram, a plot of 
current versus voltage. CV is used to investigate the reversibility of an electrochemical 
process and to provide electrochemical reaction rates, redox potential parameters and 
quantitative analysis, due to the direct correlation between current and bulk concentration 
of the electroactive species[186]. As shown in Fig. 1.8, during a CV experiment, the 
voltage applied to the working electrode starts at a value, E1, and is linearly swept to 
voltage, E2; consecutively, the scan direction is reversed returning the potential applied to 






Figure 1.8| Potential waveform applied to the WE in a CV experiment. 
 
Figure 1.9 depicts a classic cyclic voltammogram which exhibits two peaks (cathodic and 
anodic) for a quasi-reversible electrochemical process. From the voltammogram, useful 
information can be extracted such as the peak-to-peak separation (ΔEp) and the current 
peak ratio (ipa/ipc) providing evidence of the reversibility of the redox model system. 
 
 
Figure 1.9| Example of a cyclic voltammogram. 
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1.8.2.2 Chronoamperometry (CA) 
In amperometry, a constant potential is applied to the working electrode to either reduce 
or oxidise the relevant electroactive chemical species and the resulting steady-state current 
is subsequently measured. With a proper selection of the applied potential and of the 
electrode material employed, this method permits different electroactive species in 
solution to be distinguished selectively. The resulting faradaic current is associated to the 
concentration of the electroactive species according to the Cottrell equation which defines 








where I is the diffusion current, n is the number of transferred electrons per molecule, F 
is the Faraday constant, A is the electrode area, Cb is the bulk concentration of the 
electroactive species, D is the analyte diffusion coefficient, and t is the time of electrolysis. 
Thus, the current depends on both the concentration and the rate at which the analyte 
diffuses to the electrode. 
 
 
Figure 1.10| Chronoamperometry. (a) Stepping the potential from a value at which no redox reaction 
occurs to one at which a current relating to a specific redox reaction is observed. (b) Example of current 
response as a function of time. (c) Progression of the diffusion field as a function of time. Diffusion 
field is a concentration gradient which extends out perpendicularly from the working electrode surface. 






1.8.2.3 Chronopotentiometry (CP) 
Potentiometry involves measurement of the voltage across an electrochemical cell and can 
be used either when an electric current is applied or without application of current (open 
circuit)). The method is commonly employed to assess ion activities in an electrochemical 
reaction when no current is flowing[187], for example when using pH or ion-selective 
electrodes to measure the concentration of ions such as H+, K+, Na+, Ca2+ and Cl- [188]. 
In a potentiometric analysis, the Nernst equation governs the relationship between 















where 𝐸𝑐𝑒𝑙𝑙 is the open circuit potential (also referred to as electromotive force, EMF), 
𝐸𝑐𝑒𝑙𝑙
0  is the standard potential of the electroactive chemical couple, R is the universal gas 
constant, T the absolute temperature, n is the number of electrons involved in the process, 
F is the Faraday constant and Q is the reaction quotient representing the ratio of the 
activities of relevant reduced and oxidised chemical species.  
 
 
1.8.2.4 Electrochemical impedance spectroscopy (EIS) 
Electrochemical impedance spectroscopy is a recent technique and it offers  powerful tools 
to characterise electrode structures, complex interfaces and electrochemical kinetic 
parameters. EIS uses either an alternating current or a small amplitude sinusoidal voltage 
to evaluate the impedance of an electrochemical cell as a function of frequency; the output 
signal is then fitted to an equivalent circuit to extract appropriate information. Impedance 
is described as the effective resistance of an electric circuit or part to alternating current; 
it is generated from the collective effects of ohmic resistance and reactance (arising from 
circuit components such as capacitors, resistors and inductors), which impede the 
electrons flow. Therefore, impedance is the AC equivalent of the resistance concept in 
DC. The most common format used to evaluate electrochemical impedance data are the 
Nyquist and Bode plots. The Nyquist plot illustrates the ability of an equivalent circuit to 
resist the electric current flow and to store electrical energy represented respectively by 
the “real” (x-axis, Z’) and “imaginary” (y-axis, -Z’’) impedance components. The Bode 




function of the logarithm of the frequency; even though this plot clearly explicit the 
frequency dependency, hence no information is lost, it is not very sensitive to changes in 
the measured system, as long as its fundamental behaviour remains constant. 
 
 
Figure 1.11| Nyquist and Bode plots. 
 
The electrochemical interface is modelled with an equivalent circuit, including the 
Randles circuit which is the most used. This circuit comprises the electrolyte solution 
resistance (Rs) in series with a parallel circuit of double-layer capacitance (Cdl) and 
Faradaic impedance which in turn is composed of a charge transfer resistance (Rct) in 
series with a Warburg impedance (Zw), see Figure 1.11 (a). The AC current through this 
circuit generates an equivalent impedance reflecting the ratio of the applied voltage to the 
measured current  which can be interpreted using a complex notation , where the real part 
(Z’) is attributable to resistors, and the imaginary part (Z’’), to capacitors. A constant 
phase element (CPE) is often replaces the capacitance in EIS measurements, see Figure 
1.11 (b), since it compensates the deviation of a real situation from an ideal behaviour 






Figure 1.12| EIS equivalent circuits models. (a) Randles circuit; (b) modified Randles equivalent 
circuit with constant phase element (CPE). Circuits created using PSTrace 5.7. 
 
EIS has been widely used in the characterization of batteries, fuel cells, coatings and 
corrosion phenomena; however, this technique is attracting much attention also in sensing 
technologies, such as immune-sensing[189] and DNA detection[190], because of its 
efficacy in determining parameters related to conductivity, capacitance or resistivity of an 
electrochemical system which can be influenced in a specific process. In addition, EIS has 
also been used commonly to characterise materials and to investigate electrodeposition, 
passivity, electro-dissolution and ion diffusion processes and semiconductor interfaces. 
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As discussed in Chapter 1, it is essential that people with diabetes maintain tight glycaemic 
control; finger-pricking remains the most used methodology to assess blood sugar, even 
though its association with stress and anxiety results in poor compliance. Recent advances 
in non-invasive glucose sensing technology also suffer from important drawbacks 
including (1) the need for regular calibration (which is most typically achieved by finger-
pricking), (2) local irritation, and (3) skipped measurements. The sensor developed in the 
research described in this thesis aims to overcome these limitations, to increase patient 
compliance, and to better manage hypo- and hyperglycaemia [1]. The technology, which 
has evolved from this work, enables non-invasive transdermal glucose extraction via 
preferential pathways which are selectively interrogated by a miniaturised and 
multiplexed sensing platform. Glucose detection is highly sensitive and selective due to 
the electrochemical properties of the nanomaterials embedded into the sensing electrodes. 
Moreover, the sensor is fabricated in an appealing patch-like design and with cost-
effective technologies [2]. This chapter articulates the development and characterisation 
of the main components of two distinct sensor prototypes, thin-film and screen-printed 
devices, focusing on the following aspects: 
1. Sensor functional operations, extraction and detection principles. 
2. Fabrication of the prototypes. 
3. Electrochemical characterisation of the reference electrodes. 
4. Electrochemical characterisation of the working electrodes. 
5. Device stability, and enzyme and electron-transfer kinetics. 
 
2.1.1 Sensing platform features 
The proposed device consists of a miniaturised pixel array in which single units operate 
as a mediator-free amperometric biosensor; each pixel is a stand-alone electrochemical 
cell including ionic and electronic elements, see Figure 3.1. 
The ionic portion of the system consists of a 0.1 M phosphate buffer saline (PBS) solution, 
gelled with agarose, containing a highly specific enzyme, glucose oxidase (GOD), used 
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as the biological sensing element. PBS plays different roles within the electrochemical 
cell: (1) providing  physiological pH 7.4, and ensuring the GOD activity by buffering the 
protons formed in the H2O2 oxidation at the surface of the working electrode (WE); (2) 
acting as a supporting electrolyte reducing the Ohmic drop in the cell and eliminating the 
migration current contribution from the redox species of interest; (3) ensuring an adequate 
chloride ion concentration to maintain the stability of the reference electrode (RE); and 
(4) enabling the required electrochemistry at the extraction electrode (EE) surface. 
The electronic part comprises a set of electrodes which are utilized in the glucose 
extraction and detection operations. The detection system of each pixel includes a 
graphene-based WE, decorated with platinum nanoparticles (PtNPs), which is used as the 
electrochemical transducer, and a Ag/AgCl electrode as counter/reference electrode 
(CE/RE). The EE pairs are also Ag/AgCl and can be easily miniaturized.  The use of 
Ag/AgCl for both the reference and extraction electrodes facilitates fabrication (although 
it must be remembered that the standard potential of the RE is dependent on the chloride 
ion concentration in solution).  
 
 
Figure 2.1| Key features of a thin-film single pixel device. WE: Platinum nanoparticles decorated 
CVD graphene double layer. RE/CE: Silver/silver chloride thin film. Reservoir: low-temperature 
gelling agarose and GOD in PBS.  
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2.1.2 Extraction process and principle 
The sensor employs reverse iontophoresis to create an electroosmotic flow through which 
glucose is transdermally extracted. Iontophoresis enables the transport of both charged 
and neutral compounds across the skin by the application of a small electric current [3], 
as depicted in Figure 2.2.  
 
 
Figure 2.2| Reverse iontophoresis schematic. A current I is passed between two electrodes, associated 
with conductive hydrogels, and induces electromigration of ions and an electroosmotic flow of solvent 
towards the cathode where glucose (G) is extracted. (1) paracellular route; (2) appendageal route; (3) 
transcellular route. Image modified from [4]. 
 
 
This process is symmetric and chemical species are pushed into and pulled out of the 
subdermal compartment [5]. While iontophoresis has been primarily used for transdermal 
drug delivery, reverse iontophoresis has the potential to be exploited in clinical chemistry 






from the subdermal interstitial fluid consequently to the application of a small electric 
current onto the skin [3]. As a result, ions migrate towards the reservoirs in contact with 
the extraction electrodes presenting opposite charge in a process known as 
electromigration [5]. However, at physiological pH, the skin presents a net negative 
charge which affects the outward electromigration of ions by acting as a cation 
permselective membrane; therefore, the migration of negatively charged ions (e.g., Cl-) 
towards the anodic chamber is impeded, while cations (e.g., Na+, K+) effectively migrate 
toward the cathodic chamber. Lastly, ion migration generates a flux of solvent which 
transports neutral molecules (e.g. glucose) in the direction of the cathode chamber by 
electroosmosis[6].  
The mechanism of extraction involves two iontophoretic transport phenomena: 
electromigration and electroosmosis, examined in detail below. 
Electromigration results from the direct imposition of an electric field by a power supply. 
The electric field causes both the migration of electrons in the “electrical” portion of the 
circuit (electric wires, tracks and electrodes) and the flow of ions in the “ionic” part (from 
the subdermal compartment to the electrodes dipped in the reservoir hydrogel) in the 
direction imposed by their charge. As a consequence, the multitude of ions involved in 
this transport mechanism compete to carry the charge to the electrode surface balancing 
the number of electrons migrating and, thus, maintaining the electroneutrality of the 
system [7]–[10]. Faraday’s law describes the resulting steady-state transport (equation 
2.1) relating the number of moles of ions (Mi) crossing the “membrane” to time (T), 







where F is Faraday's constant (96 487 C mol-1).  Thus: 
  












Given that the total current flowing must be: 









the concept of an ion transport number (ti) can be introduced to express the efficiency of 






The extraction flux (Ji, mol s
-1) is defined by the ratio of the number of moles (Mi) to the 










Moreover, the speed of migration of an ion is determined by its physicochemical 
characteristics and the ionic composition of the reservoir into which ions are collected; an 
ion can act as a primary charge carrier if it is small, at high concentration and is not subject 
to significant protein binding. 
Electroosmosis involves the transport of polar/neutral species to the cathode. At 
physiologic pH, the skin is negatively charged, thus cation permselective. When an 
electric field is applied, negatively charged ions (such as chloride ions) are forced to move 
by electromigration into the anode chamber, encountering some resistance from the 
negatively charged skin barrier, while the movement of positively charged ions (sodium, 
potassium ions, etc.) is directed toward the cathode and enhanced. Therefore, the stream 
of solvent, which follows the movement of cations, acquires an overall momentum 
towards the cathode chamber [6],[11]. As a result, the electroosmotic flow enhances the 
transport of polar, neutral or zwitterionic molecules to the cathode as well, while hindering 
the electromigration of anions. There are two main aspects to take in account during this 
process; the solvent volume flow (Jvs) is proportional to the potential gradient across the 
skin [11], [12], and the extraction flux of solute (Ji) is relatively independent of molecular 
size (as long as the solute diameter is inferior to that of the transport pathway). Pikal and 
Shah [13] first proposed the relationship between the molar flux (Ji) and concentration 
(Ci) of the solute 'i': 
  





Moreover, Santi and Guy [14] have demonstrated that pH and ionic strength are electrode 
formulation parameters that may modulate electroosmosis. 
In addition to electromigration and electroosmosis, passive diffusion of analytes through 
the skin may also occur [15]. The resulting flux (Jp) at steady-state is directly proportional 
to the concentration gradient (ΔCi) of the analyte across the membrane in accord with 







where h is the membrane thickness and Di is the analyte’s diffusivity across the 
membrane. 
Therefore, the total flux upon application of iontophoresis is the sum of the 
electromigration (Ji), electroosmosis (Jvs) and the passive diffusion (Jp) contributions. 
While electromigration dominates for charged species with low molecular weight (e.g. 
cations), electroosmosis prevails for the extraction of neutral molecules and large 
cations[5]; passive diffusion plays a minor role. It follows that, in reverse iontophoresis, 
glucose crosses the skin membrane predominantly via electroosmosis [6], [16]. 
 
Glucose iontophoretic extraction via preferential routes  
Generally, chemical species permeate the skin barrier by passive diffusion via three main 
pathways: transcellular (passing through cells), paracellular (passing through the 
intercellular spaces) and trans-appendageal (through sweat glands, sebaceous glands and 
hair follicles) [17]. Experimental evidence from many iontophoresis studies has shown 
that electrically facilitated flow occurs through preferential appendageal and intercellular 
routes [18], with sweat glands and hair follicles identified as the critical iontophoretic 
transport routes [19]–[21]. These appendages provide access to the living skin layers 
bathed in interstitial fluid and containing the analyte of specific interest in this work, 
namely glucose. It is reasonable to assume that electroosmotic flow, and hence glucose 
extraction, proceeds through these low resistance pathways [22], [23] and iontophoretic 
transport is therefore influenced by the density of pathways where the electric current is 
applied.   
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2.1.3 Detection  
In our sensing platform the key components involved in the detection of glucose are: a 
selective biorecognition element, glucose oxidase, and a hybrid nanomaterial transducer, 
either CVD graphene or graphene ink decorated with platinum nanoparticles. The 
detection process involves an initial, selective identification of glucose, despite the 
presence of other similar sugars, and its biochemical conversion that produces hydrogen 
peroxide (H2O2), and secondly, the diffusion of H2O2 to the sensing electrode where it is 
electrochemically oxidised (Figure 2.3). The importance of platinum nanoparticles and 
their characterization is examined in Chapter 3, section S2.  
 
 
Figure 2.3| Glucose detection process. Biochemical conversion of glucose producing H2O2 which is 
then electrochemically oxidised at the WE surface.  
 
The enzyme, glucose oxidase (GOD or GOx), is widely used in glucose biosensing. GOD 
catalyses the oxidation of β-D-glucose into D-glucono-1,5-lactone and H2O2 in the 
presence of oxygen (O2). This enzyme is a dimeric protein and its polypeptide chains are 
identical and linked by disulphide bonds; each subunit contains a tightly bound flavin 
adenine dinucleotide (FAD) prosthetic group. During the oxidation reaction, FAD works 
as the first electron acceptor and is reduced to FADH2; FADH2 is then oxidised back to 
FAD by molecular oxygen, representing the final electron acceptor. The biochemical 




Figure 2.4| Biochemical cascade. The apparent formal redox potential E’0 is considered versus the 
standard hydrogen electrode, SHE. E’0 expresses the tendency of a chemical species to accept or donate 
electrons. Electrons flow from the redox couple with the lowest reduction potential to that with the 
highest through the FAD/FADH2 intermediation. 
  
Glucose detection is achieved by amperometry, which is an electrochemical technique 
involving application of a constant potential at the WE, with respect to the RE, and the 
measurement of the catalytic current arising from the redox reactions occurring at the 
electrode surface (see Chapter 1 section 1.8.2.2). The derived amperogram displays the 
catalytic current as a function of time. The resulting Faradaic current is proportional to the 
analyte concentration (C) as defined by the Cottrell equation (Equation 1.6), which 
describes the current-time (I-t) dependency for linear diffusion control at  planar 
electrodes; therefore, the current depends on the rate at which the analyte diffuses toward 
the electrode [24], [25]. For example, when calibrating a glucose sensor, an increase of 
the Faradaic current is observed after each glucose addition. This is due to the high H2O2 
concentration at the WE surface undergoing a rapid conversion. When the Faradaic 
currents reach a plateau, the concentration gradient is established. Afterwards, the current 
falls, the diffusion field reaches steady-state and its extension into the bulk solution is 
limited by convection and Brownian motion [26]. 
In our sensing platform, glucose, following its reverse iontophoretic extraction, is 
collected into gel-reservoirs where it reacts with glucose oxidase to form H2O2. 
Successively, hydrogen peroxide diffuses toward the graphene-based working electrode 
and, upon reaching the surface of the platinum nanoparticles, undergoes electrochemical 
oxidation at a voltage of 0.4 V, applied against a Ag/AgCl quasi-reference microelectrode. 
When using a bare, unfunctionalized working electrode, H2O2 oxidises at 0.7 V [27], a 
value at which known interfering species, such as ascorbic acid, uric acid and 
acetaminophen, also oxidise [28]. However, even though the interferant contribution to 
the signal of the device is not eliminated, there is virtually no response from such species 
at physiologically relevant concentrations as shown by several experiments investigating 
real life relevant glucose-to-interferant ratios (see Figures 3.7, S16 and S17). 
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2.2 Materials  
Glucose oxidase type VII, lyophilised powder, ≥100,000 units/g solid (without added 
oxygen) for the electrochemical experiments, D-glucose, Na2HPO4, KH2PO4, NaCl, KCl, 
hydrogen hexachloroplatinate (IV) hydrate, H2SO4, FeCl3, AgCl, cellulose acetate, Nafion 
5% solution, chitosan and glutaraldehyde 5% solution were purchased from Sigma-
Aldrich (Dorset, UK). Low gelling temperature agarose was purchased from Fisher 
Scientific (Loughborough, UK). MilliQ-water was used for all solutions. All the materials 
used with physical vapour deposition techniques, Palladium (Pd), Titanium (Ti), Silver 
(Ag), Gold (Au) and Platinum (Pt), were acquired from Testbourne, Ltd (Basingstoke, 
UK). To deposit thin-film electrodes and platinum nanoparticles with a defined geometry, 
polyimide (Kapton) laser-machined stencil masks were obtained from Laser 
Micromachining, Ltd (Saint Asaph, UK). Silicon/silicon dioxide (300 nm oxide) was 
acquired from IDB Technology (Whitley, UK), 495 PMMA A3 (poly(methyl 
metacrylate)) from Microchem (Rugby, UK), Silcoset 151 silicone rubber from Farnell 
(Leeds, UK), Amicon ultracell 10K centrifuge tubes with regenerated cellulose from 
Merck Millipore (Darmstadt, Germany), conductive silver paint from Agar Scientific 
(Stansted, UK), PDMS (polydimethylsiloxane) curing agent (Elastomer Sylgard 184) 
from Sigma-Aldrich (Dorset, UK). SCE reference electrode was acquired from 
Radiometer Analytical (Lyon, France) and a DriRef2 reference electrode was purchased 
from World Precision Instruments (Sarasota, FL). The potentiostats used in the 
electrochemical experiments were an Ivium technology, CompactStat instrument 
(Eindhoven, The Netherlands) and a Multipalmsense 4 (Palmsens BV, Houten, The 
Netherlands). Screen-printed arrays were commissioned commercially from Seribase 
Industries (Chateau Gontier, France), using an Ag/AgCl ink (DuPont 5874), and a 
graphene-based ink (HDPlas Graphene Ink IGSC02002 from Haydale). Fresh pig skin 
was collected from a local abattoir and dermatomed (Zimmer®, Ohio, USA) to a nominal 
thickness of 750 µm, cut into suitably sized pieces, before being frozen, within 24 hours 
of slaughter, and thawed before use.  
The equipment used for the fabrication of the thin film devices included an electron beam 
evaporator, Edwards FL-400, and a thermal evaporator, Edwards AUTO 306 acquired 
from Edwards Vacuum (Burgess Hill, UK). For the physical deposition of platinum 
nanoparticles, a sputter coater HHV 500 (Hind High Vacuum, Ltd, Crawley, UK) was 
used. The characterization of thin film thickness employed contact profilometry with a 
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Dektak 6M (Bruker Corporation, Massachusetts, US). Imaging of samples used SEM 




2.3 Sensor fabrication and experimental procedures 
2.3.1 CVD graphene-based device fabrication 
The fabrication of a CVD graphene-based device is shown schematically in Fig 2.5. 
 
 
Figure 2.5| CVD graphene-based device fabrication. Single-pixel device construction. 
 
1. Working electrode and connections 
Chemical vapour deposited (CVD) graphene sheets, with typical dimensions of 2 x 1 mm2 
and originally synthesized on copper foils, were transferred onto either SiO2/Si or plastic 
substrates using standard procedures [29]. Briefly, 495 PMMA A3 was first deposited on 
top of graphene-copper squares by spin coating for 30 seconds, and later cured at 120˚C 
for 2 minutes. The coated graphene squares were then wet etched in a 1 M FeCl3 bath for 
6 hours; samples were further washed three times, 30 min each, with Milli-Q water. 
Finally, the samples were transferred onto the supports, left to air-dry for 15 minutes and 
successively incubated in acetone for 1 hour to wash out the PMMA residues. The 




layout in Fig. 3.6. Although low-energy oxygen plasma can be also used to etch graphene 
supported by plastic substrates, mechanical cutting (using a scalpel) was successfully 
employed to remove excess graphene from the pixel patches, avoiding possible short-
circuiting between the graphene working electrode and other electrodes and tracks. Prior 
to graphene transfer and tracks deposition, the flexible substrate was sonicated three times, 
in different solutions (respectively in DI H2O, acetone and methanol), for 15 minutes. 
2. Tracks and electrodes fabrication 
Polyimide (Kapton) stencil masks, tailored to the array layout, were progressively placed 
and aligned onto the PET-supported graphene patches to deposit thin-film tracks and 
electrodes with a defined geometry. A 500 nm Ag film was deposited on top of a 20 nm 
Pd layer (previously deposited to promote adhesion of the Ag layer to the PET substrate) 
by e-beam evaporation at a deposition rate of 0.8 nm/s. The deconstructed device 
fabrication involved the deposition of Ti and Au, 10 and 60 nm respectively, by thermal 
evaporation; silver paint provided the electrical connection to CVD-graphene. 
3. Reference electrode fabrication 
During development of the CVD graphene-based sensors, reference electrodes were 
created using physical vapour deposition (PVD) techniques. E-beam evaporation was used 
to deposit 20 nm of palladium, used as an adhesive layer, and 500 nm of silver with the 
same deposition rate of 0.8 nm/s. A 500 nm layer of silver chloride was successively 
deposited by thermal evaporation at a rate of 0.4 nm/s. 
4. Platinum nanoparticles deposition 
To enhance sensitivity towards H2O2, Pt nanoparticles were deposited onto graphene 
electrodes using two distinct methods. Electrochemical deposition by chronoamperometry 
for 1000 seconds in a 10 μL drop of solution, containing 1.7 µM hydrogen 
hexachloroplatinate and 0.1 M H2SO4, at -0.35 V against a Ag/AgCl micro-reference 
electrode (or at -0.5 V against a Pt pseudo-reference electrode). Cyclic voltammetry was 
performed to determine the platinum (IV) chloride reduction potential according to the 
following reaction: 
 
PtCl6 2- + 4e- → Pt + 6Cl- 
 
Alternatively, Pt nanoparticles were deposited by DC sputtering using appropriate stencil 
masks. Unlike the electrochemical formation of nanoparticles, sputter deposition 
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simplifies the scaling-up of the process bridging the gap between fundamental research 
and industrial application. Particles showing a mean diameter of 4.5 nm were produced 
by tuning the Ar gas pressure at 10 cm3/min and applying a power of 10 W. 
Characterisation of the resulting Pt nanoparticle-CVD graphene hybrid material is 
discussed in Chapter 3 section S2. 
5. Elastomer fabrication and transfer 
After PtNPs deposition, the graphene-metal junctions were insulated with a 
polydimethylsiloxane (PDMS) or a silicone rubber frame, for the single-pixel device, 
patterning the holes which would eventually contain the hydrogel reservoirs. PDMS was 
mixed with the curing agent, spin-coated on a PET support and successively cured at 70˚C 
for 10 min, resulting in a 100-μm thick membrane. After careful underwater peeling in a 
de-ionized water bath, the PDMS membrane was transferred onto the pixel array, ensuring 
alignment of the sockets to the electrochemical cell of each pixel.  
6. Gel casting and enzyme entrapment 
The gel reservoirs of each pixel were produced as follows: (1) 12 µL of PBS, containing 
8 mg/mL of glucose oxidase, was pipetted directly onto the graphene area, as defined by 
the PDMS or silicone rubber frame; (2) a clear 0.1M, pH 7.4, PBS-agarose solution, with 
a polymeric concentration of 1% w/v, was prepared by warming the mixture at 80˚C, until 
total dissolution of agarose; (3) after cooling the solution below the gelling temperature 
of ca. 36˚C, 12 µL of the gel were added to the enzyme solution, such that the enzyme’s 
catalytic and structural properties were maintained [30] and enabling its efficient gel-
entrapment. 
 
2.3.2 Screen printed device fabrication 
The fabrication of screen-printed arrays was commissioned to a company that complied 
with industrial manufacturing standards. The design was that of CVD graphene-based 
devices described above. Serigraphy permitted the production of 6 µm-thick Ag/AgCl 
electrodes, designed to increase the stability and lifetime of the reference and extraction 
electrodes. A biocompatible, electrically insulating layer, ca.1 µm thick, was printed onto 
the device to cover the conductive tracks of the pixel array. Pt nanoparticles were sputter 
deposited as described for the thin-film/CVD graphene arrays. A PDMS layer was finally 
aligned with the pixels, and the array was completed by placing gel patches on top of the 
active areas.  
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2.3.3 Experimental procedures 
All the electrochemical measurements were made using an Ivium Technology, 
CompactStat instrument (Eindhoven, The Netherlands), at room temperature. 
1. Characterisation of thin-films and screen-printed Ag/AgCl reference 
electrodes 
Chronopotentiometry, at open circuit potential (OCP), was selected as the electrochemical 
technique to investigate the stability of the fabricated reference electrodes. Potentiometry 
evaluates the voltage between cathode and anode; if operating at OCP, no electric current 
is passed through the electrodes. The electrodes under investigation were tested against a 
commercial reference electrode, Ag/AgCl DriRef2, or a saturated calomel electrode, in 
solutions containing either 0.1M PBS or saturated KCl. Cyclic voltammetry was 
conducted in a solution containing 0.1 M PBS and 0.01 M [Fe(CN)6]
3-/4-at a scan rate of 
25 mV/s. The potentiostat was used in three-electrode mode using a glassy carbon 
electrode as a WE, platinum wire as a CE, and the various Ag/AgCl electrodes as REs. 
2. Characterisation of CVD graphene and screen-printed working electrodes 
Cyclic voltammetry was employed to characterise both the CVD graphene- and graphene 
ink-based working electrodes, with and without platinum nanoparticle decoration. The 
potentiostat was used in three-electrode mode, connecting the electrodes under 
examination to the working electrode terminal, a platinum wire to the auxiliary terminal, 
and a commercial DriRef2 reference electrode to the reference terminal. The 
voltammograms were recorded in a solution containing 1M KCl and the electrochemical 
probe employed to study the behaviour of the working electrodes was the [Fe(CN)6]
3−/4− 
redox couple at a concentration of 0.01 M. The voltammograms were acquired at different 
scan rates ranging from 12.5 to 200 mV/s. 
3. Thin-film and screen-printed devices response to glucose  
Chronoamperometry was used as the electrochemical technique to assess the response of 
the sensors to glucose. A constant voltage of 0.4V was applied to the working electrodes 
(CVD graphene or graphene ink) against the respective reference electrodes (thin-film or 
screen-printed Ag/AgCl). The potentiostat was used in two-electrode mode, connecting 
the graphene electrodes to the working electrode terminal and the reference electrodes to 
the short-circuited auxiliary/reference terminal. The device calibration was achieved by 








containing glucose oxidase. The experiments were performed using 3-8 µL reservoir 
volumes in a high humidity chamber to prevent water evaporation and gel shrinking. 
4. Graphene ink functionalisation experiments 
2 µL of a solution of either cellulose acetate 1.5%-nafion 2.5% (1:1 ratio), or nafion 5% 
and chitosan 1%-glutaraldehyde 2.5% (1:1 ratio), were drop-casted onto distinct graphene 
ink electrodes. The newly formed membranes were air-dried overnight. Then, before use, 
0.4 µL of glucose oxidase (8 mg/mL) was pipetted onto the membranes and air-dried for 
15 minutes. 
 
2.3.4 Data analysis: glucose calibration curves 
For the chronoamperometric measurements, the catalytic and background currents were 
averaged over 15 seconds and determined for each chronoamperometric step (plateau) 
according to the equation: 
 
𝐼[𝑓𝑎𝑟𝑎𝑑𝑎𝑖𝑐] = 𝐼[𝑝𝑙𝑎𝑡𝑒𝑎𝑢] − 𝐼[𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑖𝑣𝑒] 
 
The faradaic currents were subsequently plotted as a function of glucose concentration. 
The resulting calibration curves were therefore fitted to a linear model and R2 calculated 









𝑆𝑆𝑇 = 𝑆𝑆𝐸 + 𝑆𝑆𝑅 
 
 
where SST is the sums of squares of total variability about the mean, SSR is the sums of 
squares due to regression, representing the variation around the linear relationship 
between x and y: 
 
𝑆𝑆𝑅 = ∑(𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑌 𝑣𝑎𝑙𝑢𝑒 − 𝑚𝑒𝑎𝑛 𝑌 𝑣𝑎𝑙𝑢𝑒)2 
 
 
SSE is the error sum of squares representing the variability which cannot be explained by 
the regression line:  
 
 





2.3.5 Performance of the sensors 
The biosensor response to an analyte must be evaluated according to standard IUPAC 
definitions. Suitably, this work identifies different parameters describing calibration 
features (such as sensitivity, linear concentration range, detection and quantitative 
determination limits), selectivity, reproducibility and stability for the prototype sensors. 
The sensitivity can be assessed from the slope of a calibration curve (i.e., a plot of steady-
state responses, corrected for a background signal, versus the analyte concentration). This 
approach, however, is only applicable over the linear range of a calibration curve where 
the sensor signal is indeed proportional to the concentration. The limit of detection (LOD) 
is defined by the International Conference of Harmonisation (ICH) as: “the lowest amount 
of analyte in the sample, which can be detected but not necessarily quantitated under stated 
experimental conditions”, and is differentiated from the limit of quantitation (LOQ) 
defined as: “the lowest amount of analyte in a sample, which can be quantitatively 
determined with suitable precision and accuracy” [32].  
The sensor response LOD is estimated using the standard deviation of the response (σ) 
(corrected for the background noise) and the slope (S) of the calibration curve as: 
 
 











2.4 Results and discussion 
2.4.1 Characterization of the reference electrodes 
The reference electrode has a steady and defined potential and its role in electrochemistry 
is essential. The Ag/AgCl RE has various advantages compared to other materials, 
including the feasibility of scaling-down the electrode dimensions using microfabrication 
techniques [33]–[35], and thereby permitting it to be embedded in microfluidics and lab-
on-chip systems [36]–[38]. Amperometric measurements require a stable reference 
electrode to avoid variation of the sensor response throughout the detection time; however, 
despite their typical potential stability when normally fabricated [39], [40], thin-film 
Ag/AgCl electrodes usually show poor stability. This section assesses the stability of 
diverse Ag/AgCl REs in various conditions.  
 
 
Figure 2.6| Stability of thin film Ag/AgCl reference electrodes. (a) Cyclic voltammogram in 0.1 M 
PBS, 0.01M [Fe(CN)6]3-/4- solution; (b) potentiograms of the fabricated reference electrodes vs 
commercial DriRef2. 
 
An initial investigation addressed the AgCl deposition procedure, specifically thermal and 
e-beam evaporation, that produced the most stable electrodes. As shown in Figure 2.6, 
both deposition techniques produce stable Ag/AgCl reference electrodes. The cyclic 
voltammograms in panel (a) demonstrate that the laboratory-fabricated electrodes (blue 
and red curves) were qualitatively comparable to the commercial reference (green curve); 
the x-axis shifts were 93 ± 2 mV and 114 ± 3 mV, respectively, for the thermal and electron 
beam deposited electrodes, reflecting the different redox equilibria at the electrode 
surfaces. In fact, the laboratory-fabricated Ag/AgCl electrodes are quasi-reference 
electrodes meaning that, in contrast to commercial reference electrodes (which are 
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immersed in a saturated KCl solution), they are directly placed in the bulk solution and 
their potential is, therefore, directly related to the chloride ion concentration (i.e., 0.1 M 
in this experiment). Panel (b) depicts the potentiograms recorded over a 3-hour period, in 
a 0.1 M PBS solution, under an open circuit potential. The voltage difference measured 
between the fabricated reference electrodes vs the commercial reference was 82 ± 3 mV. 
As the commercial electrode has a nominal potential of 210 mV, the potential of the 
laboratory-fabricated reference electrodes is in the range of 289-295 mV (vs SHE). 
Although, the electrode samples were produced with different physical deposition 
methods, their potential difference at open circuit (vs the commercial reference DriRef2) 
was similar in samples in which AgCl deposition was tuned at a rate of 0.4 nm/s. This can 
be attributed to differences in AgCl particle dimensions which directly affect both the 
junction potentials at the interface between silver and silver chloride and between silver 
chloride and bulk solution (see Figure 2.7). 
 
 
Figure 2.7| FESEM images of a thin-film AgCl layer and a screen-printed Ag/AgCl paste. (a) 
Physically deposited silver layer; (b) physically deposited AgCl layer; (c-d) screen-printed Ag/AgCl 
ink at different magnifications. 
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The long-term stability was also assessed for second-generation prototype REs produced 
by screen printing. Potentiometric measurements vs SCE in 0.1M PBS solution are shown 
in Figure 2.8. The screen-printed reference electrode proved to be stable for >3 hours, 
and further experiments confirmed even longer-term stability after 10 hours of continuous 
exposure to a saturated KCl solution. The voltage difference (against SCE) of thin-film 
and screen-printed electrodes was comparable at 37 ± 4 mV in 0.1M PBS. Dissolution of 
the thin AgCl layer has been ascribed as a cause of electrode instability, causing the 
development of mixed potentials at the electrode/solution interface[41]. Although silver 
chloride is sparingly soluble (with a solubility product constant, Ksp, of 1.8 x 10
-10 M, Ksp 
= [Ag+][Cl-]), micro- and nano-scale phenomena, including the high surface-area-to-
volume ratio, high ionic strength and Ostwald ripening effects, may accelerate dissolution 
rate and increase the local solubility of the salt. In addition, and in contrast to macro-
reference electrodes, the stability of miniaturised reference electrodes is further 
compromised in solutions of high Cl- concentration because of the formation of chloro-
complexes of Ag(I) [42]. In fact, while the screen-printed electrode is also stable in 
saturated KCl, all the vapour-deposited Ag/AgCl electrodes lose their stability, in the same 
solution, after ca. 2 hours. As a consequence, the loss of the stability of the thin-film 
reference electrode shown in Figure 2.8 (b) can be attributed to complete depletion of the 
thin AgCl layer; a change of the electrode colour from purplish (attributed to AgCl) to 
silver has been observed. 
 
 
Figure 2.8| Stability of Ag/AgCl screen-printed reference electrode. (a) Comparison of thin-film 
Ag/AgCl screen-printed and commercial reference electrodes, at OCP, vs SCE in 0.1M PBS; 
respectively, thermally deposited RE (blue), commercial RE (green) and screen-printed RE (brown). 
(b) Long-term potentiometric measurements of thin-film and screen-printed Ag/AgCl electrodes vs 
SCE in saturated KCl. 
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The sensitivity towards chloride ions in solution was investigated to further characterize 
the reference electrodes; the experiment involved sequential additions of 0.3 mL of 
increasingly concentrated chloride ion solutions to 25 mL of Milli-Q water. Figure 2.9 
shows the response of different REs. The inset depicts the potential difference vs the 
commercial Ag/AgCl reference as a function of the chloride ion concentration on a 
logarithmic scale. The results show that all electrodes responded linearly over the chloride 
range investigated (0.001M - 1 M) with very similar slopes (sensitivities) close to that of 
the theoretical Nernstian value of 59.2 mV/p[Cl-].  The screen-printed reference electrode 
had a sensitivity of 59.08 ± 1.04 mV/p[Cl-], while that of the thin-film electrode was 57.6 
± 2.4 mV/p[Cl-]. 
  
 
Figure 2.9| Sensitivity of the reference electrodes towards chloride ions. Comparison of 
potentiometric curves showing the sensitivity of thin-film and screen-printed reference Ag/AgCl 
electrode to chloride ions. The electrodes considered were e-beam deposited at 0.4 nm/s (red), e-beam 







2.4.2 Electrochemical characterization of CVD-graphene electrodes 
The electrochemical behaviours of the bare and nanoparticle-modified CVD graphene 
electrodes were assessed by cyclic voltammetry, in 1 M KCl solution and using 0.01 M 
[Fe(CN)6]
3−/4− as a redox probe, at scan rates ranging from 12.5 to 200 mV/s (Figure 2.10). 
The addition of PtNPs onto the working electrode enhances electron transfer during the 
electrochemical reaction by increasing the electroactive surface area and acting as an 
electron transfer medium. As a result, the PtNPs modified electrode (panel b) exhibited 
higher catalytic currents and a lower peak-to-peak separation (Δ𝐸𝑝), compared to bare 




Figure 2.10| Electrochemical characterisation of CVD graphene-based electrodes. Cyclic 
voltammograms recorded at (a) bare CVD graphene, and (b) platinum nanoparticle-modified, 
electrodes. Insets show the corresponding plots of anodic peak currents versus scan rate1/2. 
 
The Randles-Sevcik equation describes the magnitude of the voltammetric current (ip) 
developed at a macroelectrode and can be used to calculate the electroactive surface area 
(A) of an electrode:  
 
𝑖𝑝 = 2.69 · 10
5 · 𝑛3/2 · 𝑣1/2 · 𝐷1/2 · 𝐴 · 𝐶 
 
where 𝑛, v, 𝐴, 𝐷 and 𝐶 are the number of electrons, scan rate, electrode area, diffusion 
coefficient (cm2 s−1) and concentration (in mol⋅L−1) of the electroactive chemical species, 
respectively [26]. The electroactive surface is related to the number of conductive sites on 
the electrode that effectively transfer charge to the electroactive chemical species in 
solution. While the geometric area of the electrodes used was 2 mm2, the real surface areas 
for the modified electrode and bare CVD graphene were calculated to be 0.51 mm2 and 






imperfect transfer of graphene or a contamination of its surface by the PMMA polymer 
used for its transfer, causing interruptions of the graphene sheet which impacts on 
electrode performance. The reversibility of the electrochemical process, at the electrode 
surfaces, can be assessed using the peak-to-peak separation of the voltammograms. For 
example, in an electrochemically reversible process, the peak separation can be calculated 
as follows: 





where Δ𝐸𝑝 is the minimum theoretical peak-to-peak separation, 𝐸pa is the anodic peak 
potential, and 𝐸pc is the cathodic peak potential. While, in a reversible electrochemical 
process both oxidation and reduction peaks are observed and the peak-to-peak separation 
approaches a value of 59 mV, only one peak can be detected in an irreversible 
electrochemical reaction [26]. The Δ𝐸𝑝 values for the bare and PtNPs-modified CVD 
graphene electrodes were 964 and 81 mV, respectively. These values are higher than the 
theoretical Δ𝐸𝑝 of 59 mV, indicating a quasi-reversible behaviour of the electrochemical 
redox reaction at both electrodes. The addition of platinum nanoparticles clearly affected 
the physicochemical properties of the CVD graphene working electrodes. Further, the 
heterogeneous electron transfer rate kinetics constants (k0) of the electrodes were used to 
examine the electrochemistry at the electrodes, via the Nicholson equation, for a quasi-
reversible electrochemical reaction: 







where 𝜓 is a dimensionless kinetic parameter, D is the diffusion coefficient of the 
electroactive chemical species, n represents the number of electrons participating in the 
process, F is the Faraday constant,  is the scan rate, R is the molar gas constant, and T is 
the absolute temperature. The kinetic parameter, 𝜓 , is calculated as a function of peak-
to-peak separation (Δ𝐸𝑝), at a set temperature (293.15 K) and for a one-electron process, 
according to the following equation [43]: 
 
𝜓 =
−0.6288 + (0.021 ∙ 𝛥𝐸𝑝)










to this method, the heterogeneous electron transfer rate constant values for the bare and 




2.4.3 Electrochemical characterization of the screen-printed graphene 
electrodes 
Cyclic voltammetry was performed on bare and platinum nanoparticles modified 
graphene-ink electrodes. Figure 2.11 shows the CV curves of the [Fe(CN)6]
3−/4− redox 
probe acquired using the thick-film devices. Graphene ink electrodes produced 
voltammograms comparable to those obtained using the CVD graphene electrodes. In fact, 
the platinum nanoparticles modification improved the catalytic current response of the 
electrodes compared to bare graphene ink; as already discussed, this effect is ascribed to 
the correlation between the electroactive sites at the working electrode surface and the 
effective charge transfer to the species in solution. Likewise, the quasi-reversible 
electrochemical response of the [Fe(CN)6]
3−/4− probe was observed at both types of thick-
film electrodes. The effect of the addition of platinum nanoparticles is thus confirmed and 
implicates the reduction of the peak-to-peak separation because of the increased 
electroactive surface area and the enhanced electron transfer constant. 
 
 
Figure 2.11| Electrochemical characterisation of screen-printed graphene ink electrodes. Cyclic 
voltammograms recorded at (a) bare graphene ink, and (b) platinum nanoparticles-modified electrodes. 
Insets show the corresponding plots of anodic peak current versus scan rate1/2. 
 
The Randles-Sevcik equation (Equation 2.15) was used to calculate the electroactive 
areas of the bare and modified graphene ink electrodes yielding, respectively, 0.49 mm2 
and 1.84 mm2. The larger electroactive area of the graphene ink electrodes could be a 
result of ‘electrocatalytic’ effects deriving from the presence of many edge plane-like sites 
and defects on the basal plane of the graphene flakes in the ink. However, the calculated 
surface area is still lower than the geometrical area of 2 mm2; given that the printing inks 
contain specific polymeric binders (such as polyvinyl chloride, cellulose acetate, 
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polyaniline, polyvinyl ferrocene acrylamide, phthalates, or silicon binder) to enhance 
adhesion [44], this observation may be due to the binders hindering analyte diffusion to 
the electroactive sites. The Δ𝐸p values for the bare and PtNPs-modified graphene ink 
electrodes were 722 and 73 mV, respectively, and are greater than 59 mV, indicating a 
quasi-reversibility of the electrochemical redox reaction at both electrodes. According to 
the Nicholson method, the calculated values of the heterogeneous electron transfer rate 
constant for the bare and PtNPs modified graphene ink working electrodes were, 
respectively, 1 x 10-4 cm/s and 1.4 x 10-3 cm/s. Figure 2.12 shows SEM images of the 
bare and PtNPs-modified graphene ink electrodes. 
 
 
Figure 2.12| SEM images of thick-film screen-printed graphene ink electrodes. (a-a’) SEM of bare 
graphene ink, and (b-b’) PtNPs-modified, electrodes.  
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2.4.4 Performance of the sensor 
The robustness and reliability of the sensor were assessed from the repeatability and 
stability of detection over time. First, the amperometric readouts were recorded for 4 
consecutive sets of glucose additions to evaluate the repeatability of the device. Figure 
2.13 illustrates the chronoamperometric curves and averaged current obtained for a CVD 
graphene-based pixel; the error bars represent the standard deviation around the mean and 
confirm, over the glucose range of 3 to 21 µM, a small variation, i.e., about ±1.2 nA, in 
the sensor response. 
 
Figure 2.13| Repeatability of a CVD graphene-based device. (a) Amperometric curves following 
consecutive calibrations. (b) Current as a function of glucose concentration plot; each point represents 
the mean ± standard deviation (n = 4). 
 
Stability of the screen-printed sensors was assessed, over 5 weeks, by measuring their 
response to glucose. In addition, to improve the performance and robustness of the device, 
a series of functionalized working electrodes was prepared and examined (Figures 2.14 
and 2.15). The devices were stored sealed, at room temperature. In this set of experiments, 
0.4 µL of glucose oxidase in 0.1 M PBS was drop-cast onto the bare and functionalised 
graphene electrodes and allowed to air dry prior to placement of the gel reservoirs onto 
each pixel. Figure 2.14 shows the repeatability of the calibration experiments for different 




Figure 2.14| Repeatability of screen-printed devices with different graphene ink 
functionalizations. Current as a function of glucose concentration for bare graphene ink, 
cellulose/Nafion, Nafion and chitosan/glutaraldehyde electrode functionalizations. Each point 
represents the mean ± standard deviation (n = 4). 
  
 
Figure 2.15| Stability of screen-printed graphene ink devices with different functionalizations. 
Amperograms of device response to glucose additions, measured over a period of 35 days: (a) bare 




Figure 2.15 illustrates the stability as a function of ageing of the electrodes. The electric 
response of the devices progressively decreased over a 5-week period due to deterioration 
of the transducer surface (especially the platinum nanoparticles); at least in part, this may 
be due to the mounting and discarding of the gels and to the repeated washing of the pixels 
which can cause mechanical damage to the electrodes. The readouts obtained after 13 and 
35 days are similar for the cellulose acetate/Nafion and chitosan/glutaraldehyde 
membranes. Overall, the performance of the various electrodes was comparable, with the 
chitosan/glutaraldehyde membrane achieving the highest sensitivity; this is probably 
because the enzyme is better incorporated in this membrane and H2O2 dispersion is 
therefore reduced. The cellulose acetate/Nafion membrane showed the least fall-off in 
catalytic efficiency, suggesting that improved robustness of the device may benefit long-
term sensitivity. The performance data are summarised in Table 2.1. 
 
 
Table 2.1: Performance of the sensing platforms with different graphene ink functionalizations. 
Functionalization 
Average sensitivity over 
35 days (µA·mM-1·cm-2) 
r2 
Decrease in catalytic 
efficiency over  5 weeks 
Bare graphene ink 45.9 0.999 -28.6% 
cellulose acetate 1.5% 
- Nafion 2.5% 
39.1 0.999 -13.3% 
Nafion 5% 50.9 0.999 -35.9% 
chitosan 1% 
- glutaraldehyde 2.5% 











2.4.5 Sensor enzyme kinetics 
In electrochemical biosensing, the upper limit of the linear concentration range is directly 
related to the biocatalytic properties of the bio-transducer element; in the case of the 
sensors developed here, this limit is related to the enzymatic reaction of glucose oxidase, 





where v is the reaction velocity, Km is the apparent Michaelis-Menten constant (the 
substrate concentration at half-maximum reaction rate), Vmax is the maximum reaction 
velocity, and [S] is the substrate concentration. Algebraical transformations of the 
Michaelis-Menten equation are typically used to plot experimental data. For example, the 
apparent Michaelis constant (indicative of the enzyme-substrate kinetics for the biosensor) 













where iss is the steady-state current after the addition of substrate, imax is the maximum 
current measured under saturated substrate conditions, and S is the bulk concentration of 
the substrate. Other methods to analyse enzyme kinetics employ the Eadie-Hofstee plot, 
defined by the equation: 














In the Eadie-Hofstee plot, Vmax is determined from the intercept and Km from the slope. 
The Hanes-Woolf plot is more complicated with Vmax being obtained from the slope, and 
Km/Vmax from the intercept. To characterise the sensor enzyme kinetics, the three 
approaches above were applied to results obtained from both the thin-film and screen-
printed devices, and Km and Vmax (i.e., the upper, limiting current) were assessed and 




Figure 2.16| CVD graphene-based device enzyme kinetics. Lineweaver- Burk plot, Eadie-Hofstee 




Figure 2.17| Graphene ink-based device enzyme kinetics. Lineweaver- Burk plot, Eadie-Hofstee 
diagram and Hanes-Woolf plot for a screen-printed device. 
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From the different approaches, it was possible to deduce averaged Km values for the thin-
film and screen-printed devices of 1.38 and 1.81 mM, respectively. These results are 
consistent with those reported for other glucose oxidase-based sensors in the literature 
(Table 2.3).  
 




 generation of 
glucose biosensors 
References 
1.67 1st [46] 
6.3 3rd [47] 
1.5 2nd [48] 
2.35 1st [49] 
1.38 
1.81 






This Chapter has introduced a novel concept for glucose sensing. The principle involves 
individually accessing preferential skin pathways for the electro-osmotic extraction of the 
ISF-borne glucose using a miniaturised pixel array device. The design of the device 
permits low gel reservoir volumes and a fixed dilution factor which is a step-change in 
glucose monitoring as it enables calibration-free operation; therefore, it is possible to 
remove the significant barriers towards ubiquitous glucose monitoring in people with 
diabetes. A prototype pixel of our proposed multiplexed platform shows dramatically 
smaller dimensions of ca. 9 mm2 compared to the sampling area of the GlucoWatch® that 
was about 1 cm2. The latter created undesirable and variable dilution that inevitably 
affected measurement accuracy and the relationship, therefore, between device response 
and glycaemia. 
 
The initial characterization of two sensor prototypes, thin-film and screen-printed based 
platforms, has also been presented. The DC-sputtered platinum nanoparticles and the 
glucose oxidase, entangled in the gel reservoirs, act synergistically in the catalytic sensing 
of H2O2, the enzyme bioproduct, enabling the application of a lower detection potential 
and enhancing the faradaic current response of the sensors. Decent stability and 
repeatability were established for different graphene ink functionalizations. In addition, 
kinetic parameters, such as the heterogeneous electron transfer rate constant and the 
apparent Michaelis-Menten constant, have been derived and demonstrate that the 
proposed sensing platform is competitive with other electrochemically-based glucose 
biosensors.   
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A., 2018. Non-invasive, transdermal, path-selective and specific glucose monitoring via a 




The chapter structure reflects that of the published paper discussing Methods after the 
Conclusion section. A Supplementary Information section will follow the main text and it 
will include few additional data to that already published. 
The primarily aim of this work is to introduce a minimally invasive glucose biosensor 
which would greatly benefit diabetics in reaching their strict glycaemic targets. The 
technology is based on an innovative principle which involves the extraction of glucose 
quanta through preferential pathways located on the skin. To fully demonstrate and 
validate this idea, preliminary tests were conducted using a deconstructed sensor model; 
besides, tremendous efforts have been made toward the fabrication of the first prototypes 
fully enabled to extract and detect the subdermal glucose concentration on the same 
platforms. Experiments were performed (1) in-vitro, primarily to characterize the sensor 
response to glucose, (2) ex-vivo on mammalian skin, to elucidate the relationship between 
number of hair follicles hit and the concentration of the extracted glucose, and finally (3) 
in-vivo on a healthy human volunteer, to proof the sensor functional operations in a real-











 Non-invasive, transdermal, 
path-selective and specific 




Currently, there is no available needle-free approach for diabetics to monitor glucose 
levels in the interstitial fluid. Here, we report a path-selective, non-invasive, transdermal 
glucose monitoring system based on a miniaturized pixel array platform (realized either 
by graphene-based thin-film technology, or screen-printing). The system samples glucose 
from the interstitial fluid via electroosmotic extraction through individual, privileged, 
follicular pathways in the skin, accessible via the pixels of the array. A proof of principle 
using mammalian skin ex vivo is demonstrated for specific and ‘quantized’ glucose 
extraction/ detection via follicular pathways, and across the hypo- to hyper-glycaemic 
range in humans. Furthermore, the quantification of follicular and non-follicular glucose 
extraction fluxes is clearly shown. In vivo continuous monitoring of interstitial fluid-borne 
glucose with the pixel array was able to track blood sugar in healthy human subjects. This 
approach paves the way to clinically relevant glucose detection in diabetics without the 
need for invasive, finger-stick blood sampling. 
 
3.1 Introduction 
The World Health Organization predicts that the worldwide incidence of diabetes will 
increase from 171 million in 2000 to 366 million in 2030[1]. An essential feature of 
diabetic care is the regular monitoring of blood glucose, which is conventionally carried 
out via an invasive finger-stick procedure. However, this approach suffers from significant 
user resistance, primarily because of the pain and discomfort associated with it. The 
relatively recently developed implantable and microneedle-based temporary sensors[2]–
[4], which are important for patients with very brittle Type 1 diabetes, are not a suitable 
or economically viable solution for the much larger (and rapidly growing) number of Type 
2 sufferers of the disease[5]. Non-invasive methods have been proposed such as the 
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detection of glucose in sweat[6]–[8], tears[9], [10] or saliva[11], but these strategies have 
two limitations. First, there is significant variability in the level of glucose detected. 
Second, the proportionality between the measured glucose concentration in these fluids 
and that in blood is unknown. Inevitably, therefore, calibration via a finger-stick is 
required. Impedance and spectroscopic (for example, infrared) techniques have also been 
investigated[12]–[14], but, in addition to the calibration challenge, these methods suffer 
from interference and a consequent lack of specificity. So far, the only technology to offer 
non-invasive, continuous glucose monitoring uses reverse iontophoresis (RI) to extract 
interstitial fluid (ISF) though the skin via electroosmosis[15]. This approach was 
embodied in the GlucoWatch Biographer[16], [17], which received US Food and Drug 
Administration approval in 2001. With this method, a small electric field is applied across 
the skin, causing ion flow to occur. Because, under normal physiological conditions, the 
skin is net negatively charged, there is an electroosmotic flow of ISF from within the skin 
towards the cathode on the skin surface[18], where glucose is detected and quantified. The 
GlucoWatch exploited the known correlation between ISF and blood glucose 
concentrations[19], [20] (and the inter-individual consistency of the overlap between 
glucose levels in the ISF and capillary and venous blood levels during rapid changes in 
glycaemia[21]–[23]) to provide essentially continuous monitoring of blood sugar for up 
to 12 h. However, a finger-stick calibration remained a requirement, primarily because 
glucose was extracted indiscriminately and variably across a relatively large area of skin 
(> 3 cm2) and underwent substantial dilution before quantification. Therefore, the device 
did not exploit the fact that most of the electroosmotic flow during iontophoresis follows 
low-resistance, preferential pathways associated primarily with hair follicles[24]–[26]. 
This is the basis for the concept proposed and tested here (Fig. 3.1), specifically a device 
with an array of miniature ‘pixels’, into some of which ISF drawn through the skin is 
captured electro-osmotically into a known, small volume, permitting calibration-free 
detection of systemic glucose concentration. This is achieved by fixing the area and 
volume of the pixels so that the dilution factor of the extracted glucose is constant and 
independent of follicular density (Fig. S1). Given the range of hair densities on 
conveniently accessible sites on the human body (for example, 18–36 hairs per cm2 on the 
arms, thorax and thighs[27]), a correctly chosen array ensures that the majority of 
individual pixels interrogate a single preferred pathway, that a redundancy of these 
pathways can be interrogated (Figs. 3.2) and that the variability in detection seen with the 
GlucoWatch (and a more recent ‘tattoo’-type version thereof[28]) can be avoided and the 
fingerstick calibration requirement relaxed.  
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3.1.1 Concept of path-selective glucose monitoring platform 
A miniature, individual pixel of such an array that embodies/ achieves this principle 
comprises the following (Fig. 3.2 (a)): (1) a glucose oxidase-bearing hydrogel reservoir, 
into which glucose is transdermally extracted, (2) an electrochemical glucose sensor, 
specifically a graphene-based film decorated with Pt nanoparticles for enhanced 
sensitivity, and (3) miniaturized electrodes suitable for sensor electrochemistry and RI, all 
supported by a flexible substrate. The first-generation prototype we produced relied on 
thin-film technology, including chemical vapour deposition (CVD) graphene incorporated 
in a Pt nanoparticle–graphene hybrid material. Graphene is the preferred material because 
of its mechanical resilience, high conductivity and low capacitive background[29], large 
surface area, suitability for patterning and device integration via standard microfabrication 
techniques[30], environmental sustainability and anticipated low cost[30], [31] (relative 
to the use of noble metals) in a commercial product. A second-generation prototype used 











Figure 3.1| Sensor working principle, exploiting the preferential pathways of the skin. Preferential 
glucose pathways (that is, hair follicles) are targeted by individual, miniature pixel extraction–detection 
devices. With a sufficiently dense pixel array and the correct pixel size, a number of such pathways are 
sampled randomly and individually by the pixel devices. In this way, the concentration of glucose 




Glucose extracted by RI reacts with glucose oxidase to produce hydrogen peroxide, which 
is detected by the electrochemical sensor. Crucially, the active area of the pixel device 
(into which glucose is extracted) enables access to a single follicular pathway (Fig. 3.1). 
Assuming an average follicular density of 27 follicles per cm2 (at the sites mentioned 
above[27]), an active area of 2–6 mm2 maximizes the probability of hitting a single follicle 
in a randomly positioned, untargeted measurement (Fig. 3.2 (a)). A 4 × 4 array of pixels 
guarantees at least one follicular hit, while larger arrays ensure useful redundancy. Further 
restricting the pixel active area to 2–5 mm2 ensures the dominance of single follicular hits 
per pixel across the follicular density range of 18–36 hairs per cm2 (Figs. 3.2 (b), S2 and 
S3). The gel volume in a pixel additionally determines the extent of dilution of the 
extracted glucose, and hence the concentration range over which the sensor operates.  
 
 
Figure 3.2| Principle of a pixel-based array targeting transdermal individual preferential glucose 
pathways. (a) probability P that the array has at least one working pixel with just a single pathway per 
pixel (calculated at 27 follicles per cm2; that is, the median value across a typical follicular density 
range at easily accessible skin sites in humans), as a function of pixel active area and for various 
numbers of pixels in the array. Here, the active area is defined as the pixel device area through which 
glucose extraction takes place, coinciding with the footprint area of the gel reservoir (Fig. 3.4). (b) 
probability P as a function of pixel active area for a 4 × 4 array for three selected follicle densities 
spanning the follicular density over a wide range of suitable sites (for example arm, back and thigh). A 
common range of pixel areas exists that guarantees interrogation of individual follicular pathways in 
these convenient body regions.  
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To provide a proof of principle, we first tested a deconstructed individual pixel device 
(Fig. 3.3), where a detachable gel reservoir was placed on top of excised porcine skin (an 
excellent model for the human skin barrier[32], [33]) and into which glucose was 
extracted. Subsequently, the reservoir was transferred onto a Pt nanoparticle-decorated 
graphene electrode for glucose detection. Both extraction and detection circuits were 
completed by miniaturized wire electrodes to provide a more customary, three-
dimensional geometry for benchmarking measurements. In this way, dual glucose 
extraction– detection through single follicular pathways using miniature pixel geometries 
was demonstrated, and both follicular and non-follicular glucose extraction fluxes were 
quantified. Second, a 2 × 2 pixel array was created with all elements integrated on a 
flexible substrate (Fig. 3.4) following the concept design and geometric requirements 
outlined above, and the pixels’ performance was compared with that obtained with the 
three-dimensional geometry. A first-generation prototype, based on thin-film technology 
and CVD graphene, demonstrated all functional aspects of the array. In particular, ex vivo 
porcine skin-based experiments enabled direct visualization of the follicular pathways 
probed and, using specific subdermal glucose concentrations, showed that the glucose 
detection current (the output of an extraction–detection cycle) is ‘quantized’, with a 
‘quantum’ corresponding to the readout from a single follicular pathway. Finally, a 
second- generation prototype 2×2 pixel array of similar architecture, but based entirely on 
screen printing (including a graphene ink), was then used to demonstrate the concept in 





3.2 Results and discussion 
3.2.1 Response to glucose: deconstructed sensor. 
Essential criteria to be met for the success of the approach were (i) an adequate sensitivity 
of the sensor to glucose, and (ii) a clear demonstration of preferential follicular extraction. 
Figure 3.5 (a) displays the electrochemical current versus glucose concentration 
calibration curve of a 3 × 3 mm2 Pt-nanoparticle-decorated CVD graphene sensor 
measured with the three-dimensional set-up in Fig. 3.3 (b). In this experiment, glucose 
was presented to the sensor in a 24 µL enzyme-encasing gel reservoir. Data were obtained 
from the sensor’s chronoamperometric response, at an operational potential of 0.4 V, to a 
wide range of concentrations, from sub-micromolar to more than millimolar (Fig. S18). 
A sensitivity of ~2.2 µA mM−1 cm−2 was determined, with a limit of detection (LoD) of 
2.8 μ M (see Methods). For specific RI extraction conditions (extraction current of 0.2 
mA, current density of ~2.2 mA cm−2 and time of 1 h, respectively), the hypo- to hyper-
glycaemic range in diabetics (3.5–12 mM in the blood[34]), after dilution within the 
reservoir gel volume, maps completely onto the sensor calibration curve (Fig. 3.5 (a)). 
The corresponding glucose concentration range in the gel was 8–25 µM (see Methods), 
well above the sensor’s LoD. Clearly, a significant decrease in reservoir volume (for 
example, to the microlitre range), while maintaining the same operational concentration 
range, proportionally decreases the glucose extraction current and time. This informed the 
further design and operational parameters of the individual pixel devices within the planar 
array. 
 
3.2.2 Follicular versus non-follicular glucose extraction fluxes. 
The preferential RI extraction of glucose through hair follicles was first established in two 
experiments using the deconstructed configuration (Fig. 3.3 (a)): (1) via hair ‘targeting’, 
where the miniature gel ‘pixel’ was positioned directly on a single hair follicle and (2) by 
comparing extraction across skin samples with varying amounts of hair. In both 
experiments, RI was conducted under the same conditions on two skin samples with 
different follicular densities. Identical gel reservoir volumes (24 µL) were used and the 
electrochemical detection of glucose therein was performed with the same graphene 
sensor. This approach used the experimental configuration in Fig. 3.3, with the gel pixel 





Figure 3.3| Individual pixel concept. (a) Deconstructed, three-dimensional pixel configuration. Top: 
glucose extraction by RI. Excised porcine skin separates the two halves of a Franz diffusion cell, with 
the epidermal side facing the upper compartment; the lower, subdermal compartment contains glucose 
in phosphate-buffered saline (PBS), and hosts a silver anode. The enzyme-containing gel reservoir is 
positioned on the skin surface, with the Ag/AgCl cathode contacting the gel. As mammalian skin carries 
a net negative charge at pH 7.4, iontophoresis (red arrow) induces electroosmosis, and the transport of 
glucose (G) in the direction of cation migration. (b) glucose sensing. After extraction, the gel is placed 
on top of the pixel-sized graphene sensor, and a three-dimensional electrochemical cell is formed by 
contacting the gel with Ag/AgCl (reference) and Pt (counter) electrodes. 
 
 
Single-follicle, hair-targeted, preferential extraction on a skin sample with 34 hairs per 
cm2 was compared with that from another that was relatively devoid of follicles (6 hairs 
per cm2), and the relative RI extraction fluxes via follicular and non-follicular pathways 
were estimated. For this, the chronoamperometric curves obtained after glucose extraction 
were used to determine an average detection current (Fig. 3.5 b), which, when interpolated 
on the current– concentration calibration curve of the sensor, provides the extracted 
glucose concentration within the pixel gel (Fig. 3.5 c) and hence the glucose extraction 
flux (see Methods).  At a subdermal concentration of 10 mM, glucose flux via the 
preferential pathways was 3.5 nmol mA−1 h−1, and that across non-follicular skin was 0.4 
nmol mA−1 h−1. These values are consistent with the glucose extraction flux (4.5 nmol 





More importantly, they agree with data from the planar pixel arrays developed next (Figs. 
3.8 and 3.10). The preferential pathway result also concurs with direct observations of 
enhanced follicular electroosmotic transport of hydroquinone and the independent 
quantification of electroosmosis using scanning electrochemical microscopy[26]. The 
research described here, however, represents the first direct demonstration of extraction 
and quantitative detection at a single follicle level using a technology platform compatible 
with the construction of a fully integrated glucose monitor. The electrochemical detection 




Figure 3.4| Pixel array concept, and extraction–detection operation cycle. (a) Generic individual 
miniature pixel: electrodes 1 (Ag/AgCl) and 4 (Ag) perform glucose extraction; electrodes 1 (Ag/AgCl, 
reference), 2 (Pt nanoparticle-decorated graphene, working electrode) and 3 (Pt, counter electrode) 
detect glucose electrochemically. Pt nanoparticles on graphene boost the detection signal. Electrodes 1, 
2 and 3 contact a miniaturized enzyme-encasing gel reservoir, into which glucose is extracted, and the 
area of which defines the pixel active area. The gel reservoir is formed inside the holes of a supporting 
elastomer membrane. (b) Planar 2 × 2 array, on a flexible substrate, performing non-invasive glucose 
extraction–detection ex vivo (on porcine skin). For simplicity, both electrodes 1 and 3 (reference, in 
detection) are Ag/AgCl, conferring increased chemical stability after repeated extraction–detection 
cycles (see Methods). Extraction occurs within pixel A via electrodes 1 (cathode) of pixel A and 1′ 
(anode) of pixel B. In the next cycle, cathode and anode roles are reversed, with extraction occurring in 



















Figure 3.5| Deconstructed pixel device. (a) Calibration curve for a typical Pt-nanoparticle-decorated, 
CVD graphene-based electrochemical glucose sensor (3 × 3 mm2) with Ag/AgCl and Pt wires as 
external electrodes (Fig. 3.3 (b)). Glucose is dispensed into the 24 µL enzyme-containing reservoir, and 
H2O2 produced by the reaction of glucose with glucose oxidase is detected in the chronoamperometric 
current recorded at 0.4 V applied to the graphene electrode against the micro Ag/AgCl reference. The 
hypo- to hyper-glycaemic range, after dilution in the pixel gel, maps as indicated in purple (see 
Methods). (b-c), Glucose extraction–detection: determination of follicular versus non-follicular glucose 
extraction fluxes. Glucose was extracted for 1 h using the configuration in Fig. 3.3 (a), at an 
iontophoretic current of 0.2 mA (corresponding to a current density of 2.2 mA cm−2), and with 100 mM 
subdermal glucose, through (1) a single hair follicle (using a skin sample with 32 hairs per cm2) and (2) 
non-follicular skin (using a skin sample with only 6 hairs per cm2), into two separate 24 µL enzyme-
containing gel reservoirs. (b): The samples were then measured by chronoamperometry by the same 
graphene-based sensor using the configuration from Fig. 3.3 (b). Chronoamperometric current 
baselines were also recorded before RI in both cases. (c): After subtraction of the respective baselines, 
average values of the detected current, I1 and I2, were determined over the 50–600 s range. Then, with 
reference to the detection current–concentration calibration curve of the sensor, glucose concentrations 
C1 and C2 for the two cases were determined by interpolation (see Methods). Subsequently, these 
values, reflecting the concentration of extracted glucose after dilution in the volume of the pixel gel, 
were used to calculate follicular and non-follicular extraction fluxes (see Methods). 
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3.2.3 2×2 pixel array on a flexible substrate 
Figure 3.8 compiles representative ex vivo extraction–detection experiments with three 
different 2×2 thin-film/CVD graphene-based arrays, compatible with a final 
implementation. The volume of the pixel gel reservoirs was significantly reduced to 1–2 
μL, enabling the array’s operational parameters to be appropriate for realistic applications 
(for example, 5 min periods of extraction at a current density of ~0.5 mA cm–2). The 
outcome is an operational range (see Methods) for the glucose concentration in the pixel 
gel indicated by the area defined by purple lines in Fig. 3.8. With an increased density of 
graphene-decorating Pt nanoparticles, the detection current normalized to the macroscopic 
area of the sensing electrode is more than an order of magnitude greater than that for the 
deconstructed, three-dimensional pixel device (Fig. S18): that is, the sensitivity increases 
to 37 μ A mM−1 cm−2, while the LoD is improved to about 0.76 µM (Fig. 3.7 (a)). The 
viability of the array design was also demonstrated using gold (a more conventional 
sensing material) and resulted in very similar calibration curves to CVD graphene when 
integrated in an identical array design (compare Fig. 3.8 a, Fig. S19). As detailed in the 
following, the Pt nanoparticle–CVD graphene array demonstrated all the required 
functional aspects: (1) lack of response to interfering species in real-life conditions (Fig. 
3.7 (b), and Fig. S16), (2) targeted extraction, (3) correlation and proportionality with the 
number of hair follicles probed by the respective pixels (Figs. 3.8 and 3.9), (4) capability 
to detect glucose extracted through a single hair follicle (Fig. 3.9) (5) proportionality with 
the concentration of subdermal glucose (Figs. 3.8 (b), and 3.10), and (6) close operational 
characteristics of pixels both within an array and between different arrays (Fig. 3.8 (a), 





Figure 3.6| Complete layout of CVD graphene-based 2 × 2 pixel array on a flexible substrate. 
Complete layout, comprising electrodes for extraction–detection, sensing regions (Pt-nanoparticle-
decorated graphene, 2 mm2 each), and an elastomer membrane with perforations (bottom left) within 
which a glucose oxidase-encasing hydrogel was deployed forming extraction regions of about 6 mm2 
each (dashed contours, bottom right). Electrodes 1 to 3 participate in extraction–detection (4, unused). 
 
A number of potential interfering species can be found in the ISF, such as acetaminophen 
and ascorbic acid (up to 0.1 mM)[36], [37] and uric acid (up to 0.25 mM)[38]. Uric and 
ascorbic acids are negatively charged and are therefore extracted to the anode, that is, the 
opposite electrode to that where glucose is found (electroosmotic flow across the net 
negatively charged skin carrying neutral compounds to the cathode; Fig. 3.3 (a)). Only 
acetaminophen (also uncharged), therefore, is a potential interfering species for glucose. 
Figs. S16 and S17 demonstrate the lack of response of the array sensor to all the 





Figure 3.7| CVD graphene-based single pixel functionality and interferant response. (a) Linear 
response (see Methods) of a pixel sensor to 0.006–0.7 mM glucose. Error bars determined as outlined 
in Methods. (b) Response to glucose (red), PBS (cyan), acetaminophen (teal) and ascorbic acid (purple) 
for the in-gel concentrations shown in inset (Fig. S16).  
 
For glucose extraction, the RI extraction circuit employs the largest of the Ag/AgCl 
electrodes (labelled 1 in Fig. 3.6), located on two adjacent pixel devices, as the anode and 
cathode. In this configuration, during half of the operation cycle, glucose is extracted into 
one of the pixels while, in the second half, the direction of the extraction current is 
reversed, and glucose is extracted in the other pixel. In this way, the AgCl content of the 
extraction electrodes remains essentially constant (see Methods). Figure 3.8 (b) shows 
the set of chronoamperometric detection curves obtained after extraction via each of the 
pixels of an array (for which sensitivity calibration curves are in Fig. 3.8 (a)); each pixel 
probed a certain number of follicular pathways, determined by visual inspection. Each of 
these chronoamperometric curves was analysed in a manner similar to that utilized in Fig. 
3.5 (b): where the time-averaged readout current between 50 and 600 s was used with the 
current–concentration calibration curve of the respective pixel (from Fig. 3.8 (a)) to 
obtain, by interpolation, the concentration of glucose extracted within the pixel. The 
glucose concentration thus determined is quantized, that is, proportional to the number of 
follicles probed by each pixel. To convey this result simply, the inset of Fig. 3.8 (b), 
presents the four average readout currents of the array versus these quantized 
concentration values via the average of the four calibration curves from the main panel of 
Fig. 3.8 (a) (instead of showing, for each pixel, its individual calibration curve, as used in 





Figure 3.8| CVD graphene-based 2 × 2 pixel array calibration and current detection from ex-vivo 
extracted glucose. (a) 10 mM subdermal glucose was extracted across porcine skin ex vivo for 5 min 
under ~0.5 mA cm−2 RI current. a, sensitivity calibration curves (raw chronoamperometry data in Fig. 
S9) for the four-pixel devices, demonstrating very similar current–concentration dependencies. The 
targeted concentration operational range (see Methods) is indicated by purple lines. (b) Detected current 
versus time after glucose extraction within each of the four pixels. Numbers of follicles targeted by 
each of the pixels are indicated. PBS extraction was used as negative control (black baseline). Inset, 
averaged detected current correlated with in-gel glucose concentrations. (c) Detected current versus 
time after extractions using the same pixel device for 10- and 100-mM subdermal glucose 
concentrations. Extracted, in-gel glucose concentrations agree with calculations based on the follicular 





Figure 3.9 shows chronoamperometric detection curves correlated with images of the hair 
follicles targeted by the pixels of an array to show how the extraction–detection is 
practically performed. In this case, detection after extraction through a single follicle could 
also be probed, corresponding to the quantum of extracted glucose concentration. 
Measuring all pixel devices across all three arrays yielded quanta of 18.9 ± 2.1 µM glucose 
in the pixel gel and 8.97 ± 1.01 nA readout current per follicle, for a 5 min period of 
extraction into a 1 µL gel, at 0.5 mA cm–2 RI current density, and with 10 mM subdermal 
glucose. This is consistent with a glucose follicular extraction flux of 4.6 ± 0.5 nmol mA−1 
h−1, a value slightly higher than that determined with the deconstructed pixel and possibly 
attributable to the different two- and three-dimensional geometries used. Furthermore, 
extraction via non-follicular skin in similar conditions results in a detected current that 
decays much faster than that observed after follicular extraction (Fig. 3.8 (b)), due to the 
very low glucose content within the pixel gel.  
 
 
Figure 3.9| Porcine skin visual examination and CVD graphene-based sensor current correlation. 
(a) Example of visual correlation between number of follicles probed by each array pixel (6 mm2 
extraction area, dashed contour, over skin with ~28 follicles per cm2). (b) Current detected after 
extraction of 10 mM subdermal glucose. Array electrodes are visible through the skin. 
 
Taken together, these experiments unequivocally demonstrate that the array operates as 
designed, by exploiting the hair follicles as the preferential transdermal extraction paths 
for glucose. In addition, Fig. 3.8 (c), shows that, after extraction to the same pixel device 
under identical conditions, the detected current is proportional to the subdermal glucose 
concentration (10 and 100 mM were used here; see also Fig. 3.10).  
115 
 
3.2.4 In vivo monitoring with a 2×2 screen-printed array 
In preparation for in vivo experiments, similar ex vivo measurements were extended to a 
prototype, second-generation, screen-printed array, based on the same architecture as the 
thin-film/ CVD graphene-based arrays above. The CVD graphene working electrodes of 
the first-generation arrays were replaced with graphene ink-based electrodes decorated 
with Pt nanoparticles.  
 
 
Figure 3.10| Second-generation, screen-printed, 2 × 2 array, ex vivo testing. (a) Ex vivo (porcine 
skin) testing over the hypo- to hyper-glycaemic range. a, chronoamperometric detection curves after 5 
min of extraction at 0.5 mA cm–2 current density across 6 mm2 extraction area, and subdermal glucose 
concentrations spanning the hypo- to hyper-glycaemic range; extraction through two hair follicles into 
~2 µL of gel (equivalent to 1 hair follicle per 1 µL gel). (b) Proportionality of the readout current (that 
is, the detection current averaged over the 50–600 s range) to the subdermal concentration. (c) The 
readout current maps onto the linear calibration curve, yielding ‘in-gel’ glucose concentrations C1* to 
C4*, in agreement with the follicular extraction flux determined from Figs. 3.8 and 3.9.  
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The first- and second-generation prototypes have close operational characteristics, as 
shown, for example, by their calibration (Fig. S18) and chronoamperometric curves (Figs. 
3.8 and 3.10). The screen-printed arrays are expected to sustain more extraction–detection 
cycles (suitable for continuous in vivo use) than those based on thin films due to the six-
fold increase in Ag/AgCl electrode thickness (see Methods). The readout current of 
screen-printed pixel devices in ex vivo experiments (determined from the 
chronoamperometric curves by averaging, as above) was proportional to the subdermal 
glucose concentration across the entire hypo- to hyper-glycaemic range (Fig. 3.10 (a) and 
(b)), and a plot (Fig. 3.10 (c)) of readout current as a function of expected values of in-gel 
extracted concentration (C1* to C4*, as calculated using the same extraction–detection 
conditions as for the CVD graphene-based arrays, the follicular flux determined from Fig. 
3.8 and 3.9, and the four subdermal concentrations used for extraction) maps very well 
onto the calibration curve of the device. A conversion factor F (characteristic of the current 
pixel device architecture and extraction conditions, see Methods), from the subdermal 
glucose concentration to that in 1 µL of pixel gel (and per follicular pathway), on the order 
of 2.4 × 10−3 was then determined.  
 
Finally, in vivo testing was performed on two healthy volunteers, and representative 
results are presented in Fig. 3.11. The left panel shows the wired array strapped to the 
volunteer’s forearm. Glucose was monitored over 6 h, during which lunch and a snack 
were ingested (Fig. 3.11 (c)). parallel, RI-extracted ISF-borne glucose was monitored by 
two of the array’s pixel devices working in tandem (see Methods and Fig. 3.4 (a)) and 
produced well-matched readout values that provided further confidence in the 
performance of the array. The ISF glucose profile closely follows that of the blood 
glucose, with a lag of about 15 min, as expected[19], [39]. Importantly, control 
experiments, shown in Supplementary Figure S20, demonstrates that, without RI, no 
glucose was detected confirming that, under normal transdermal monitoring conditions 
(that is, when the user is not actively perspiring, for example, due to strenuous exercise or 
high ambient temperatures), there is no contamination of the ISF-borne glucose by that in 







Figure 3.11| Second-generation, screen-printed, 2×2 array, in vivo continuous glucose monitoring. 
In vivo continuous glucose monitoring on healthy human subjects. (a) Screen-printed array fixed onto 
a volunteer’s forearm and connected to a potentiostat. Array layout and components are as in Fig. 3.6; 
additionally, an electrically insulating layer (green) covers all interconnects, underlying the perforated 
elastomer membrane aligned on top of it. (b) Example of chronoamperometric detection curves 
(corresponding to various blood glucose concentrations), acquired during alternating 5 min periods of 
extraction–detection (see Methods); shorter detection times than used in Fig. 3.8 and 3.9 enabled good 
tracking of the blood glucose profile shown in the right panel. (c) Two pixels (a and b) worked in 
tandem (ensuring periodic AgCl recycling in each pixel; see Methods), alternately delivering readout 
values of ISF-borne glucose. For each pixel, a larger RI current density (∼ 1 mA cm–2) was used to 
extract glucose through two follicles into ~3 µL gel (the larger extraction current compensates for the 
larger pixel gel volume; compare this with our benchmarking parameters of one follicle per µL of gel 
and 0.5 mA cm–2 extraction current density). Finger-stick measurements of blood glucose were taken 
before each extraction. 
 
Nonetheless, it is essential for future development of the approach described to 
characterize, in comprehensive clinical experiments, the device response to the full range 
of hypo- to hyperglycaemia in diabetics, as well as in individuals undertaking physical 




Proof of concept is demonstrated for non-invasive, transdermal, path-selective and 
specific glucose monitoring, based on an array of miniature pixel devices integrated on a 
flexible substrate. In this way, ISF-borne glucose is extracted via individual, privileged 
follicular pathways across the skin and detected, producing ‘quantized’ readouts of 
subdermal glucose. The concept is founded on the array architecture rather than the 
specific sensor implementation. Pixel arrays (2 × 2) on mammalian skin ex vivo enabled 
the evaluation and demonstration of all critical parameters and functional aspects of the 
monitor, and future work focuses on extending the array size to at least 4 × 4 (to ensure 
random sampling of single follicles). In vivo testing on healthy human subjects 
demonstrated the ability to continuously track blood sugar for 6 h and extending this 
operation time is an ongoing objective. Graphene-supported platforms (for example, 
incorporating CVD graphene, or graphene inks via screen printing, as shown here) are 
preferred implementations for cheap, flexible, high-throughput and green arrays. Unlike 
other wearable approaches for glucose monitoring, the technology described here should 
ensure that the relationship between measurements made by the device and the actual 
blood glucose concentrations is not subject to inter- and intra-individual fluctuations in 
skin characteristics. This achievement should pave the way to calibration-free non-





3.4 Materials and experimental methods 
3.4.1 Device fabrication 
3.4.1.1 Planar thin-film/CVD graphene array.  
CVD synthesized graphene, grown on a copper substrate, was transferred onto a flexible, 
previously polished polyethylene terephthalate (PET) sheet using a standard wet transfer 
procedure[40]. For a 2 × 2 array, four such graphene patches (larger than the final, desired 
size) were placed on the PET sheet roughly in the desired locations using a stencil mask 
(designed for subsequent electrode and track definition) to guide alignment. The graphene 
patches provide the working electrodes for each of the pixels of the array in the 
electrochemical detection of glucose.  
To prevent potential structural discontinuities/tearing in the graphene layer (occurring 
either during CVD growth or as the result of mechanical stress during the transfer 
procedure), leading to electrical discontinuity, a second graphene layer was subsequently 
transferred on top of each of the original patches. To deposit thin-film electrodes with a 
defined geometry, sets of polyimide industrial tape (Kapton) and laser-machined stencil 
masks were placed successively and aligned on top of the PET-supported graphene 
patches. The stencil mask sets were tailored to the array layout. To complete the 
reference/counter Ag/AgCl electrodes, a 500 nm Ag film was deposited on top of a 20 nm 
Pd layer previously deposited to promote adhesion of the Ag layer, followed by a 500-
nm-thick AgCl layer. Such thick layers of Ag and AgCl are needed to ensure a long 
lifetime of the reference electrode[41].  
Ag/AgCl was chosen as the material for the extraction electrode couple due to the ability 
of AgCl to recover its surface chemical composition after electrochemical stress, hence 
ensuring its stability after repeated cycles of extraction–recovery (which require 
alternation of electrode polarity). It was found that after performing four extraction–
detection cycles with the array, the potential across the Ag/AgCl electrodes changed only 
negligibly (by only ~30 mV), demonstrating their recovery. For detection, one of the 
extraction electrodes was then used as the counter electrode instead of Pt. In this way, the 
number of steps required for array fabrication was greatly reduced, while not affecting 
electrochemical detection. Use of Ag/AgCl as a pseudo-reference is well documented[28], 
[41], [42]; here, its stability was verified in potentiometric experiments relative to a 
standard saturated calomel electrode (SCE).  
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The graphene patches defining the sensing areas were then patterned in the pre-defined 
geometry (for example, into 1 × 2 mm2 areas according to the layouts in Fig. 3.6). 
Although low-energy oxygen plasma can be used to etch graphene supported by plastic 
substrates, mechanical cutting (using a scalpel) was successfully employed in the current 
realization to remove the excess graphene from the pixel patches.  
For the realization and transfer of an elastomer membrane designed to support the 
enzyme-encasing gel, polydimethylsiloxane (PDMS) mixed with a curing agent was first 
spin-coated on a PET support sheet and cured, leading to a ~100-μ m-thick membrane. 
Circular holes (1.5–3 mm diameter) or rectangles (~2 × 3 mm2) of similar area were then 
cut to create sockets for the reservoir gel. After careful underwater peeling in a de-ionized 
water bath, the PDMS membranes were transferred onto the array with defined electrodes 
and tracks, ensuring alignment of the sockets to the electrochemical cell region of each 
pixel. The assembly was then left to dry in air.  
Pt nanoparticles were formed and deposited on the graphene sensing regions of the pixels 
through appropriate stencil masks by DC sputtering under Ar. Unlike electrodeposition, 
sputtering is a method that allows easy scale-up of Pt-nanoparticle deposition. By tuning 
the Ar gas pressure and sputtering time, particles with 4.5 nm mean diameter were 
produced. See supplementary information in Chapter 3 section S2 and Fig. S4 for further 
characterization of this Pt nanoparticle–CVD graphene hybrid material.  
For gel casting and enzyme entrapping (Fig. 3.6), 1 ml of a clear 2% wt/vol solution of 
agarose in phosphate-buffered saline (PBS) at pH 7.4 was formed by warming above 80 
°C and was then cast on a glass slide (allowing it to spread and flatten). The gel was left 
to shrink under accelerated drying in a fume hood for 10 min, after which blocks of gel 
(of ~1–2 µL, determined by weighing), with footprint areas corresponding to 
predetermined pixel regions, were excised. Then, 0.5–1 µL of enzyme (12 mg mL−1) was 
placed on and absorbed into the electrode side of the gel blocks. Finally, the gel blocks 
were positioned on top of the individual pixels, inside the sockets of the PDMS membrane, 
and glucose subsequently extracted into them. Once in contact with the skin (and 
sandwiched between the skin and the surface of the device), the gel did not shrink any 
more over the duration of the extraction and detection experiments presented in Figs. 3.8 




3.4.1.2 Screen-printed array.  
Screen-printed arrays (Fig. 3.11) were commissioned commercially with the same 
architecture as in Fig. 3.6, using an Ag/AgCl ink (DuPont 5874), and a graphene-based 
ink (HDPlas Graphene Ink IGSC02002 from Haydale). The process allowed the thickness 
of the Ag/AgCl electrodes to be increased to ~6 µm, with the aim of increasing the stability 
and lifetime of the pixel devices. A biocompatible, electrically insulating layer (~1 µm 
thick) was also printed around the active areas of the pixel devices, covering the 
conductive tracks of the array.  
Pt nanoparticles were deposited, using stencil masks, in similar conditions as described 
for the thin-film/CVD graphene arrays. A PDMS layer, as described above, was then 
aligned with the active areas of the devices, and the array was completed by placing gel 
patches on top of the active areas.  
The gel composition was changed to improve stability (and maintain volume) during long-
term operation. For gel formulation, an agarose–glycerol–water hydrogel was prepared by 
dispersing agarose (2.5 wt%) within an aqueous solution of glycerol (50 wt% in 0.1 M 
PBS, pH 7.4). The dispersion was first stirred at 50 °C for 1 h to allow sufficient swelling, 
then heated at 95 °C for another hour to ensure complete agarose dissolution, and finally 
cooled to 50 °C before pouring it between two glass slides to allow the formation of a thin 
film. Once jellified, the gel was excised using a razor blade according to the pixel 
dimensions. The addition of glycerol as co-solvent increased the stability of the hydrogel 
by delaying water loss during pixel device operation, without compromising its 
performance during either extraction or detection. This new formulation was used in all 
the ex vivo and in vivo experiments presented in Fig. 3.10 and 3.11. The gel is stable 
(decreasing by ~10–15%) when in contact with the skin over ~6 h of continuous glucose 
monitoring in vivo; the robust structure of the gel is still evident when the experiment is 
terminated. Beyond this proof of concept, we are pursuing the development and 




3.4.2 Calibration of pixel sensors and interference tests. 
To completely characterize a generic sensor (whether in a deconstructed configuration as 
in Fig. 3.3 or in a pixel within an array), a chronoamperometric current versus glucose 
concentration calibration curve was established. In chronoamperometry, the change in the 
electrochemical current with time is tracked at the working electrode as a function of 
increasing glucose concentration, at a fixed applied potential (here, 0.4 V) against an 
Ag/AgCl electrode. A constant volume of increasingly concentrated glucose solutions (in 
PBS) was successively added at regular intervals to the enzyme-containing gel reservoir 
(raw chronoamperometry data are presented in Fig. S9), and the increase in catalytic 
current relative to the background (that is, in the absence of glucose) was determined; an 
average of 10 readings in the plateau region of the current step were recorded for this 
purpose.  
For the pixel array devices, delivery on top of the counter electrode mimics the glucose 
path during actual extraction conditions (see description of extraction circuit in Fig. 3.4), 
while at the same time allowing the system to stabilize after each glucose addition. 
Reservoirs larger than 3 µL are preferable to minimize occasional current transients 
associated with mechanical effects due to manual delivery of analytes. All calibration 
experiments were performed in a glove box in conditions of high humidity to prevent 
shrinking of the gel reservoirs. From five successive replicate calibration curves obtained 
with the same device, the standard deviation in the data broadly equated to 10–12% of the 
corresponding mean. We attribute this variability to pipetting accuracy and to small 
variations in the original pixel gel volume. We use this error across all the calibration data 
presented in this work. Having established similarity in the response of several batches of 
devices for the routine characterization of similarly produced sensors, fewer glucose 
concentrations were used to create the calibration curve. To correlate the calibration curve 
and chronoamperometric detection current we verified that the averaging procedure over 
the time interval mentioned in the main text of the chronoamperometric detection current 
produces values that match well the calibration curves obtained from step glucose 
additions to the pixel gel. Figure 3.10 presents an example of such good correlation. 
Interference tests with pixel arrays were carried out with acetaminophen, ascorbic acid 
and uric acid as potential interferants to glucose detection (although only acetaminophen 
is expected to be extracted within the pixel reservoirs by RI). Throughout the experiments 
on pixel arrays, additions to the gel reservoirs created physiologically pertinent 






pixel reservoirs was close to the LoD of our pixel devices (Figs. S16 and S17). CS, the 
subdermal glucose concentration, corresponding to C, the in-gel concentration, can be 
determined via the relationship: 





 where V is the volume of the gel reservoir and F is the subdermal to in-gel conversion 
factor evaluated for 1 µL of gel. For a single follicular path, and for the extraction 
conditions used throughout this work for the pixel arrays, F was estimated to be about 2.4 
× 10−3. Further data and related discussion can be found in the supplementary information 
of Chapter 3 sections S6.1 and S6.2  
 
3.4.3 LoD, sensitivity and operational range.  
The LoD of a generic sensor (in a deconstructed configuration or in a pixel within an 





where σ is the standard deviation of the noise (as determined from the raw 
chronoamperometry data from Fig. S9), and S is the slope of the sensor’s linear calibration 
curve. Sensitivity was defined as the slope of the sensor’s calibration curve (for example, 
as shown in Fig. 3.7) normalized to the geometrical area of the pixel electrode (that is, 
3×3 mm2 for the deconstructed pixel device, and 1 × 2 mm2 for electrode 2 in Fig. 3.6); 
further relevant discussion can be found in Chapte 3 section S7.1.  
The operational range for the glucose concentration in the pixel gel (C) can be established 
using the relationship  
𝐽 ∙ 𝛥𝑡 ∙ 𝐼 ∙ 𝑁 = 𝐶 ∙ 𝑉 
where j, the glucose extraction flux (see below), scales with the subdermal glucose of hair 
follicles through which extraction takes place. The operational range can be adjusted by 
varying parameters such as Δ t and I, the extraction time and current, respectively, as well 
as V, the volume of the pixel gel (equal to the active (extraction) area of the gel multiplied 
by the thickness of the gel).   
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3.4.4 Determination of follicular vs non-follicular glucose extraction fluxes. 
The procedure described in Fig. 3.5 allowed C1 and C2, the glucose concentrations within 
the pixel gel corresponding to follicular and non-follicular extraction, respectively, to be 
determined. Using these values, and the relationship expressed in equation 3.3, the 
follicular and non-follicular glucose extraction fluxes were determined. The values 
obtained are proportional to the subdermal glucose concentrations (100 mM in the data 
from Fig. 3.5), and scaling is therefore required when the subdermal concentration 
changes. The follicular and non-follicular fluxes reported in the main text were scaled to 
10 mM subdermal glucose concentration. Data from Figs. 3.8 and 3.9 (corresponding to 
the planar thin-film/CVD graphene arrays) were used to independently determine a value 
for the follicular extraction flux. This also allowed us to determine whether the extraction 
geometry of the planar pixel array has an influence over the extraction process.  
 
3.4.5 Extraction–detection cycle with a pixel array.  
For ex vivo experiments, fresh abdominal pig skin was dermatomed (Zimmer) to a 
nominal thickness of 750 μm and then cut into suitably sized pieces, before being frozen 
until use. In contrast to the deconstructed device in Fig. 3.3, the anode and cathode now 
contacted the skin on the same side (Fig. 3.4) making the measurement truly non-invasive. 
The dermatomed pig skin was placed over the sensor, with the external side in direct 
contact with the pixel array, while the subdermal side faced the operator, allowing 
alignment of the gel reservoir regions (that is, the active areas of the pixel devices) to the 
clearly visible follicles (made possible by the partial transparency of the skin). Buffer-
saturated absorbent tissue was used as the subdermal compartment in which glucose 
solution was dispensed. A piece of paraffin film was placed over the impregnated tissue 
and pressure was applied to ensure contact between the skin and the gel reservoirs. We 
did not specifically perform an analysis of behaviour under stress, but, under the current 
conditions, the extraction results are reproducible and compatible with what is expected 
from glucose flux estimations. Hence, stress, at least thus far, does not negatively affect 
the operation of the device. Glucose was extracted under a current density of ~0.5 mA 
cm–2 for 5 min into the gel reservoir (1–2 µL volume, ~6 mm2 cross-section) using an 
Ag/AgCl electrode couple provided by two adjacent pixels, and detected for 10 min. Once 
the extraction was completed, glucose detection was performed (procedure described in 
Fig. 3.5) without changing the sensor position. No significant gel volume variation was 
recorded in these experiments when the gel was sandwiched between the pig skin and the 
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device surface, and laterally confined by the PDMS membrane. The cathode and anode of 
the iontophoresis circuit are provided by two different pixels and alternate from cycle to 
cycle (Fig. 3.4). Thus, the two-pixel extraction–detection cycle follows the following 
steps: (1) extraction in pixel a, accompanied by depletion of AgCl from the pixel a 
electrode (the cathode in the electrochemical reaction); (2) detection of extracted glucose 
by chronoamperometry in pixel a; (3) pixel a gel cleaning—with a high glucose subdermal 
concentration (for example, 100 mM), two or three chronoamperometry detection cycles 
are performed to completely deplete the extracted glucose from the gel; and (4) glucose 
extraction in pixel b, accompanied by recovery of the AgCl surface layer of the pixel a 
electrode (now the anode in the electrochemical reaction).  
For in vivo experiments, the protocol (REACH EP 17/18 94) was approved by the 
University of Bath Research Ethics Approval Committee for Health. Healthy, non-
diabetic volunteers underwent an overnight fast, and the area of the forearm where the 
sensor would be applied had been carefully shaved and cleaned. The array was strapped 
onto the skin with mild pressure, as shown in Fig. 3.11. Good contact between the skin 
and the device is indicated by low resistance during RI extraction. In such conditions, the 
device works within the expected parameters, and in agreement with all the other results 
in this Article. The sensor was first stabilized by performing several chronoamperometric 
detection cycles without RI extraction until the results superimposed. Concurrently, blood 
glucose concentrations were measured via conventional finger-sticks at regular intervals 
(using a commercial glucose meter, Accu-Chek Mobile). Subsequently, the subject 
consumed a carbohydrate-rich meal (~200 g of pasta), triggering the expected response in 
blood glucose concentration (that is, a clearly perceptible increase in glycaemia followed 
by its normalization in response to insulin secretion) over the next 2–2.5 h. Then, the 
subject consumed a snack containing ~60 g of sugar and the change in blood glucose was 
followed as before for a further period of about 1 h. During this provocation of changes 
in blood glucose levels, RI extraction and electrochemical detection cycles were 
performed every 10 min (the detection stage having been reduced from 10 min to 5 min 
to permit collection of more frequent data points). Measurements with two pixels, working 
in tandem, were alternated as detailed above. The RI glucose signal versus time profile in 
Fig. 3.11 (c), in this case did not use the readout current averaged over 50–600 s (as 
employed in the rest of the work), but instead employed the instant current detected at t = 
300 s. This alternative method of displaying the output data from the device clearly tracked 
with fidelity the variation in blood glucose concentration. Notably, both the instant 
measurement (at t = 300 s, in this case) and the averaged current correlated similarly with 
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the subdermal concentration. With the current pixel characteristics and dimensions, 
measurement time sequence, and overall monitoring period, we did not observe glucose 
accumulation in the pixels and the lack of memory effect is also supported by the ex vivo 
results in Fig. 3.10. After extraction, complete glucose conversion to H2O2 is anticipated 
due to the excess quantity of enzyme in the pixel gel; in addition, with the 15 min delay 
between each detection step within that pixel (1) there is no concern about analyte 
diffusion–limitation as the pixel size is so small, and (2) disproportionation of any residual 
H2O2 (leading to pixel clearing) is expected, catalysed by the Pt[45] and Ag 
nanoparticles[46] (present in the screen-printed ink) of the various electrochemical 
electrodes. No perceptible discomfort was perceived by the volunteers during the 
extraction. Only mild tingling under the extraction electrodes was transiently (a few 
seconds) experienced at the beginning of current passage. Furthermore, no skin irritation 
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This chapter revealed the proof of concept for an innovative principle involving the 
accurate probing of analytes, especially glucose, contained in the subdermal interstitial 
fluid. Validation of the principle has been achieved ex-vivo using a miniaturised, 
multiplexed, graphene-based glucose monitor on porcine skin, utilized as a testing model. 
Moreover, the proposed sensor efficiently proved to track blood glucose changes in-vivo, 
on a healthy human volunteer, and no skin irritation was observed afterward. The device 
development involved the production of different prototypes: the first generation was lab 
fabricated integrating CVD graphene and thin-film electrodes, while the second prototype 
generation was fabricated by screen-printing of graphene and metals inks establishing the 
scaling-up feasibility of the manufacturing process. Finally, the impact of common 
interferant species was almost absent proving that the sensing device specificity towards 
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S1 Conceptual considerations and array design 
S1.1 Rationalisation of the path-selective concept and limits of 
miniaturisation 
This research aims to overcome potential drawbacks of reverse iontophoresis-based 
technologies by mean of a miniaturised, multiplexed biosensing platform which enables 
the targeting of preferential glucose extraction pathways. Each of the pixel devices of the 
array allows for the RI extraction and electrochemical measurement of glucose at a 
specific skin site; in this sense, the values measured are “quantised”. For those pixels 
aligning with a hair follicle (the preferential, privileged pathway for RI), the quantum 
signal is much higher than those which do not. For an optimized array geometry, the 
majority of positive pixel readings correspond to single follicles and, clearly, any pixels 
located over multiple follicles will produce signals that are n-fold greater (where n is the 
number of follicles involved). The conversion factor between the subdermal glucose 
concentration and the quantity of analyte measured in the pixels aligned with a follicle is 
set by known geometrical characteristics of the pixel array, and the extraction conditions 
(such as time of extraction and current applied). In this way, the detected level of glucose 
in the pixel can be converted into the subdermal concentration a priori and is independent 
of the density of hair follicles probed. The need for periodic finger-stick calibration is 
thereby rendered redundant. For example, the proposed concept is easily visible in 
Supplementary Figure S1 as a comparison between “GlucoWatch”[1] and our proposed 
concept with respect to glucose sampling through skin samples of different hair density 
(low density, left-hand side; high density, right-hand side). 
 
 
Supplementary Figure S 1| Glucose 
sampling area comparison between 
GlucoWatch and our proposed 
sensor. (a) large area (~1 cm2) 
sampling of the GlucoWatch; (b) 





S1.2 Calculation of the probability P that one pixel hits a single hair follicle 
Considering that the electroosmotic flow proceeds through low-resistance pathways 
(predominantly via hair follicles, as shown in Figure 2.2), an efficient glucose extraction 
can be achieved employing a miniaturised, multiplexed platform. The rationalisation of 
the miniaturised pixel array concept has been possible by calculation of the probability for 
each pixel to hit a hair follicle. The probability P that one pixel of a working array device 
hits a single hair follicle is expressed as a function of the pixel area, for an increasing 
number of pixels within the array, and values of follicular density spanning the typical 
range in humans (Figs. 3.2, and S2). 
 
The probability pF1 that a pixel of area a hits a single follicle given m follicles per cm2 
and a probed area of size A (in which there are m⋅A follicles) is: 
𝑝𝐹1 = 𝑚 ∙ 𝐴 ∙ (
𝑎
𝐴






In this case, one follicle is hit by the pixel (probability a/A), while all other follicles (m⋅A 
- 1) are not (probability 1 - a/A). 
 
The most basic definition of a working array device is that it has at least one working 
pixel, defined as a pixel for which there is just a single follicle ‘hit’ (i.e., the opposite of a 
non-working pixel, for which there is either no or more than one follicle ‘hit’). This is 
described by the probability P: 
𝑃 = 1 − (1 − 𝑝𝐹1)
𝑁 
where (1 - pF1) is the probability of a given pixel not working, N is the number of pixels 
in the array device, and (1 - pF1)
N is the probability that none of the pixels within the array 
are working. Typically, with A = 1-2 cm2, simulations show that P has only a weak 
dependence on A for pixel sizes of interest here. Figure 3.2 in Chapter 3 main text shows 
that an array with N = 4 x 4 pixels is the smallest that ensures at least one (if not more) 
‘working’ pixels for which there is a single follicular hit per pixel (i.e., P reaches 1). 
Supplementary Figure S2 (a-c) shows that there is a common range of values for which 
P is maximised across all size arrays and that this range shifts towards smaller values with 
increasing follicular density. Supplementary Figure S2 (d) shows, for a 4 x 4 pixel array, 
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when P reaches 1, that a suitable range for the pixel area a is 2-5 mm2 for the range of 
typical human follicular densities on the ventral forearm (i.e., 18 - 36 follicles/cm2). 
 
 
Supplementary Figure S 2| Probability P that one pixel of a working array device hits a single 
hair follicle. (a-c) Probability P, as a function of pixel area and for different size arrays, that a device 
with n× n pixels (where n = 1-4) has at least one working pixel when applied to skin with (a) 18, (b) 
27, and (c) 36 follicles/cm2. (d) P as a function of pixel area for a 4× 4 array for the three selected 
follicle densities, showing that an overlapping range of pixel area values exists, thus, enlightening the 
design of a working array. 
 
 
Similar results are obtained when a Gaussian distribution centred about a particular 
follicular density is considered instead of discrete follicular density values. The decrease 
in the probability P for larger pixel areas is due to the increased chance of more than a 





area a (again given m follicles per cm2 and a probed area A in which there are m⋅A follicles) 
is: 
𝑝𝐹2 = (




























and equals the number of combinations of two follicles out of 𝑚 ∙ 𝐴 total follicles. Figure 
S3 shows that, when the pixel area a is 2-5 mm2, the probability pF1 of a pixel hitting a 
single follicle dominates (i.e. pF1/pF2 > 1), over all typical follicular densities; the 




It is important to note that, although a majority of pixels with single follicle hits is 
preferred in an array device, a small proportion of pixels with double or more follicle 
hits can be exploited in a beneficial way as they provide corroborative readings that are 
multiples of the single follicle signal (as shown in Figs 3.8 and 3.9). 
  
Supplementary Figure S 3| Ratio 
of probabilities pF1/pF2 as a 
function of pixel area for 18, 27, 
and 36 follicles per cm2. With a 
pixel area dimension < 6 mm2 the 





S2 Characterization of Pt nanoparticle-CVD graphene hybrid films 
Nanomaterials have an ever-increasing role in sensors and biosensors due to their unique 
physicochemical properties which significantly improve the sensing performance; above 
all, the high surface-to-volume ratio in nanoparticles enhances crucial parameters such as 
sensitivity and detection ranges. In addition to an improved Faradaic-to-capacitive current 
ratio, higher current densities and faster mas transport, the quantum confinement of 
conductive nanostructures, immobilised on electrode surfaces, enhances the 
electrocatalytic behaviour in electrochemical sensing systems[2], [3]. The combination of 
metal nanoparticles with carbon nanostructures has demonstrated to enhance the electron 
transfer and electrocatalytic activity in sensors. Moreover, noble metals, and in particular 
platinum, have already been used for their outstanding electrocatalysis properties towards 
H2O2[4].  
Therefore, in an attempt to increase the electro-reactivity towards H2O2 oxidation[5]–[7], 
Pt nanoparticles were deposited onto CVD graphene or graphene ink (later in the second 
generation of sensor prototypes). Two deposition techniques were used to embody the 
PtNPs in the fully functional pixels: physical vapour deposition (Fig. S4), achieved by DC 
sputtering, and electrodeposition (Fig. S5). 
In Supplementary Figure S4 (c) the Raman peaks characteristic of graphene are 
identified; those peaks aid in the graphene type and quality assessment as follow: the ratio 
of the intensities of the 2D and G peaks (located at ~2683 and 1583 cm-1, respectively), 
I(2D)/I(G) = ~1.71, while the 2D peak has a single Lorentzian profile for the bare graphene 
(upper spectrum), confirming its presence as a monolayer[8], [9]; further, the intensities 
of the D (disorder-induced) peak (located at ~1344 cm-1) and the second-order D+D’ peak 
(located   at ~2928 cm-1) are small, indicating little disorder within the graphene sheet[9]. 
After Pt nanoparticle deposition, the disorder of the graphene sheet increases: the 
intensities of the D and D+D’ peaks increase relative to the other peaks, so that the 
I(D)/I(G) ratio increases to about 0.51; the I(2D)/I(G) ratio decreases to about 1; and the 
D’ peak (located at ~1644 cm-1) is now visible as a small shoulder on the G peak. These 
changes are consistent with an increased defect density within the graphene sheet[10], 
and, thus, a reduced distance LD between defects; based on the I(D)/I(G) ratio, LD is 
estimated to be ~17 nm[11]. This increased disorder can be linked to the large density of 
Pt nanoparticles on the graphene sheet, see Supplementary Figure S4 (a), of about 3.6 x 
104 particles/μm2. The modifications noted in the Raman spectrum are consistent with 
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other Pt nanoparticle- CVD graphene hybrid films created by sputtering, such as those 
reported in Yuan Y et all [12].  
 
 
Supplementary Figure S 4| Pt nanoparticles deposited by sputtering on CVD graphene. (a) 
Transmission electron microscopy (TEM) of sphere-like Pt nanoparticles on a CVD graphene 
membrane. Defocussing has been adjusted so that fringes from both graphene and Pt nanoparticles are 
visible and thereby demonstrating their crystallinities. The inset shows the hexagonal symmetry of the 
graphene sheet; the point resolution of the TEM (JEM-2100 Plus) is ~0.23 nm, insufficient to atomically 
resolve the individual carbon atoms in the graphene sheet. There are about 3.6 x 104 Pt 
nanoparticles/μm2. (b) Histogram showing the particle size distribution: a Gaussian fit gives 4.5 nm as 
the most probable diameter, while the FWHM is 2.7 nm. (c) Raman spectra (using a 514 nm wavelength 




The increased defect density after Pt nanoparticle deposition affects the CVD graphene 
sheet resistivity, which increases to ~3.1 kΩ/sq for the Pt nanoparticle-graphene hybrid 
(compared to only ~ 1.1 kΩ/sq for bare graphene). The sheet resistivity of the bare 
graphene sheet (of interest for electrical interconnects) is therefore comparable with 
expected values for CVD graphene[13].  Concerning the Pt nanoparticles-graphene hybrid 
material, used in the electrochemical sensors, the sheet resistivity is less consequential: 
for electrochemistry applications, defective graphene was found to favour (fast) electron 
transfer and is thus preferred to high-quality graphene[14]. The Pt nanoparticles strongly 
boost the Faradaic current; hence, they are the component of the system that determines 
the sensitivity and limit of detection of the electrochemical sensor. Supplementary 
Figure S5 shows Pt nanoparticle-CVD graphene hybrid films with Pt nanoparticles 
formed on graphene by electrodeposition (see Supplementary, section 4). This method has 
been employed for testing individual and deconstructed devices (such as that shown in 
Figure 3.5), but, as explained in Chapter 3 main text, has not been used for the realisation 
of the pixel array devices. 
 
Supplementary Figure S 5| Electrodeposited Pt nanoparticle-CVD graphene hybrid. (a) and (b) 
Scanning electron microscopy (SEM) of electrodeposited Pt nanoparticle-CVD graphene hybrid films 
on SiO2/Si substrates. The graphene sheet appears to have a homogenous thickness; a defect line, where 
Pt nanoparticles electrodeposited in preference, is indicated in (a) by a red arrow. (c) Histogram 
showing the particle size distribution: a Gaussian fit gives 86 nm as the most probable diameter, while 
the FWHM is 87 nm. There are about 8 Pt nanoparticles/μm2.  
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S3 Deconstructed pixel supporting data 
S3.1 Raw calibration curve data 
 
 
Supplementary Figure S 6| Deconstructed pixel device, Pt nanoparticle-graphene sensor response 
as a function of glucose concentration. Raw chronoamperometric data from which Figure 3.5 (a) was 
generated based on the procedure described in Methods. Regular additions of glucose over various 
concentration ranges to the pixel gel are indicated with arrows of different colours (red, green, purple 
and yellow in panels a, b, c, d, respectively); additions of phosphate-buffered saline (PBS) are shown 
by blue arrows. The chronoamperometric current increased after each of glucose addition, but decreased 
after addition of PBS, consistent with dilution of the glucose already present in the pixel gel. The 






Supplementary Figure S 7| Deconstructed pixel device calibration curve. Originally shown as a 
log-log representation in Figure 3.5 (a) presented here on a linear scale. Excellent linearity was 
observed over the 0.005 to 0.7 mM range. Error bars indicate standard deviations which are typically 
10 to 12% (Methods) of the plotted average values. 
 
 
S3.2 Reverse iontophoresis (RI), ex vivo, with the deconstructed pixel 
Materials. Fresh abdominal pig skin was dermatomed (Zimmer®, Ohio, USA) to a 
nominal thickness of 750 µm and then cut into suitably sized pieces, before being frozen 
until used. The follicular density of each skin section was determined visually under an 
optical microscope. 100 mM D-glucose (Sigma-Aldrich, U.K.) solutions were prepared in 
PBS and allowed to mutarotate overnight. The quantity of chloride ions required for the 
Ag/AgCl electrochemistry during RI was estimated to be 0.9 mM, and was comfortably 
supplied by the PBS in which the glucose solutions were prepared. 
 
Transdermal RI glucose extraction. A vertical Franz diffusion cell set-up (Figure 3.3 (a), 
main text) was used, in which the lower, sub-dermal chamber of the cell was filled with 
7.5 mL of 100 mM glucose solution, and magnetically stirred for 1 hour. RI was performed 
by passing a constant current of 0.2 mA (corresponding to 2.2 mA/cm-2) for 1 hour 
between the anode and cathode from a power supply (Kepco, MB Electronic, USA); the 
potential across the skin was monitored regularly during current passage. The anode and 
cathode were located on opposite sides of the skin meaning that the electrical resistance 
of the iontophoresis circuit was about one-half of that expected in vivo (i.e., in a non-
invasive configuration where both electrodes would be located on the skin surface and the 
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iontophoretic current must as a consequence cross the skin twice[15]). However, because 
RI extraction is undertaken at constant current, the only difference between the ex-vivo 
and in vivo situations is the approximately two-fold higher voltage required to drive the 
current used in the latter case[15]. 
 
S3.3 Validation of electrochemical detection of extracted glucose using 1H-
qNMR 
A sufficient quantity of glucose as required for 1H-qNMR was obtained using the 
relatively large volume (24 µL) of gel reservoir in the deconstructed device; indeed, this 
required a large extraction current and a relatively long time (neither of which are 
compatible with the use of the small gel volumes (1 to 2 µL) present in the pixels of the 
array as this dries the gel and prevents extraction). Table S1 collects the results of several 
experiments in which the efficiency of glucose extraction was correlated with the hair 
density, and the analyte was detected either electrochemically or by 1H-qNMR. The data 
show a clear correlation between the ratios of concentrations extracted through twinned 
follicle-rich (23 follicles/cm2) and follicle poor (8 follicles/cm2) skin samples and the 
respective hair density ratios thereof. This strongly supports the hypothesis that glucose 
extraction by reverse iontophoresis (RI) into the miniature “pixels” indeed occurs 
primarily through preferred follicular pathways. The excellent agreement between the 
amperometric and NMR analytical techniques provides further confidence in the dual 
extraction-detection functions of this miniaturised, graphene-based platform. 
 
Supplementary Table S 1. Validation of electrochemical detection of extracted glucose using 1H-
qNMR. Correlation between extracted glucose concentration and follicular density ratios in twinned 
experiments, in which RI extraction was conducted under identical conditions on two skin samples with 
different follicular densities, and into identical gel reservoir volumes (24 µL). Each data point represents 
a different extraction-detection “twin” experiment, in which detection was performed via either 
chronoamperometry (using the same graphene sensor to measure the twinned reservoirs), or qNMR. 
The results from both techniques indicate a linear relationship between the two quantities. 
Hair density ratio 




2.1 2.0 Chronoamperometry 
2.3 1.2 Chronoamperometry 
2.9 3.5 1H-qNMR 




Methods: Glucose extraction and 1H-qNMR 
Reverse iontophoresis experiments were performed for 1 hour at 0.2 mA extraction 
current (i.e., ~2.2 mA/cm2) using the set-up in Figure 3.3 (a), main text, on two skin 
samples having follicular densities of 23 and 8 hairs/cm2, respectively. Extractions were 
performed in twin, 24 µL gel reservoirs without glucose oxidase, and with 100 mM 
glucose in the subdermal compartment. Subsequently, the gel reservoirs were diluted (to 
a final volume of 120 µL) in bis/tris-EDTA (10 mM/1mM) buffer at pH 6.5. The mixture 
was warmed at 65°C for 10 minutes, and then cooled to 42°C before being incubated with 
one unit/100 µL of β-agarase for 1 hour. The enzyme dissolved the agarose, yielding liquid 
samples for NMR analysis. 
 
In parallel, a calibration curve of the NMR signal as a function of glucose concentration 
within the (glucose oxidase-free) gel (Supplementary Figure S8 (b)) was constructed 
using similarly liquefied gel samples from a set of 24 µL gel reservoirs into which glucose 
had been dispensed to yield a series of known concentrations. The glucose solutions were 
allowed to mutarotate overnight at room temperature before being added to the gel. 
 
1H-NMR spectra (Supplementary Figure S8 (a)) were recorded using a Bruker Avance 
III NMR spectrometer operating at 500.13 MHz for 1H. The probe used was a BBFO+ 
with three channels. Samples were analysed using a pre-saturation pulse sequence 
(noesygppr1d) at 25°C after addition of a small amount of D2O, with a known amount of 
3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TMSP) as reference and internal 
standard. Standard Bruker software (Topspin 2.1) was used for acquisition and processing, 
while the spectral window was 10330 Hz, with typically 256 transients. 
 
Glucose oxidase reacts with β−glucose[16]. Upon liquefaction of the gel reservoirs post-
RI, the 1H-qNMR signal clearly revealed a doublet at ~5.1 ppm, attributed to D-α-glucose 
(Supplementary Figure S8 (a))[17]. The signal for β-glucose, however, was anticipated 
around 4.6 ppm[17], a spectral region in which other (unidentified) species had similar 
chemical shifts and made it impossible to isolate the β-glucose contribution at low 
concentration. Instead, the β-glucose concentration was calculated from the α-glucose 1H-
qNMR signal using the known α/β ratio of 0.56 at equilibrium[18], and interpolation on 
the NMR signal versus concentration calibration curve previously determined 





Supplementary Figure S 8| 1H-qNMR for evaluation of RI-extracted glucose. (a) Raw 1H-NMR 
spectra of samples corresponding to two extraction experiments through skin samples with different 
follicular densities, specifically 23 and 8 follicles/cm2. Peaks corresponding to α-glucose, located 
around 5.1 ppm[17], are indicated. (b) 1H-qNMR-based calibration curve obtained using samples of 
known glucose content (black dots). The coloured symbols correspond to glucose extracted in the two 
RI experiments from (a); the corresponding glucose concentrations are found by interpolation with the 
calibration curve of the α- glucose 1H-qNMR signals determined from the raw spectra shown in (a). 
 
α-glucose concentration was determined from the peak areas in Supplementary Figure 
S8 (a) and the 1H-qNMR calibration curve (Supplementary Figure S8(b)), for the two 
extracted glucose samples; the corresponding β-glucose concentrations were determined 
in both cases from the known thermodynamic α/β = 0.56 content ratio[18]. The extracted 
glucose concentration ratio from the two experiments was then found, and compared with 
the respective follicular density ratio. The result of this analysis (Table S2) is incorporated 
into the information presented in Table S1, above. 
 
Supplementary Table S 2. 1H-qNMR information from Figure S8. 
Technique 















α = 0.050 α = 0.172 
3.44 2.88 




S4 Thin film/CVD graphene pixel array response to glucose 
S4.1 Raw calibration curve data 
Calibration data were obtained by chronoamperometry which examines the electric 
current variation with time, at a fixed voltage (0.4 V) against a silver/silver chloride 
reference electrode. The devices calibrations were conducted adding, at regular intervals, 
constant volumes of increasing glucose concentrations to the gel reservoirs containing 
glucose oxidase. Here, a wide range of glucose concentrations was added to the thin-film 
sensor to assess the sensitivity, linear range and limit of detection of the device. 
Supplementary Figure S9 shows the raw chronoamperometry data for a thin-film CVD 
graphene-based pixel; faradaic currents are observed after each glucose addition are 
attributed to the electrochemical oxidation of H2O2 at the working electrode surface.  
 
 
Supplementary Figure S 9| Thin film/CVD-graphene pixel array: Pt nanoparticle-graphene 
sensor response as a function of glucose concentration. An example of raw chronoamperometry data 
as a function of pixel gel-incorporated glucose concentration, from which a sensitivity calibration curve 
was obtained based on the procedure described in Chapter 3 section 3.4.2. The inset tables indicate the 
glucose concentrations in the gel reservoir after each glucose addition. 
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The standard deviation is in the 10-12% range for five calibration curves replicates; this 
variability can be attributed to the deviation of gel volumes and pipetting accuracy. 
Supplementary Figure S10 depicts a comparison of distinct arrays in a current against 
glucose concentration plot; in the plot is observed the linearity of the glucose 
concentrations with respect to the measured current among different pixels of distinct 
arrays wherein all the points exhibit a similar behaviour. The plot demonstrates a broad 
linear response over the concentration range from 3 µM to 1.5 mM. 
 
 
Supplementary Figure S 10| Comparison between different arrays. Sensitivity calibration curves 
for pixel devices from two different planar 2 x 2 arrays (labelled as arrays #1 and #4) showing similar 
behaviour. Current vs glucose concentration data, represented on a logarithmic graph, conformed to 
slightly supra-linear functions. 
 
 
S4.2 Thin film/CVD graphene pixel array ex-vivo follicular extraction 
The glucose extractions through porcine skin, using thin-film pixel array devices, were 
conducted for 5 min applying a current of 0.05 mA through the Ag/AgCl extraction 
electrode couple. A glucose concentration of 10 mM was used as a subdermal 
compartment. Jellified agarose 3% (w/w) solutions containing glucose oxidase enzyme 
(12 mg/mL) and 0.1 M PBS with volumes of 4 µL each were employed as reservoirs. 
After each extraction, the array was turned upside down to run the detection experiments. 
The detection was performed applying a fixed voltage of 0.4 V to the PtNPs modified 
CVD-graphene working electrode (vs the thin film Ag/AgCl reference electrode). Pixels 
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were gently washed after each extraction-detection cycle to avoid cross contaminations. 
Supplementary Figure S11 supports the data for Figure 3.8 (c) portraying the porcine 
skin used in the ex-vivo experiment; the hair follicles (density about 24 follicles/cm2) 
interrogated during RI extraction are contained in the pixel areas (dashed squares) of about 
9 mm2 each. Panel b shows the amperometric data acquired for pixel C, which probed 4 
hair follicles and its calibration curve; the point highlighted in purple corresponds to the 
concentration of glucose extracted and collected in the pixel (using an extraction current 
density of ~0.5 mA/cm2, for 5 minutes, and 10 mM glucose subdermal concentration). 
 
 
Supplementary Figure S 11| Porcine skin visualisation and fitting of the acquired amperometric 
data. (a) Visualisation of the porcine skin hair follicles; (b) amperometric data for pixel 2c of the array 
plotted vs glucose concentration. 
 
The bar chart shows the averaged glucose concentrations extracted from different hair 
follicles targets. As observable, the linear relationship between the glucose extracted and 







Supplementary Figure S 12| 
Glucose concentration in 
gel against number of hit 




S5 Thick film screen-printed graphene array ex-vivo follicular 
extraction 
The glucose extractions through porcine skin, using thick-film pixel array devices, were 
conducted for 5 min applying a current of 0.075 mA through the Ag/AgCl extraction 
electrode couple. A glucose concentration of 10 mM was used as a subdermal 
compartment. Jellified agarose 2.5% (w/w) solutions containing glucose oxidase enzyme 
(14 mg/mL) and 0.1 M PBS with volumes of 3 µL each were employed as reservoirs. 
Subsequently to each extraction, the pixels which have collected glucose were used for 
the detection experiments. The detection was performed applying a fixed voltage of 0.4 V 
to the PtNPs modified graphene ink working electrode (vs the thick-film Ag/AgCl 
reference electrode).  
 
 
Supplementary Figure S 13| Porcine skin visualisation and hair follicles counting. (a) Visualisation 
of the pixels (with an area of 9 mm2) underneath the porcine skin; (b) hair follicles association to each 
pixel. 
 
The extraction/detection operations were carried out in series and the sensor was allowed 
to stay on the external surface of the porcine skin throughout the experiment. Figure S13 
portrays the porcine skin for the ex-vivo experiment, with the screen-printed device 
attached to it, through which the hit hair follicles were counted. The correlated 
amperograms are shown in Figure S14 (a); the electrochemical signal amplitudes 
matched the interrogated number of hair follicles for each pixel. Also, it appears that the 
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catalytic currents scale up as a function of the number of hair follicles hit in a directly 
proportional relationship, as observable in Fig S14 (b). 
 
 
Supplementary Figure S 14| Amperometric curves and in gel glucose concentration after specific 
hair follicles interrogations. (a) Amperogram correlated to Figure 3.22; (b) Chart plot of the extracted 
glucose against hair follicles hit. Error bars correspond to the standard deviation. (N=22) 
 
In addition, to further confirm the follicular extraction in the cathodic chambers, in Figure 
S15 is depicted the result of an alternative detection method used to assess the 
iontophoretically extracted glucose, via preferential pathways, excluding any possible 
interference caused by the extraction procedure. In panel a is depicted a control 
experiment where amperometric curves were acquired for glucose-containing gels (10 
µM), at 300 s glucose oxidase was spiked in provoking the immediate conversion of 
glucose in H2O2, thus producing clear associated amperometric peaks. Whereas, for the 
ex-vivo experiment depicted in panel b, the method involves the use of two different 
sensors: the first is employed in the sole extraction procedures, the second exclusively 
exerts the detection processes. In this experiment, the gels used in the extracting pixel pair 
do not contain the enzyme and, after each half cycle, were displaced from the extraction 
sensor and located onto the other. The detection device was therefore activated and, after 
300 s, a volume of 0.4 µL containing glucose oxidase (14 mg/mL) in 0.1 M PBS was 
added to the reservoirs. The resulting amperometric curves are shown in panel a and 
increasing peaks matching the hair follicles targets were found in the cathodic gels; as 
expected, no significant peaks were produced after the addition of the glucose-selective 
bio-transducer in the anodic reservoirs. 
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The ex-vivo work using pig skin was necessary to demonstrate that transdermal extraction 
(and subsequent detection) using small extraction areas is “quantised” (with the number 
of follicles). With the ex-vivo experiments, the correlation between the current measured 
and the number of follicles providing the glucose was confirmed. As a result, one follicle 
per pixel provided a “quantum” of current, while pixels accessing a higher number of 
follicles, would provide multiples of this quantum, hence validating the novel idea of 
focusing on privileged follicular pathways and using pixel gel reservoir for controlled 
dilution to achieve a calibration-free approach which promises to render blood sugar 
testing completely non-invasive. 
 
 
Supplementary Figure S 15| Alternative ex-vivo extraction/detection procedure. (a) Amperogram 
showing an increase of the electric current upon addition of the specific enzyme to gels containing 10 





S6 Multiplexed array response to interferant species 
S6.1 Thin film/CVD graphene pixel array  
Glucose and common potential interferant species (acetaminophen, ascorbic acid, and uric 
acid) in concentrations and ratios that are relevant to physiological conditions were 
delivered to a pixel device of the array. PBS acted as a blank control. Both thin film/CVD 
graphene (Figure S16) and screen-printed arrays (Figure S17) were tested. In Figure 
S16, glucose, interferants or PBS were added successively to the same gel reservoir. The 
chronoamperometric current increases after each glucose delivery and is allowed to reach 
its plateau value before the subsequent analyte addition; in contrast, each interspersed 
addition of interferant or PBS does not increase the current level. In the second part of the 
experiment (after 1900 s), when only PBS and interferants were added to the system, the 
level of the stabilised current never increases, unequivocally demonstrating the absence 
of sensor response to the presence of interferants. Instead, in this part of the experiment, 
a consistent decrease in the stabilised current is observed, which we attribute to the 
dilution of the glucose already accumulated in the pixel gel by the additions of interferants 
or PBS. We also note that, in this experiment, small transients sometimes altered the 
current at the beginning of an addition, which we attribute to a mechanical disturbance of 
the system during pipetting (see the results of better-controlled experiments in Figure 
S17). 
 
Supplementary Figure S 16| Thin-film/CVD graphene array response to interferants: 
acetaminophen, ascorbic and uric acids. The 6 µL reservoir gel is a mixture of agarose and PBS; 0.4 
µL additions of interferants in PBS. The inset tabulates the ‘in-gel’ concentrations of various analytes 
after each addition, to be read in ‘down & right’ order starting from the top-left corner. Key: 
acetaminophen additions (teal arrows), ascorbic acid (purple), PBS (cyan), and glucose (red). 
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S6.2 Thick film/ graphene ink array  
Supplementary Figure S17 shows a series of experiments in which glucose additions are 
interspersed with additions of only one type of interferant, and sufficient monitoring time 
was permitted to pass demonstrating the system stabilisation after each addition. Glucose 
and interferant were carefully delivered onto the top of the counter electrode of the pixel 
device (i.e., avoiding the working electrode), and every effort was made to minimise 
mechanical disturbance of the system during pipetting achieving a steady-state diffusion 
in the gel microcavity. In general, delivery on top of the counter electrode mimics the 
glucose path during actual extraction conditions while at the same time allowing the 
system to stabilize after each glucose and interferant addition. We have also delivered the 
interferants (acetaminophen, ascorbic acid, uric acid, and PBS) first, before glucose is 
introduced to the system, and none of the interferants elicited a response from the sensor. 
 
 
Supplementary Figure S 17| Response to interferants: acetaminophen, ascorbic and uric acids. 
Screen printed array. The ~7 µL reservoir gel is a mixture of agarose and PBS (Methods); 0.1 µL 
additions of interferants in PBS. Glucose additions alternate with additions of (a) ascorbic acid, (b) uric 
acid, (c) acetaminophen, and (d) PBS (control experiment). The inset tabulates the ‘in-gel’ 
concentrations of the various analytes after each addition, to be read in ‘down & right’ order starting 
from the top-left corner. Key: acetaminophen additions (teal arrows), ascorbic acid (purple), uric acid 




In Figures S16and S17, the equivalent subdermal concentrations, corresponding to those 
collected in the gel, can be calculated from the inset tables as described in Methods: the 
in-gel concentration, C, and its subdermal equivalent, Cs, are related via the relationship 
described in Equation 3.1. Accordingly, to give an example, the smallest equivalent 
subdermal concentrations of interferants used in Figure S17 were about 0.9 mM for 
acetaminophen and ascorbic acid, and 1.5 mM for uric acid. These values are larger than 
the relevant physiological concentrations (of 0.1 and 0.25 mM, respectively), but ensure 
a measurable signal, while the glucose-to- interferant ratios used are physiologically 
pertinent. The ratios of interferant-to-glucose concentration increments were about 1/30 
for acetaminophen and ascorbic acid, and 1/20 for uric acid, i.e., very close to 
physiological ratios (e.g. ratios of 1/50 and 1/20, respectively, are within the physiological 
range). In Figure S16, these ratios were larger, specifically 1/10 and 1/5, respectively, 
favouring interferant detection. Both Figures S16 and S17 demonstrate that none of the 
interferants elicits a response from the respective sensor. Only upon glucose addition is a 
significant increase in the amperometric current recorded.  
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S7 Comparison between various implementations of the array 
S7.1 Calibration curves: screen printed array, thin film/CVD graphene 
array, deconstructed 3D pixel 
Figures 3.8 and 3.10 in Chapter 3, main text, presented the detection current versus the 
glucose concentration in the pixel gel for the two types of devices used in this work. For 
further comparison, the detection current was normalised to the macroscopic area of the 
sensing electrode (i.e., 3 x 3 mm2 for the deconstructed pixel device, and 1 x 2 mm2 for 
the working electrode of the array pixel devices) in each of these cases. This normalisation 
eliminates the geometrical differences between the different generations of devices; 
however, it retains the potential effect of different electrochemically active surface areas 
(ECSA) of the electrodes (i.e., as determined by their nanostructure).  
 
 
Supplementary Figure S 18| Comparison of chronoamperometric current density versus glucose 
concentration calibration curves: screen printed array, thin-film/CVD graphene array, and 
deconstructed, three-dimensional pixel device. The three curves correspond to representative 
devices: for each of the array types, the plots shown are representative pixel calibration curves, 
normalized to the 2 mm2 area of the Pt nanoparticle-graphene pixel working electrode; the plot for the 
deconstructed pixel device is obtained from the curve in Figure 3.5 (a), after normalization to the 9 
mm2 of the Pt nanoparticle-graphene working electrode.  
 
Supplementary Figure S18 shows the resulting current density versus glucose 
concentration in pixel gel for representative screen-printed arrays, thin-film/CVD 
graphene arrays, and CVD graphene-based deconstructed pixel devices. When plotted in 
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a log-log format the three curves show similar, supra-linear behaviour but with clearly 
larger current densities for the pixel array devices. When plotted on a linear scale, the 
sensitivity of the devices can be determined as the slope of the curves: both planar array 
prototypes show 10 to 15-fold larger sensitivity compared to the deconstructed device. 
This is attributed to the different density and morphology of the sputtered Pt nanoparticles 
used for the array devices, compared to the electrodeposited ones used in the 
deconstructed devices. As previously described, with sputtering, there were 3.6 x 104 
particles/μm2 of 4.5 nm mean diameter whereas, by electrodeposition, there were 8 
particles/μm2, of 86 nm mean diameter. Notwithstanding the size difference, which is 
known to affect catalytic activity, it is expected that sputtering, where the particle surface 
is not covered by residual chemical groups (as in electrodeposition), favours increased 
electroactivity, as noted also in ref.[19]. There, as here, the detected species was H2O2. 
Both log-log and linear plots of the data confirm the similar performance characteristics 
of the screen printed and thin-film/CVD graphene arrays, as expected from their common 
architecture. This reinforces the consistent behaviour of the two prototypes, as reflected 
in the ensemble of ex-vivo data from Figures 3.8, 3.9 (thin-film/CVD graphene 
prototype), and 3.10 (screen-printed prototype). The performances of the distinct sensor 
designs are listed in Table S3.  
 












2.2 4 2.8 0.004 to 2.83 
2x2 CVD graphene array 37 5 0.76 0.005-1.5 
2x2 screen-printed graphene 
ink array 
56 3 0.016 0.003-1.5 
 
Here the limit of detection has been calculated according to Equation 2.14. The values of 
the thin-films and screen-printed devices are in close agreement with each other and 
discrepancies are mainly due to the different nature of the working electrodes and error in 




S7.2 Characterization of Au-based array 
All the process steps used for the fabrication of CVD graphene-based arrays remained the 
same except that, instead of graphene, gold pixel regions, of about 150 nm thick, preceded 
by 20 nm Pd as an adhesion layer, were deposited by thermal evaporation in the desired 
locations through appropriate stencil masks. Together with sputtered Pt nanoparticles, 
these formed the working electrodes. Figure S19 shows current versus glucose 
concentration in pixel gel calibration curves for the individual pixels of Au-based thin-
film arrays. These curves are very similar to those corresponding to the thin film/CVD 
graphene and screen-printed arrays shown in Figure S18. 
 
 
Supplementary Figure S 19| Calibration curves for a Pt nanoparticle-decorated, Au-based array. 
(a) Image of the 2x2 Au-based pixel array. (b) Calibration curves related to the Au-based array. The 
geometrical design of the array and the method of deposition of the Pt nanoparticles are identical to 




S8 Support data for continuous in-vivo measurements 
S8.1 Control experiment in the absence of RI extraction and skin 
tolerability 
To demonstrate that no glucose is delivered to or sensed by the pixel devices without 
applying reverse iontophoresis (RI), successive “extraction control”/detection cycles were 
performed in vivo using two pixels in tandem (as for the experiment in Figure 3.11 (c), 
main text; see Methods) and glycaemic changes were provoked by food ingestion. While 
the blood sugar profile, monitored with a commercial glucose meter (Accu-Chek® 
Mobile), increased and then fell in response to insulin secretion in the healthy volunteer 
as expected, the read-out from the two-pixel devices did not show any significant change 
in the device response. Therefore, it was confirmed that, in the absence of RI-extracted, 
ISF-borne glucose, there is no other source of glucose available for detection by the array. 
 
 
Supplementary Figure S 20| Skin tolerability in-vivo and control glucose monitoring experiment. 
(a-b) Skin shows no signs of irritation after being subjected to (a) 6 hours of extraction-detection cycles 
at 1 mA/cm2 extraction current density, or (b) when the extraction current density was increased to 2 
mA/cm2. The two experiments used two different arrays, and for each array pixels a and b were used in 
tandem. In (a), extraction takes place across two hair follicles for each of the pixels a and b. (c); without 
RI extraction, blood sugar varies (black), while the alternating read-out currents from the two-pixel 
devices (green) do not. 
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No sign of skin irritation was observed (Figure S20 (a)) after the 6-hour in-vivo glucose 
monitoring experiment shown in Figure S20 (c), in which the extraction current density j 
was 1 mA/cm2 across an area of about 0.06 cm2; even when the current was raised to 2 
mA/cm2 (Figure S20 (b)), no erythema was observed. 
Ledger[20] reports that the tolerable current density increases as the skin area exposed to 
current decreases, i.e., as the total current passed is decreased. This is consistent with a 
simple analysis that, to a first approximation, relates skin irritation to Joule power 
dissipation (P) during RI extraction across the skin. As P is proportional to the product of 
the current density j and the current I, it can be maintained within certain limits; for 
example, j can be increased if I is decreased proportionately. Although there are no reports 
of RI extraction through areas as small as those used in our work, Table I of Ledger[20] 
cites various sensations felt in conditions relatively close to ours: ’tingling’ when j = 0.4 
mA/cm2 across an extraction area of 0.64 cm2 (i.e., corresponding to I = 0.26 mA); and a 
'discernible sensation' for j = 3.2 mA/cm2 across an area of 0.13 cm2 (i.e., corresponding 
to I = 0.4 mA). Comparatively, the skin tolerance to the current density values used in the 
in vivo experiments reported here adheres to, and can be explained, by this trend. Figure 
S20 (b) also shows three pieces of gel (prepared as described in Methods) intentionally 





S8.2 Alternative read-out for continuous in-vivo measurements 
The alternative read-out procedure used for the in-vivo measurements shown in Figures 
3.10 (b) and Supplementary Figure S21 (b) is justified below using the detection data 
covering the whole hypo-to-hyper glycaemic range from Figure 3.10 (a). Figure S21(a) 
shows the respective detection curves recorded over 10 minutes, while Figure S21(b) 
compares two read-outs displaying: (i) the current averaged over 50 to 600 seconds (as 
used throughout all the ex-vivo experiments reported in the main text), and, alternatively, 
(ii) the instant detection current measured at a shorter time, e.g., t = 300 s. The later method 
allows one to shorten the duration of the extraction-detection cycle, by reducing the 
detection stage to 5 minutes. Both currents appear to have the same gradient as a function 
of the subdermal concentration (Figure S21(b)), demonstrating that the two read-outs are 
similarly sensitive. The soundness of this alternative read-out, based on an instant current 
reading at a shorter time, is intrinsically supported by its ability to track the blood glucose 
variation in real-time, as demonstrated in Figure 3.11 (c). 
 
 
Supplementary Figure S 21| Alternative read-out. (a) Read-out (detection) current from Figure 3.10 
(a), covering the whole hypo- to hyper-glycaemic range and recorded over 600 s. (b) Two read-out 
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 Device further optimizations 
and in vivo study 
 
4.1 Introduction 
In Chapter 3 we demonstrated proof-of-concept of how quantitative, calibration-free 
glucose measurements could be achieved with the non-invasive, transdermal technology 
proposed in this work. This chapter takes that work further, in respect of two main aspects: 
(i) optimization of sensor implementation, and (ii) further pilot in-vivo testing of the 
technology on a small number (n =10) of healthy human volunteers. Hence, the chapter is 
divided in several subsections addressing: 
• Sensor design optimization for improved glucose collection where different sensor 
layouts are proposed and assessed, followed by a proposal of a fast and cost-
effective surface activation protocol for increasing sensor sensitivity.  
• In-vivo validation of the concept of “quantized” follicular extraction in 
deconstructed experiments on human subjects.  
• In-vivo pilot trial of the proposed technology on healthy human volunteers, and 
assessment of full functionality of the monitoring device. This was followed by 
an analysis of plausible phenomena related to aging effects of the sensor during 





All experiments discussed in this chapter used a common set of materials, as described 
below. 
Glucose oxidase type VII, lyophilised powder, ≥100,000 units/g solid (without added 
oxygen), D-glucose, Na2HPO4, KH2PO4, NaCl, KCl, H2SO4 were purchased from Sigma-
Aldrich (Dorset, UK). Low-gelling temperature agarose was purchased from Fisher 
Scientific (Loughborough, UK). MilliQ water was used for all solutions. A platinum (Pt) 
target, used to create the Pt nanoparticles that decorate the working electrodes, was 
acquired from Testbourne Ltd (Basingstoke, UK). To physically deposit Pt nanoparticles 
a HHV 500 sputter coater  (Hind High Vacuum ltd, Crawley, UK) was used, and 
polyimide (Kapton) laser-machined stencil masks, obtained from Laser Micromachining 
Ltd (Saint Asaph, UK), were used to define the metal evaporation pattern. Amicon 
ultracell 10K centrifugal tubes with regenerated cellulose were acquired from Merck 
Millipore (Darmstadt, Germany). A SCE reference electrode was acquired from 
Radiometer Analytical (Lyon, France) and a DriRef2 reference electrode was purchased 
from World Precision Instruments, Inc. (Sarasota, FL). The potentiostat used in the 
electrochemical experiments was a four-channel MultiPalmSense 4 (Palmsens BV, 
Houten, The Netherlands). Screen-printed arrays were commercially commissioned to 
Gwent Electronic Materials Ltd (Sun Chemical Corporation, Slough, UK), using a 
Ag/AgCl ink (C2130809D5) for the extraction and reference electrodes, a graphene-based 
ink (C2171023D1) for the working electrodes, a flexible silver paste (C2080415P2) for 
the connection tracks, and a green dielectric paste (D2081009D6) to insulate and protect 
the tracks from exposure to chemicals and to skin contact. 
A Phoresor II Auto (Iomed Inc., Vista, CA) was used to regulate and pass a DC current 
through the skin in the experiment investigating the working electrode deactivation 
presented in Section 4.4.3.1. The Phoresor device is a US Food and Drug Administration 
approved constant current, iontophoretic power supply. 
Amino acid standard and amino acid standard physiological solutions were acquired from 
Sigma-Aldrich (Dorset, UK). Liquid chromatography-mass spectroscopy (LC-MS) 
analysis was performed using an Agilent QTOF 6545 with Jet stream ESI spray source 
coupled to an Agilent 1260 Infinity II Quat pump HPLC with 1260 autosampler, column 
oven compartment and variable wavelength detector (VWD) (Material and Chemical 
Characterisation Facility (MC2) at the University of Bath (http://go.bath.ac.uk/mc2)).  
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4.2 Sensor design and optimization 
The patch-like glucose monitoring array described in Chapter 3 proved to be a valid 
platform to conduct experiments in a first proof-of-concept embodiment of the 
technology. Nonetheless, sensor performance enhancement can be achieved by 
modifications of the electrodes and pixel design and layout, as well as pre-treatment of 
the electrode surfaces. In this section, investigations on new geometric electrode layouts 
aim to study the time response of the sensors, and how this affects glucose collection, to 
establish the best performing design to be progressed in further in vivo experiments. 
Moreover, an electrode treatment protocol is proposed to establish a recovery procedure 
for aged sensors, as well as enhance the electrochemical response of the sensing devices 
incorporated in the array devices. These improvements were implemented in the next 
generation of prototypes, where increased performance and accuracy are necessary for 
real-life monitoring scenarios on human volunteers.  
 
4.2.1 Experiments to assess sensor design and electrode surface treatment 
All electrochemical measurements were conducted using a MultiPalmSense4 
(Netherlands) four-channel potentiostat, interfaced with a PC with PSTrace (version 5.7) 
and MultiTrace (version 4.2) software. Experiments were performed at room temperature 
and measurements and treatments were made simultaneously with multiple pixels in the 
array.  
The amperometric experiments were handled as described in Chapter 3 section 3.4.2 and 
using the same configuration as in Figure 3.4. Briefly, 0.2 µL volumes of PBS solutions 
containing varying glucose concentrations were delivered to the gel by pipetting, and the 
droplets were homogeneously spread onto the collection gel surface. The sensors were 
then placed in a high humidity chamber (relative humidity > 80%) to avoid water 
evaporation from the gel during testing.  
Surface treatment and subsequent characterization experiments were performed to try and 
improve/recover the surface active area of the electrochemical sensors used in this work. 
In this case, the pixels were used without their typical ionic compartments, i.e., the gel 
reservoirs; moreover, the sensors were connected to a custom-made switching board to 
permit easy switching operations of the electrode circuitry. The electrodes undergoing 




the pixel devices. These were screen-printed on a flexible PET support and made of a 
proprietary graphene-based ink, see 4.1.1 Materials section. Two types of electrodes were 
examined: those made with pristine graphene ink, and those based on the same ink but 
decorated with platinum nanoparticles (PtNPs), namely SP-G and SP-G-PtNPs, 
respectively. The bare sensor, without the topping gel reservoir, was the WE in a standard, 
solution-based electrochemical circuit, with a platinum rod as the auxiliary electrode and 
a commercial Ag/AgCl electrode (DriRef2) as the reference electrode. The sensor design 
selected was the one shown in Figure 4.1a, with a central, rounded working electrode 
having an area of 2.85 mm2. The surface treatment consisted of the application of a cycling 
voltage on the WE in a 0.1 M NaOH solution, and four cyclic voltammograms (CVs) were 
performed. CV scans were recorded at a rate of 50 mV s-1 with a step potential of 5 mV, 
and over the -1.1 to 1.2 V range for the SP-G electrodes, and the -1.1 to 1V range for the  
SP-G-PtNPs electrodes.  The surface-treated electrodes were investigated by CV in a 
solution containing 0.5 M KCl and 4 mM [Fe(CN)6]
3−/4-, a redox probe. In this case, CVs 
were obtained at a scan rate of 100 mV s-1 with a step potential of 5 mV, and over a voltage 
range of -0.25 to 0.8V for the SP-G electrodes, and 0 to 0.4 V for the SP-G-PtNPs 
electrodes. Electrochemical impedance spectroscopy (EIS) was then performed over the 
100 mHz to 100 KHz frequency range, operating in single-sine-wave mode, with a RMS 
AC voltage of 10 mV oscillating around the open-circuit-potential (OCP); such conditions 
ensure operation in the linear zone of the voltage-current  response curve. Finally, the 
effect of the electrode surface treatment on the sensitivity of the sensors was assessed by 
calibration as previously described in Chapter 3, section 3.4.2. 
The effective area, Ae, of the electrochemical sensors was derived from the Randles-
Sevcik plot, (see Equation 2.15, Chapter 2) using the CV scans obtained in 4 mM 
[Fe(CN)6]
3−/4-, 0.5 M KCl solution. A cross-examination of the heterogeneous electron 
transfer rate kinetics, k0, for the graphene screen-printed electrodes was performed using 
both CVs and EIS measurements. The CV determination of k0  was achieved using the 
Nicholson equation, see Chapter 2 Equation 2.17, while EIS k0 calculations were made 







where Ae is the effective area, C, the bulk concentration of the oxidized and reduced 
analyte forms, and Rct, the electron transfer resistance (see Annex I for further details).  
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4.2.2 Sensor design optimization 
The prototypes used in Chapter 3 had the “square” layout shown in Figure 4.1 (b). In this 
configuration, extraction is performed using the grey, L-shaped electrode, while the 
working electrode is the black, rectangular one in the centre. 
  
 
Figure 4.1| Sensor performance optimization via comparison of three layout designs. (a, c) rounded 
designs, (b) square design. EE, extraction electrode; WE, working electrode, RE/CE, reference/counter 
electrode; black and grey depict graphene and Ag/AgCl electrodes, respectively. 
 
Two additional designs (Figures 4.1a,c) were proposed and investigated in this chapter, 
with the aim of improving both extraction and detection efficiencies. Both geometries 
consist of a rounded pixel design, while the working and extraction electrodes are swapped 
between the external, ring-shaped and internal, circular electrodes. These new layouts are 
aimed to increasing the area of the WE, from 2 mm2 in the squared geometry to 2.85 mm2 
and 2.7 mm2 for the circular and ring-shaped electrodes, respectively, in the rounded 
geometries. Increasing the geometric area of the WE results in a larger electrochemically 
active area and, therefore, the rounded design is expected to boost the response of the 
sensor in terms of electric current output. In the new pixel architecture, the distance 
between electrodes (fixed at 0.3 mm) and the pixel area (9 mm2) remained identical to the 
previous design. Another important aspect is the response time of the sensor to glucose 
extraction: it is expected that the designs with a central working electrode would perform 





Figure 4.2| Glucose electrochemical detection using the three different electrode designs. (a and 
a’) Chronoamperogram and calibration graphs for the “peak detection” experiment. (b and b’) 
Chronoamperogram and calibration graphs for the “step detection” experiment. Error bars indicate the 
standard deviation (N=3 per pixel). 
 
Assessment of the sensor layouts shown in Figure 4.1 was performed in-vitro by 
amperometric detection of successive glucose additions. Fig. 4.2 (a) shows the response 
of the sensors to injection of glucose of increased concentration that was then allowed to 
be consumed (hence the sensors were allowed to recover their baseline). The 
amperometric current first rises rapidly, reaching a peak (a quasi-plateau state persisting 
less than 25 s), after which it decays due to low gel reservoir volumes (< 6 µL) and glucose 
concentrations used (which mimic the in-vivo operational conditions). In this way, the 
kinetics of glucose consumption was also accessed; the time constants related to the 
plateau states are 8 ± 1 s, 12 ± 2 s and 22 ± 2 s respectively for the central rounded, square 
and the peripheral rounded geometries, while the glucose consumption characteristic 
times, calculated from the three lowest concentrations from Figure 4.2 (a), are 
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respectively 123 ± 23 s, 136 ± 19 s and 190 ± 42 s. In this method, named “peak 
detection”, the current under each of the rise-and-decay profiles was integrated resulting 
in a charge, which was then divided by the consumption time and normalized to the 
respective working electrode area: these points of current density were plotted as a 
function of glucose concentration, yielding the sensitivity curves in Figure 4.2 (a’). In an 
alternative method, amperometric curves were obtained by successively adding the same 
amount of glucose at regular time intervals. The current recorded after the sensor reached 
a quasi-steady state was plotted as a function of the glucose concentration, yielding 
alternative sensitivity curves. The results of this approach (named “step detection”) are 
presented in Fig. 4.2 (b) and the amperograms were obtained by adding glucose when the 
sensor response reached steady-state. Each pixel of the 22 arrays of the three designs 
was tested in triplicate, and the resulting sensor sensitivities, determined as gradients of 
the curves from Figures 4.2 (a’, b’), are summarised in Table 4.1.  
 
Table 4.1: Sensitivity values obtained for the three sensor layouts considered.  
Electrode design 





Rounded (internal WE) 109.7 ± 3.8 86.3 ± 6.8 
Squared (internal WE) 93.6 ± 12.1 58.1 ± 4.3 
Rounded (peripheral WE) 29.9 ± 4.5 32.3 ± 2.9 
 
 
The amperograms from Figure 4.2a also reveal that the WE positioning critically affects 
the kinetics of glucose detection and consumption. Sensor time response was greatly 
improved by placing the working electrode centrally (as for the designs in Figures 4.1a, 
b), as opposed to peripherally (as for the design in Figure 4.1c). This performance boost 
is attributed to faster glucose diffusion towards the centre rather than a centrifugal flow. 
Generally, the sensitivity values are comparable for the two central WE designs, with the 
highest values attributed to the central rounded geometry which, despite the higher 
surface, exhibited greater current densities compared to the other designs. Furthermore, 
as shown in Table 4.2, the rounded design with the central WE shows the lowest intra-
pixel and inter-pixel coefficients of variation, followed by the square geometry with 
central WE, and the rounded one with the peripheral ring-shaped WE, respectively. 
169 
 




Inter-pixel variation               









Rounded (internal WE) < 7.9 < 7.6 5.5 ± 1.6 5.1 ± 1.5 
Square (internal WE) < 12.9 < 13.7 10.8 ± 1.7 11.6 ± 2.2 
Rounded (peripheral WE) < 11.4 < 14.6 8.9 ± 1.4 9.8 ± 4.2 
 
Consequently, the geometry shown in Figure 4.1 (a) was chosen as the prototype used for 
the pilot in-vivo experiments described below.  
 
 
4.2.3 Electrochemical surface treatment of the working electrode 
Screen-printing pastes used as the active material in electrochemical sensors usually 
contain a mixture of conductive material (in this case, graphene flakes), polymeric binders 
and solvents [2], [3]. The binder material is electrochemically inert, and it might impede 
the diffusion of analyte towards the conductive component, obstructing the 
electrochemically active surfaces and, therefore, resulting in slower kinetics of 
heterogeneous reactions [4]. Different pre-treatment methods have already been reported 
for carbon-based screen-printed electrodes (C-SPEs) [5], [6], primarily because of their 
wide-ranging use in sensing technologies and low production cost. However, fewer efforts 
have been directed to investigating the surface treatment of metal-based screen-printed 
electrodes. Surface treatment methods for platinum-based screen-printed electrodes (Pt-
SPEs) have been studied for gas sensing applications [7], [8] to extend long-term sensor 
stability; for example, mechanical and electrochemical polishing techniques have been 
used as pre-treatments for Pt-SPEs [8]. 
We developed a new method for treating Pt-SPE surfaces to enhance glucose detection, 
for implementation in the next generation of prototypes of our technology. The process 
consists of dipping the sensors in a NaOH solution and applying a cycling voltage to the 
glucose-sensing electrodes so that the binding material directly exposed to the solution 
undergoes a dissolution process and causes erosion of the electrode surface. This surface 
treatment eventually results in an increased total effective surface area for the sensing 
electrode, enhancing the exposure of the conductive material to the solution. Figure 4.3 
schematically illustrates a screen-printed electrode surface before and after being 




Figure 4.3| Screen-printed electrode surface after NaOH electrochemical treatment. The 
schematic shows that the NaOH electrochemical treatment increases the effective active area of the SPE 
surface. 
 
To characterize the effect of the NaOH electrochemical surface treatment, treated and 
untreated electrodes were subjected to cyclic voltammetry and electrochemical impedance 
spectroscopy (EIS) in aqueous [Fe(CN)6]
3−/4- solutions. Chronoamperometry was finally 
used to assess the response to glucose of the electrodes under examination. Figure 4.4 
shows the cyclic voltammograms (CVs) for untreated screen-printed graphene electrodes 
(SP-G) and for platinum nanoparticle-decorated electrodes (SP-G-PtNPs), compared to 
the CVs for the treated electrodes, referred to as activated screen-printed graphene 
electrodes (ASP-G) and activated platinum nanoparticle-decorated electrodes (ASP-G-
PtNPs). Notably, the CVs for the ASP-G electrodes show a boost in the current response, 
faster electron transfer kinetics, and a reduction of the peak-to-peak separation of the 
voltammograms, ΔEp, from 555 mV to 122 mV compared to the untreated electrodes 
(Figure 4.4(a)). The voltammograms obtained before and after treatment from the Pt-
decorated electrodes are qualitatively similar, with a current boost observable in the 
voltammogram of the treated electrodes with respect to the oxidation and reduction peaks; 
ΔEp changed only slightly, from 107 mV for the untreated electrodes to 93 mV for the 
treated electrodes. Thus, the NaOH electrochemical treatment was found to be effective 
in improving the performance of the screen-printed graphene electrodes, especially for the 
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bare, undecorated examples. Nevertheless, the CV scans related to the platinum 
nanoparticle-decorated electrodes did not show a particularly strong improvement and, 
therefore, electrochemical impedance spectroscopy (EIS) was used to identify what drives 
the kinetics of the system and to evaluate the heterogeneous electron transfer kinetic 
constant for the different electrodes. 
 
 
Figure 4.4| Cyclic voltammetry of screen-printed graphene electrodes before and after NaOH 
treatment. (a) CV of treated (red) and untreated (blue) bare graphene ink electrodes (ASP-G and SP-
G, respectively). (b) CV of treated (orange) and untreated (light blue) Pt nanoparticle-decorated 
graphene ink electrodes  (ASP-G-PtNPs and SP-G-PtNPs, respectively). 
 
EIS is a powerful technique to describe charge transfer processes taking place at the 
electrode-electrolyte interface; therefore, this technique was used to further describe the 
effects of the electrochemical surface treatment on the working electrodes. The EIS data 
are shown here as Nyquist plots, wherein the real and imaginary elements of the 
impedance are plotted as a function of each other, and as Bode plots graphically 
illustrating the dependency of both impedance and phase shift on frequency (see Chapter 
1 section 1.8.2.4 for more details). The Nyquist plot typically comprises two elements, a 
semicircle and a straight line, as shown in Figures 4.5 and 4.6. The semi-circular portion, 
which is located at higher frequencies, indicates the charge transfer process, whereas the 
linear element, positioned at lower frequencies, is characteristic to the diffusion process 
[9]. The untreated electrodes show a well-defined semicircle indicating a slow charge 
transfer process. After surface treatment, the semi-circular portion almost disappeared 
suggesting that the NaOH electrochemical treatment facilitated electron transfer by 
exposing more electroactive sites. These results are in agreement with the CV scans from 
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Figure 4.5| EIS of bare graphene ink electrodes before and after NaOH treatment. (a) Nyquist 
plot of treated ASP-G (red triangles) and untreated SP-G (blue circles) bare graphene ink electrodes. 
(b) Bode plots of treated (circles) and untreated (triangles) bare graphene ink electrodes: log of the real 
impedance (blue symbols) and the phase shift (red symbols) plotted as a function of frequency. 
 
 
Figure 4.6| EIS of platinum nanoparticle-decorated electrodes before and after NaOH treatment. 
(a) Nyquist plot of treated ASP-G-PtNPs (orange triangles) and untreated, SP-G-PtNPs (light blue 
circles) bare Pt NP-decorated graphene ink electrodes. (b) Bode plots of treated (circles) and untreated 
(triangles) bare graphene ink electrodes: log of the real impedance (blue symbols) and the phase shift 
(orange symbols) plotted as a function of frequency. 
 
For the untreated electrodes, the higher impedance in the low frequency range confirms 
that the dielectric binder provided a barrier towards the probe redox reactions; while the 
qualitative Bode phase angle plot exhibits one time constant which is also attributed to the 
dielectric features of the screen-printed electrodes and is associated with the binder 
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component of the ink. The NaOH treatment erodes the binder effectively exposing to the 
bulk solution the electroactive sites of the screen-printed ink; as a result, the Bode plot 
shows significantly lower impedance in the low frequency range and the peak, which is 
associated with a time constant, disappears in the phase angle plot of the activated 
electrodes. 
Table 4.3 summarises the electrode materials, electrochemical active surface areas 
(calculated from the CVs according to the Randles- Sevcik plot, see Chapter 2 Equation 
2.15), and EIS parameters. It can be observed that the real surface area of the treated 
electrodes is higher than the untreated electrodes and, as a result, the charge transfer 
resistance of the activated screen-printed electrodes is much lower than that of the 
untreated electrodes.  
 
Table 4.3: Effective surface areas (ECSAs) and EIS parameters for various electrodes. 
Electrodes 
ECSA 

































As expected, the heterogeneous electron transfer rate constants, k0, calculated according 
to Equation 4.1, reflect the improvement in the Ae and Rct values and the fastest kinetics 
were observed for the treated electrodes.  
Table 4.4 presents the k0 values calculated form these experiments compared to common 
literature values and shows that the commercial graphene inks employed here were 
perhaps not the best choice in terms of fast electrochemical response. However, inclusion 












Figure 4.7| Comparison between NaOH-treated and untreated SP-G-PtNPs electrodes, with and 
without prior exposure to Fe(CN)6. Electrochemical current as a function of glucose concentration 
for the treated and untreated electrodes with [Fe(CN)6]3−/4- adsorbates (brown and orange circles, 
respectively), and without [Fe(CN)6]3−/4- adsorbates (blue and light blue circles, respectively). Error bars 
indicate the standard deviation (N=3). 
 
As predicted, the sensor electrochemical current was greater for the treated devices. 
Surprisingly, sensor exposure to potassium ferricyanide solution prior to NaOH surface 
treatment resulted in an even more strongly amplified signal. This phenomenon might be 
Electrode material 
Heterogeneous electron transfer rate 
constant, k0 (cm s-1) 
Reference 
Glassy carbon electrode 3×10-3 [10] 
SP- carbon electrode 1.67×10-5  -  3.09×10-4 [11] 












explained by the presence of [Fe(CN)6]
3−/4- adsorbates on the electrode surface which 
facilitate the electrochemical oxidation of H2O2, hence, acting, de facto, as an 
electrochemical mediator between the analyte and platinum nanoparticles. The sensitivity 
values corresponding to the gradients of the plots showed in Figure 4.7 are 87.0 ± 8.2 µA 
cm-2 mM-1 for the activated WE with Fe(CN)6 adsorbates, 69.2 ± 9.6 µA cm
-2 mM-1 for 
the untreated WE with Fe(CN)6 adsorbates, 42.6 ± 4.2 µA cm
-2 mM-1 for the activated WE 
without adsorbates, and 29.1 ± 2.7 µA cm-2 mM-1 for the untreated WE without adsorbates. 
It is noted that harsher treatment conditions, including an increased number of scans or 
higher NaOH concentration, weakened the polymeric binder holding the conductive 
materials together, and compromised the physical integrity of the electrodes. As a 
consequence, the electrical contacts were degraded resulting in more capacitive electrodes 






4.3 Further validation of the principle of follicular glucose extraction 
in human volunteers  
The core principle of the sensor developed in this work is the extraction of glucose 
“quanta” via preferential pathways such as hair follicles. Despite the earlier demonstration 
of the concept on porcine resected skin, and a limited number of in-vivo experiments, as 
presented in Chapter 3, further in-vivo validation was clearly necessary prior to the 
execution of clinical studies. Here we describe a series of experiments on human 
volunteers, so-called “deconstructed in-vivo testing”, aimed at exhaustively 
demonstrating the principle of quantized, in vivo follicular glucose extraction. The 
experiments are based on the in vivo measurements described in Chapter 3, using the 
screen-printed 22 sensor arrays described therein. The method, however, has been 
“deconstructed” into two steps, involving the decoupling of measurements through the 
use of sensors from two different arrays: in the first step, a sensor from the first array 
performs extraction into its gel reservoir while, in the second step, the gel reservoir in 
which glucose was extracted is analysed by a sensor from the second array. In this way, 
any possible crosstalk/artefacts between extraction and detection, that could affect the 
quantitative assessment of the  glucose extraction process, are eliminated.  
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4.3.1 “Deconstructed in-vivo” measurements: experimental procedure 
Experiments were performed in two ways:  
(i) Volunteers fasted for 8 hours prior to the experiment allowing low blood 
glucose levels to be examined. The position of the extraction sensor on the 
skin was changed every measurement cycle, so that a varying number of hair 
follicles was accessed. 
(ii) Volunteers again fasted for 8 hours before the experiment, and were then 
administered a standard 75 g glucose solution was administrated permitting a 
glycaemic excursion to be tracked. The location of the extraction sensor on 
the skin was kept constant, so that the same follicular paths were engaged at 
each measurement. 
The experimental procedure was as follows: (1) Placement of the extraction sensor onto 
the volunteer dorsal forearm and execution of reverse iontophoresis applying a DC current 
of 75 µA for 5 min. Importantly, the gel reservoir did not contain the GOx enzyme in this 
case. (2) Transfer of the gel reservoirs to the second sensor array, and into a high humidity 
chamber to avoid dehydration of the gel. (3) Application of a constant voltage of 0.4 V 
(vs Ag/AgCl RE) to the WE of the detection sensor on the second array for ca. 10 min to 
stabilize the sensor background and remove the capacitive current contribution to the 
signal. (4) Electrochemical detection of glucose extracted in the gel reservoir by addition 
of 0.4 µL PBS solution containing 16mg/mL of glucose oxidase (GOx) enzyme to the gel, 
and subsequent glucose detection until its total consumption. (5) Placement of fresh gel 
reservoirs onto the first array, and repetition of the extraction cycle by inverting the 
extraction current polarity. The reservoirs, shared between the two arrays, were 2% w/w 
agarose gelled with PBS (pH =7.4) in 0.5 M KCl. 
 
4.3.2 “Deconstructed in-vivo” measurements: results and discussion 
The outcomes of the “deconstructed in-vivo” experiments are shown in Figures 4.8 and 
4.9. As described above, the first variant of the experiment was performed at steady 
glycaemic levels of ca. 5.5 mM after overnight fasting and for the duration of the test. The 
chrono-amperograms shown in Figure 4.8 (a) examined both the anodic and cathodic gel 
reservoirs involved in the two-sensor pair extraction procedure: as expected, the cathodic 
reservoirs showed the presence of glucose, while no glucose was detected in the anodic 
reservoirs. This demonstrated that the cathodic currents correctly established 
177 
 
electroosmotic glucose fluxes during extraction. Figure 4.8 (b) shows an example of 
chronoamperometric responses of the detection sensor to distinct glucose quanta; the 
peaks reflect clearly defined glucose concentrations in the gel and are related to extractions 
through multiple follicular pathways.  
 
 
Figure 4.8| In-vivo deconstructed extraction-detection experiments: chronoamperometric 
response to constant blood glucose levels. Chrono-amperograms acquired after placement of the 
extraction reservoirs on a sensor from a second array. The amperometric signal was investigated 
following the addition of GOx enzyme to the gel. (a) Recorded glucose response in the cathodic and 
anodic reservoirs. (b) Signal response of the glucose extracted through various numbers of hair follicles 
at constant blood glucose concentration. The volume of the gel reservoirs was ca. 7 ± 1µL, i.e., 
somewhat larger than the volumes used in the proof-of-concept ex-vivo and in-vivo experiments in 
Chapter 3.  
 
Notably, the timescale associated with glucose consumption is larger than that expected 
in a real in-vivo glucose tracking experiment. This phenomenon is readily explained by 
the volumes used for the glucose collecting gel reservoirs, which were ca. 7 ± 1µL, i.e.,  
at least two times larger than the gel volumes used in the experiments reported in Chapter 
3 (and also in the second variant of deconstructed in vivo experiment - see below - and the 
in vivo pilot trial discussed later in section 4.4). Larger gel volumes were chosen in the 
first variant of the deconstructed experiment to minimize errors due to potential gel 
evaporation (a decrease of about 15% in the gel volume was reported for the proof-of-
concept in vivo experiments in Chapter 3). In addition, a larger gel volume enables good 
contact to be made between the gel reservoir and the skin. 
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The data collected from the totality of the deconstructed experiments was included in the 
histograms shown in Figure 4.9, which are discussed in detail below. Hence, the 
deconstructed experiments, performed at a constant glycaemic level, corroborate the 
initial hypothesis of quantized extraction of glucose, and the proportionality between the 
total amount of glucose transported by the electroosmotic flow and the number of hair 
follicles interrogated per array pixel. The anodic reservoirs did not show any Faradaic 
current after addition of enzyme during the detection procedure; even when a small 
increase in the current levels were observed upon enzyme addition, the corresponding 




Figure 4.9| Glucose values calculated from the “deconstructed” in vivo experiment at constant 
blood glucose. The histograms show glucose concentrations extracted from amperometric data of the 
type shown in Figure 4.8, from a different number of hair follicles and for a constant blood glucose 
concentration of ~6 mM: (a)  using Faraday's law of electrolysis; (b) using the quasi-steady state 
currents of the curves from Figure 4.8 (b) with the calibration curves of each pixel sensor. Error bars 
indicate standard deviations (N=12). 
 
The histograms in Figures 4.9 (a) and (b) show the glucose amounts collected into the 
gel per hair follicle, as determined by two different estimation models. The first relates 
the area under the chronoamperometric peaks obtained after enzyme addition (such as 
those shown in Figure 4.8) to the moles of extracted glucose using Faraday's law of 
electrolysis (Equation 1.7). In this case, the analysed signal corresponds to the number of 
charges liberated from the H2O2 electrochemical oxidation at the surfaces of the sensing 
electrodes. Application of this model resulted in typical glucose quanta values of 15.0 ± 
0.4 µM and 3.6nmol mA-1 h-1 for the follicular flux, normalised to 1 µL of gel volume, 50 
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µA extraction current and 10 mM of subdermal blood glucose. The second model uses the 
quasi-steady-state current, established around the peak region of each detection curve (see 
inset in Figure 4.8 (b)) with the calibration curve of the corresponding pixel to estimate 
the glucose quantities extracted per follicle. The results were 19.6 ± 0.7 µM for the 
detected glucose in gel and 4.7 nmol mA-1 h-1 for the follicular flux, normalised as before 
to 1 µL of gel volume, 50 µA extraction current and 10 mM of subdermal blood glucose. 
Significantly, these figures approach the median values of 18 ± 2 µM, for the glucose 
“quanta”, and 4.6 ± 0.5 nmol mA-1 h-1, for the follicular flux, reported in Chapter 3 [13]. 
Nevertheless, independent of the calculation model used, the core principle of the 
technology, namely to extract glucose in a quantized manner, proportional to the number 
of follicular pathways being interrogated, is unambiguously supported by the data. The 
experiments were conducted with 22 arrays with each pixel performing detection in 
triplicate for a total of 12 individual measurements.  
Sieg et al. reported a glucose flux of 54.3 nmol cm-2 h-1 from a subdermal glucose 
concentration of 10 mM [14] and employing  an iontophoretic current of 0.39 mA passing  
across 0.78 cm2 of porcine skin for 1 h. Considering that pig skin has an average hair 
density of 23 hair follicles per cm2 [15], the electroosmotic glucose flux in this earlier 
work can be approximately calculated to be ~4.7 nmol mA-1 h-1 per hair follicle, i.e., in 
close agreement to the in vivo value determined here in human volunteers.  
In second variant of the in vivo “deconstructed extraction-detection” experiment, the 
procedure involved tracking in real time the blood glucose levels varying over  a 10 mM 
range after intake of a standard glucose solution. The extraction sensors of the array were 
applied repeatedly to the same locations on the skin throughout the experiment, allowing 
access to the same number of hair follicles each time the extraction procedure was 
performed. Measurements with both AccuCheck (providing the reference blood glucose 
levels) and our array devices were taken at regular time intervals. Figure 4.10 (a) shows 
the chronoamperometric curves measured with the sensor from the detection array and 
after addition of the GOx enzyme to the gel reservoir into which glucose had been 
extracted. Figure 4.10 (b) shows the glucose concentration data obtained from the 
chronoamperometric curves in Figure 4.10 (a) after time-averaging the areas under the 
peaks. The extracted glucose concentration data obtained from our deconstructed 
experiment tracked well the blood glucose profile obtained with the AccuCheck device: a 
clear peak is observed at about 60 minutes after the ingestion of a Rapilose® OGTT 
Solution (AAH Hospital ltd, Coventry, UK), which is a 300 mL sugar-rich solution 
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containing 75 g of glucose, corresponding to a glycaemic peak of 10.5 mM; the successive 
amperometric signals at 90 and 120 minutes exhibited a progressive tendency to reach the 
baseline established by the first measurements corresponding to blood glucose levels 
before the OGTT solution ingestion. Taken together, the data from this deconstructed 
experiment provides further confirmation of the tracking ability of the technology. 
 
 
Figure 4.10| “Deconstructed” in vivo experiment demonstrating real time tracking of blood 
glucose levels. (a) Chronoamperometric data after addition of GOx enzyme to the gel reservoirs, taken 
at regular time intervals before and after glucose solution (OGTT) ingestion. (b) Glucose concentration 
tracking profile obtained from the analysis of the chronoamperometric data shown in (a), compared to 




4.4 In-vivo glucose monitoring pilot trial  
In Chapter 3, proof-of-concept in vivo operation of the technology presented in this thesis 
was demonstrated. The data obtained on a very limited number of healthy human 
volunteers (N=2) showed that the arrays developed were able to track blood glucose (BG) 
variation using single pixel pairs configured in the layout shown in Figures 3.4 (b). Here, 
we present further in vivo data obtained in a larger pilot trial involving 10 healthy subjects. 
The experiments used the second generation of prototypes, based on the optimised device 
layout in Figure 4.1 (a). The study also provided the opportunity to extend the array 
operation from just a single pair of devices (as used in Chapter 3) to two pairs, i.e., the 
maximum number possible in the 2x2 array. Finally, some issues and implications related 
to the operational stability of elements of the extraction and detection devices were 
investigated in more depth.  
To date, only a handful of published papers have reported in vivo data in man. In this 
context, the trial discussed below is a relatively large study that involves a cutting-edge, 
non-invasive glucose monitoring technology. The state-of-the-art of other such 
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4.4.1 In-vivo pilot trial setup and procedures 
Prior to the in-vivo test, the array sensors were calibrated, usually within a week of being 
used, according to the procedures previously described in Chapter 3. The device was 
connected to a custom-made switching board linked, in turn, to a commercial multi-
channel potentiostat (MultiPalmsense4, Palmsens BV, The Netherlands). The board was 
used to easily switch between the electrode circuitry for glucose extraction and that for 
glucose detection, for each of the pixel pairs. A medical-grade double-sided adhesive tape 
(Miilye), with a pattern of openings matching the layout of the sensor pixels, was overlaid 
onto the sensing device; this tape replaced the PDMS membrane used in the experiments 
described in Chapter 3. But, like the PDMS membrane, the tape acted as a supporting 
membrane at the interface between device and skin; it provided mechanical support for 
the array of miniaturized gel reservoirs, defining their volumes, and ensured adherence to 
and a stable position of the sensor and hydrogels on the skin. The gel was not entirely 
levelled to the outer surface of the membrane  to ensure optimum contact with the skin. 
The “pilot trial” experimental procedure involved the following steps: (1) Prior to 
attaching the  sensor to the volunteer’s skin, 0.4 µL of PBS solution containing 16 mg/mL 
of GOx enzyme was pipetted onto each working electrode and allowed to  air-dry for ca. 
15 minutes. Agarose-water hydrogels were prepared as described in Chapter 3; once 
gelled, portions were mechanically excised and placed into the holes of the supporting 
membrane. (2) The sensor was positioned onto the dorsal forearm skin of the volunteer 
and the chronoamperometric current was subsequently stabilized to reduce the 
contribution of capacitive currents to the signal. The stabilization process involved 
performance of amperometric cycles for each pixel until the amperograms superposed, 
testing the extraction process to ensure stable and low resistive interface contacts (see also 
section 4.4.3 and Figure 4.20), and an “initial state preparation” in which a DC current of 
75 µA was applied for 150 s (see Figure 4.11). (3) Next, reverse iontophoresis was 
conducted to extract glucose using electrode pairs from two different pixels to pass a small 
DC current (75 µA equivalent to an average current density of 0.83 mA cm-2) for 300 s. 
(4) Subsequently, electrochemically-based glucose detection in the pixels into which 
glucose was extracted, was accomplished by applying a constant voltage of 0.5 V to the 
WE (vs the Ag/AgCl RE) and monitoring the chronoamperometric current for 300 s, after 
which a second chronoamperometric scanline was repeated (see also Figure 4.12). This 
results in two successive detection chronoamperometric profiles, the second designed to 
demonstrate complete glucose consumption. (5) At the end of each half-cycle, lasting 15 
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min, the extraction current polarity is inverted enabling the recovery of the extraction 
electrode material and the collection of glucose in the opposite pixel. A full operational 
cycle lasts 30 min and is accomplished when both pixels of a working pair finish the 
detection steps (see Figure 4.11).  
 
 
Figure 4.11| Schematic of an operational cycle of a pixel pair. (a) and (b) show time-dependent 
Coulograms where the red and black lines represent anodic and cathodic charges, respectively, that 
develop on the pixels A and B when working in tandem in a full extraction-detection cycle. The 
maximum charge corresponds to a DC current of 0.1 mA applied for 300 s. The time sequence in (a) is 
such that both pixels A and B build-up a similar amount of charge, which alternates in sign; as opposed 
to (b) where charge builds on the two pixels in an asymmetric manner. The schematic also shows the 
electrochemical reactions taking place at the cathode/anode surfaces, as well as how extraction is 
interspersed with detection.  
 
The cycle starts with an “initial state preparation”, in which current is applied for a certain 
period to the extraction circuit. The time sequence is shown in Figure 4.11(a), such that 
the amount and sign of charge built up on the two pixels working in tandem (A and B) 
alternates. The sequence in Figure 4.11(a) is contrasted with that in Figure 4.11 (b), 
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where charge builds up on the two pixels in an asymmetric manner. The electrochemical 
reactions involved in the recovery of the extraction electrode material that accompany 
glucose extraction are summarised in Figure 4.11 (a), and show the periodic creation and 
removal of chloride ions. The “initial state preparation” shown in Figure 4.11 (a) is 
required to establish a stable iontophoretic flux and, importantly, to ensure that an equal 
concentration of chloride ions builds is maintained in each of the detection pixel pair. The 
absence of (or an incorrectly timed sequence for) this “initial state preparation” leads to 
unequal chloride ion concentrations in the gel reservoirs, as shown Figure 4.11 (b). This 




4.4.2 In vivo tests and pilot trial on healthy human volunteers 
4.4.2.1 In vivo testing at constant blood glucose level 
Before the pilot trial on healthy human volunteers, an in vivo test at constant blood glucose 
was performed. This control experiment aimed to address whether: (i) A “warm-up” 
period of the sensors is required (as was the case for the GlucoWatch) and, if so, for how 
long1. (ii) The stability over time of the read-out signal while the blood glycaemic level 
remained approximately constant; the latter signal depends on many elements of the 
sensing device, including the electrodes, gel reservoirs and active enzyme availability. 
Figure 4.12 depicts the chronoamperogram acquisition procedure in the in vivo tests and 
the data processing used to obtain the read-out values from each of the extraction-
detection cycles. Each read-out corresponds to the sensor response to the amount of the 
glucose extracted in the gel and this, in turn, is related to the glucose concentration in the 
blood. Read-out values are calculated by subtracting a baseline from the first 
chronoamperometric scan of a detection cycle (named “detection 1”), and averaging over 
a period of 50 to 250 seconds. For a given extraction-detection cycle, the baseline 
chronoamperometric curve is obtained by taking an arithmetic average of (a) the last 
 
1 The “warm-up” terminology is somewhat inaccurate as it was needed, in fact, to deplete glucose 
present in the stratum corneum due to metabolism of skin lipids (from the conversion of 
glucosylceramides to ceramides) [25]. The initial glucose read-out was therefore non-zero and 
required a couple of hours for depletion via multiple extraction-detection cycles [25]. In contrast, as 
the electrochemical sensors in the pixel array are ~20 times smaller than that in the GlucoWatch, 




chronoamperometric curve recorded prior to the start of the first extraction-detection cycle 
(the “stabilization curve”), and (b) the second chronoamperometric scan of the preceding 
detection cycle, (the “previous curve” or “detection 2”) - see Figure 4.12 (b). This 
procedure was necessary to account for a certain amount of observed signal drift due, for 








Figure 4.12| Procedure used to acquire in vivo chronoamperograms. (a) Example of 
chronoamperometric signals obtained during an in vivo extraction-detection cycle. The different colours 
mark the stabilization baseline (grey), the “detection 1” line (blue), the “detection 2” line of the same 
cycle (red), and the baseline for the next cycle obtained by averaging the “stabilization” and “detection 
2” curves (green); (b) Diagram illustrating the interrelation between the various chronoamperometric 
curves obtained in successive cycles.  
 
Figure 4.13 shows tracking profiles over a period of three hours of relatively steady 
glucose levels of about 4.5 mM for the four sensors of a pixel array. The pairing of the 
pixels in the extraction process was A with B, and C with D. Pixels A and C showed 2 




there was little or no variation in the response of the sensors. However, for all four sensors, 
the read-outs generally decayed with the approximately same slope over the three hours 
of glucose tracking. Divergence of the initial measurement points that do not sit on the 
otherwise linear profiles to be due, perhaps, to glucose in the stratum corneum (see 
footnote above); a similar behaviour was also seen on occasion at the beginning of 
tracking experiments discussed below.  Unlike the situation with the GlucoWatch, though, 
this residual glucose was eliminated in 30 minutes or less.  
 
 
Figure 4.13| In vivo tracking profiles at constant blood glucose. Two pairs of sensors worked in 
tandem, A with B, and C with D. The data points sit linearly on the tracking profiles, except a couple 
of points in the beginning of the sequence. The slow and approximately linear decay of the read-out 
suggests changes within the sensing pixels during continuous operation. The different current levels in 
the four sensors is attributed to different numbers of follicles being probed, as well as slightly different 
sensitivities to glucose detection. 
 
The slow, monotonic decay of the read-out signal over 3 hours of glucose tracking,            
(I  2−4 nA) may be due to a progressive loss of sensitivity of the sensors. Overall, the 
decay in sensitivity was stronger within the first couple of measurement points, while by 
the end of the 6 hour cycle this reached, in some cases, up to 60%. The sensitivity of the 
electrochemical sensors is determined mainly by the activity of the Pt catalytic particles 
decorating the WE.  It was therefore important to investigate the effect of the complex 
extraction/detection operation of the array on WE performance -see section 4.4.3.  Overall, 
Figure 4.13  provides three observations of practical importance: (i) as expected in this 
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control tracking experiment, the read-out signal showed no obvious excursions since 
essentially no blood glucose changes took place over the 3-hour period of observation; (ii) 
a “warm-up” period for the pixel sensors may be required but no more than 30 minutes is 
necessary; and (iii) there is a slow, monotonic decay of the read-out signal, the origin of 




4.4.2.2 In-vivo pilot trial on human volunteers 
Preparations for the pilot trial.  
Ten healthy subjects participated in this study, 2 women and 8 men, whose mean age was 
27 years (range: 22 to 33 years). Subjects were asked to gently shave a zone of the dorsal 
forearm (where the sensor would be placed) the day preceding the test, and to have fasted 
at least 10 hours before the start of the experiment. The skin trans-epidermal water loss 
(TEWL) rate was measured with an AquaFlux device (Biox Systems Ltd., London, UK) 
and, if the recorded values were lower than 20 g m-2 h-1, the shaved skin site would be 
wrapped in parafilm for 20-30 minutes; lastly, prior to placing the sensor, the skin was 
cleaned with ethanol-soaked tissue. Each volunteer participated in one occasion. Both 
samples of blood glucose (BG), obtained with an Accu-Chek Mobile glucose meter (F. 
Hoffmann-La Roche Ltd, Basel, CH), and subdermal interstitial fluid (ISF) glucose, 
obtained with our transdermal pixel array, were recorded every 20 minutes, though not 
simultaneously for the two methods. After about 60 minutes, each subject ingested a 
Rapilose® OGTT Solution. The experiments were terminated following the glycaemic 
peaks dropping in the range of 7 to 6 mM.  The protocol for the study was approved by 
the Research Ethics Approval Committee for Health (REACH) [reference: EP 17/18 94] 
at University of Bath. Written informed consent was obtained from all subjects. 
 
Procedure for acquiring the data and generation of data points.  
The basic procedure for generating a data point on the chronoamperometric current-based 
glucose tracking profile was described in section 4.4.2.1. Figure 4.12 showed the use of 
a two-pass detection procedure, where the second detection chronoamperometric curve in 
an extraction-detection cycle becomes the reference baseline for the first detection 
chronoamperometric curve in the subsequent cycle. In some cases, the tracking of the 
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blood glucose profile can be improved by performing an averaging between these 
“dynamically”-determined baselines and the “stabilization” baseline obtained for each 
sensor before the extraction-detection cycles began. Such a situation is shown in Figure 
4.14, where distinct models have been used to improve the removal of non-faradaic 
current contributions to the detection signal: (a) uses as cycle-dependent baseline the 
second detection of the “previous” cycle, (b) uses the fixed, “stabilization” baseline, and 
(c) uses the arithmetic average between the “previous” and “stabilization” baselines.  
 
 
Figure 4.14| Effect of different data analysis models on device current response. The device current 
response was calculated using three distinct models: (a) “previous baseline” subtraction; (b) 
“stabilization baseline” subtraction; (c) subtraction of the arithmetic average between the “stabilization” 
and “previous” baselines. 
 
The interrelationship between these chronoamperometric curves is shown in Figure 4.12.  
In this particular case and as shown by Figure 4.14 (c), a qualitative improvement in the 
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shape of the tracking profile is obtained by performing this baseline averaging, but, most 
importantly, the total swing in the detection current between the minimum and maximum 
glucose concentration detected is in better agreement with the current value corresponding 
to the initial glucose concentration. This indicated a satisfactory removal of non-faradaic 
current contributions, which are not always easy to quantify (at least at this point of 
development of the technology). We also note that in Figure 4.14 the profile in green 
indicates a sharper peak, which is not observed in the reference blood glucose profile: as 
this profile corresponds to the highest chronoamperometric current, it suggests an instance 
where residual glucose accumulation has built in the pixel, so that two successive 
detection scans were not sufficient to deplete the glucose extracted in the pixel. In general, 
as explained in Chapter 3, complete glucose conversion to H2O2 is expected after 
extraction, due to the excess enzyme adsorbed on the working electrode surface, small 
quantities of extracted glucose, and miniaturization of devices that decreases the overall 
glucose diffusion time between various parts of the device; furthermore, any residual H2O2 
still present within the pixel reservoirs after glucose reaction with GOx is expected to be 
cleared by disproportionation catalysed by the Pt [26] and Ag nanoparticles [27] contained 
in the screen-printed inks of the various electrodes. 
 
 
Clark Error Grid Analysis 
Clark Error Grid Analysis (EGA) [28] represents one of the gold standards for the clinical 
accuracy evaluation of brand-new glucose sensors, including continuous glucose 
monitoring devices (CGM). This technique is a graphic presentation of blood glucose 
concentration values estimated from the sensor under investigation against reference 
values from a commercial glucose meter. The acquired scatterplot is divided into five 
zones (A, B, C, D and E) of the Clark Error Grid, describing the accuracy of the 
measurements in terms of clinical utility. The data points falling in zones A and B are 
accurate (within 20% of the reference) or acceptable (outside the 20% threshold but not 
leading to incorrect treatment) glucose results, respectively. Zone C identifies with 
unnecessary correction of a clinical treatment and a poor outcome. Values in zone D are 
associated to a dangerous failure in detecting, hence treating, hypoglycaemic and 
hyperglycaemic events. Lastly, those in zone E would lead to the treatment of 




The assignment of the various data points obtained experimentally to the various Error 
Grid zones was made based on the values of three variables: the absolute relative error 
(ARE) parameter (defined below), the Sensor interstitial fluid (ISF) glucose concentration, 
and the Reference blood glucose (BG) concentration (expressed in mg/dl). ISF glucose 
concentration is measured using our technology (or, in general, with the new technology 
that needs to be assessed), while the Reference BG concentration is obtained with the 
Accu-Chek Mobile glucose meter. ARE is defined as: 
 
𝐴𝑅𝐸 % =




The partition of the (Sensor Interstitial Fluid Glucose vs Reference Blood Glucose) space 
into the zones of the Clarke Error Grid was based on the original Clarke EGA [28], [29]. 
For example, a data point falls in zone A if ARE   or both Reference BG and Sensor 
ISF are less than 70 mg/dl; while a data point falls in zone D if the Reference BG < 70 
mg/dl and Sensor ISF is between 70 and 180 mg/dl, or the Reference BG > 240 mg/dl and 
Sensor ISF is between 70 and 180 mg/dl.   
Figure 4.15 shows how one progresses from the measured data to populating the Clarke 
Error Grid. Figure 4.15 (a) shows the tracking chronoamperometric current related to the 
ISF glucose, measured with our technology, vs time, together with the tracked BG profile, 
measured with the Accu-Chek Mobile glucose meter. In general, there is a lag between 
the ISF glucose and the BG [30] (see Chapter 1), and here a shift of 21 minutes was applied 
to the measured current profile in order to superpose the two profiles. From Figure 4.15 
(a), one can then generate Figure 4.15 (b) by plotting the measured chronoamperometric 
current values vs the BG values to which they correspond by interpolation with the BG 
profile; then a linear fit is performed that gives a “current vs BG glucose” calibration for 
our in-vivo measurements. Deviations from this calibration curve allows one to calculate 
the ARE parameter for each of the data points. Finally, Figure 4.15 (c) displays on the 
left Oy axis the measured ISF glucose concentration vs the BG reference concentration, 
while the ARE parameter (determined based on the relationship Equation 4.2) is 
displayed on the right Oy axis The example in Figure 4.15 shows a data set for which all 
the data points fall in region A of the Clarke error grid as all the ARE values are less than 
20%. Other data sets included in Annex II show situations where some of the data points 





Figure 4.15| How to correlate ISF glucose measured with our technology to reference blood 
glucose, and determine the associated ARE parameter. (a) Device amperometric signal tracking BG 
fluctuation vs time; (b) Plot of the amperometric currents vs reference BG values; (c) Plot of glucose 
concentrations, measured with our device, vs the BG reference concentrations and respective absolute 
relative errors. 
 
This procedure was applied to the in-vivo sets collected, resulting in the Clarke Error Grid 
analysis shown in Figure 4.16. This analysis includes 111 data points, collected across 8 
different experiments, whose corresponding primary results are shown in Annex II. Out 
of the 111 data points included, 93% fall within region A (i.e. within 20% of the 
reference), where the sensor response to glucose is considered accurate, while the 
remaining 7% fall within region B, where the sensor delivers an acceptable measurements 
for clinical treatment. One also notes the relatively limited range of glucose values probed; 
this is due to all subjects being non-diabetic, their response to the Rapilose® OGTT 
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Solution falling within a median range of glucose concentrations. Hence, the hypo- or 
hyper-glycaemic regimes were never probed.  
 
 
Figure 4.16| Clarke Error Grid Analysis (EGA) for the in-vivo pilot trial. The data points shown 
fall in zone A, i.e. accurate (within 20% of the reference) glucose concentration measurements; or in 




The results from Figure 4.16 are very positive and clearly demonstrate the ability of this 
technology to access ISF glucose and correctly track blood glucose profiles. However, 
they come with some caveats. Some of the results obtained in the pilot study were 
excluded from the Clarke EGA based on acknowledged issues with the data acquisition. 
In this respect, two types of problems were identified: (i) in two experiments, there was 










































poor skin contact leading to a very large voltage drop across the skin during the extraction 
stage (see also Figure 4.20 and associated discussion in section 4.4.3.3); (ii) in about 50% 
of the experiments only one pair of pixels, out of the two available on the array, was 
functional, the non-functional one displaying a clear lack of tracking of blood glucose. 
This can have different causes, such as the short circuit of detection electrodes during 
operation. Nevertheless, there were also cases where all four pixels of the array, or at least 
three of them, were operational (such as in Figure 4.14), demonstrating that, in principle, 
the array can function as expected. 
In general, glucose profile tracking can be improved by a more careful design of low-
noise switching circuitry, which will decrease contributions of non-faradaic signals in the 
detection circuits. Full automation of the raw data acquisition and addressing of the 
multiple pixels of the array needs to be implemented so that data acquisition takes place 
at entirely periodic intervals: since in a pixel device, the processes that occur during a full 
extraction - detection cycle are very complex (e.g. involving periodic formation/removal 
of double layers or creation/removal of chloride ions), it is important that all data points 
are taken at same moment in time in all cycles, so that the state of charge distribution 
within the system is kept as similar as possible across cycles. Furthermore, any effect of 
the extraction process on the detection (see section 4.4.3) needs to be minimised as much 
as possible. Finally, processes that lead to evolution of the various pixel device elements 
(such as changes to the state of the detection/extraction electrodes, evolution of gel 
reservoirs, accumulation of poisoning/biofouling analytes, slow build-up of unconsumed 
glucose) all need to be minimised or removed in order to extend the operational life-time 
of a pixel device; section 4.4.3 makes a critical analysis of some of these processes and 
identifies ways to address negative effects resulting from them. 
Another positive aspect resulting from this pilot trial was the absence of skin irritation of 
the subjects, as shown in Annex II. Photographs taken just after the end of the tests 
showed only a faint redness in some of the cases (and no irritation at all in other cases), 
and a completely normal aspect of the skin 24 hours later. This contrasts with the 




Assessment of effects of long-term in-vivo operation   
The first type of effect concerns potential irritation of the skin of the volunteers. This is 
important because this was ultimately the main reason for the GlucoWatch failure on the 
market [31]. In our experiments, volunteers did not perceive any discomfort throughout 
the experiment and no skin irritation was noticed after the experiment was concluded, see 
Annex II. In general, at most, there was only very low-grade redness (while in other cases 
there was no discernible redness at all) just after the end of the in-vivo session, which 
completely subsided after 24 hours. In the case of the GlucoWatch, the irritation was 
already very pronounced at the conclusion of 24 hours of usage of the device, which 
became even more pronounced after 24 hours. In Chapter 3 we explain the significantly 
lesser irritation of the skin noted in our case by a decrease in the power dissipated through 
the skin when the operational area of the sensor decreases – as is the case for our miniature 
pixel devices.  
The second type of effects relates to the state of the devices themselves. We noted that 
when in contact with the skin, gel volume and structure appeared stable and its mass 
decreases by ca. 10–15% over 6 hours of continuous glucose monitoring; the robust 
structure of the gel is still evident when the experiment is terminated. However, the 
sensitivity of the electrochemical sensors was found to decrease, in some cases by up to 
50%. Various effects affecting different electrodes in our devices were noted, as discussed 
in section 4.4.3 below, and attempts to identify causes and provide solutions for 




4.4.3 Operational stability of extraction, detection and reference electrodes 
The repeated extraction-detection cycles over many hours of operation can induce gradual 
changes to multiple elements of the pixel array. Such changes are not unexpected given 
the miniaturization of the devices involved and they need to be understood so that their 
effect is minimised/eliminated or, if not, compensated in a final embodiment of the 
technology. One example of evolution of device performance has been already identified 
in Figure 4.13.  
In this section, the stability of the electrodes involved in detection or extraction during the 
in-vivo operation is investigated; specifically, the working electrode (WE), the reference 
electrode (RE), and the pair of extraction electrodes. In some cases, changes in one 
electrode can indirectly affect the performance of others.  
 
4.4.3.1 Deactivation of the working electrode 
General considerations 
Several hypotheses were tested to explain the slow, gradual decay in the read-out signal 
at constant glucose noted in Figure 4.13. 
Whether this effect could be the result of degradation of the GOx structure was first 
considered as a progressive loss of the enzyme activity would obviously affect sensor 
performance [32]. However, the experiment summarised in Figure 4.13 (and, in general, 
all the glucose tracking experiments) was conducted with freshly prepared GOx, 
suggesting that enzyme instability cannot be a significant contributing factor. Second, the 
read-out signal decay may be “apparent” rather than real, and the result of some residual 
glucose accumulation in the gel reservoir; given that each read-out point is determined 
from the difference between the measured chronoamperometric signal obtained just after 
extraction and a baseline which corresponds to the previous measurement (see Figure 
4.12 and associated discussion), incomplete glucose consumption would lead to an 
apparently lower signals for subsequent measurement points. Third, and probably the most 
important hypothesis is that the read-out signal decay is due to decline in the sensor 
sensitivity associated with deactivation of the catalytic PtNPs (which catalyse the 
electrochemical oxidation of H2O2) present on the surface of the WE. The WE delivers 
the amperometric signal of the redox reaction to the device acquisition system. 
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Nanoparticles are typically less stable than the bulk material, and several degradation 
mechanisms may compromise their structural integrity [33]–[35], including: (1) 
dissolution, which is favoured by the large surface area available, may lead to the loss of 
catalyst in solution and its redeposition on larger particles (via Ostwald ripening); (2) 
leaching of nanoparticles into solution or into the screen-printed electrode following 
detachment from the support; (3) nanoparticle sintering due to Ostwald ripening or 
agglomeration and the consequent loss of active surface; or (4) corrosion of the conductive 
(carbon) and inert (binder) support structures, that can also lead to nanoparticle 
detachment or agglomeration. In addition, WE deactivation can also be ascribed elsewhere 
[36], [37]; for example, (a) by-product chemisorption and poisoning of the catalyst 
surface; (b) active site biofouling and in-situ product build-up; or (c) chemical or 
electrochemical transformation of the catalyst. Three of the major deactivation 
mechanisms are schematically shown in Figure 4.17. 
 
 
Figure 4.17| PtNPs deactivation mechanisms.  The central panel of the diagram represents the starting 
point from which the undamaged WE undergoes deactivation processes.  
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For example, Pt deactivation has been attributed either to decarbonylation of gluconic acid 
or through direct adsorption of gluconic acid onto the PtNPs (111) surface [38]. Certain 
endogenous amino acids are also able to poison platinum electrodes [39], an effect 
associated with adsorption of the amino acids and/or their oxidation products [40] that 
impairs electrochemical sensing. Amino acid chemistry determines the degree of 
poisoning of the catalyst with stronger effects induced by basic amino acids, those with 
sulphur-containing functional groups, and the hydrophobic aromatic amino acids [41], 
[42]. All deactivation mechanisms decrease the availability of the catalytic active sites and 
reduce the sensitivity of the PtNPs to analyte detection. The experimental procedures 
developed to evaluate the PtNPs active sites on the PtNPs examined two specific 
deactivation mechanisms: (i) poisoning with iontophoretically extracted biological and 
biochemical entities, and (ii) the effect of the extraction process, causing the PtNPs to 






To evaluate the poisoning attributed to the ISF-extract, in vivo reverse iontophoresis was 
first performed on a healthy human volunteer, and then ex-situ, and intentional, 
“poisoning” of the WE was undertaken using the ISF extracted.  
ISF extraction was performed into two cylindrical glass cells (diameter 1.6 cm, extraction 
area 2 cm2), placed 6 cm apart and taped to the volunteer’s dorsal forearm (Mefix®). The 
chambers were filled with 1 mL of 20 mM ammonium chloride solution. Custom-made 
Ag/AgCl electrodes were introduced into the collection reservoirs at a distance of 4 mm 
above the skin surface thereby avoiding any physical contact. A Phoresor II Auto was 
used to pass a DC current of 1 mA (current density =0.5 mA/cm2) between the electrodes, 
for a total of 14 × 5 min, and alternating the current polarity every 5 minutes. The extracted 
ISF sample solutions were passed through a sterile syringe filter (Minisart RC 4, 0.45 µm, 
4 mm diameter, Sartoris Stedim Lab Ltd, Stonehouse, UK), into centrifugal tubes and 
immediately frozen (and stored in a freezer at -20°C) until analysed (Material and 
Chemical Characterisation Facility (MC2), University of Bath) by HPLC-MS [43].  
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Poisoning of the WE was achieved by pipetting 1 µL of the sample solution onto the gel 
reservoir (4 µL, 2.5 % w/w agarose, 0.1 M PBS, 0.5 M KCl) of a sensor device, and the 
performing amperometry at a constant voltage of 0.4 V (vs the screen printed Ag/AgCl 
RE), for 7 cycles with a detection time of 10 minutes. 
The effect of RI extraction process on the WE was investigated by mimicking the in vivo 
experiment in humans in an in vitro experiment using excised porcine skin. A 2×2 pixel 
array, with 4 µL volume gel reservoirs (2.5 % w/w agarose, 0.1 M PBS, 0.5 M KCl), was 
placed in contact with a sample of porcine skin and a direct current of 75 µA was applied 
between the extraction electrodes of a pixel pair, for 14 cycles, alternating the polarity 
every 5 min. The subdermal compartment was a PBS-soaked tissue. 
WEs, after both the poisoning and extraction-mimicking experiments, were examined by 
assessment of the electrochemical active surface area (ECSA) and of the open circuit 
potential (OCP). The ECSA was determined from the variation of the platinum oxide 
reduction peaks obtained from cyclic voltammetry in a 0.5 M H2SO4 solution, with the 
voltage ranging from -0.2 to +1.3 V, a scan rate of 0.05 V/s and 5 mV potential steps. 
Chronopotentiometry was performed at OCP, in a 0.1 M PBS for 20 minutes. A platinum 
rod was used as an auxiliary electrode, and a commercial Ag/AgCl electrode (DriRef2) 
was used as a reference for both experiments. The experimental details are in Table 4.6. 
 





0.5 V, 7 x 10 min 
Extraction-mimicking 
Chronopotentiometry  
14 cycles x 5 min, 0.075 µA 
OCP, pre- and 
post-deactivation 
Potentiometry, 20 min, 0.1 M PBS 
ECSA, pre- and 
post-deactivation 





Results and discussion 
Figure 4.18. shows typical variations of the ECSA and OCP of the WE after the poisoning 
and extraction-mimicking experiments (performed on different sensors) to be determined.  
 
Figure 4.18| Effect of poisoning and extraction on the working electrode (WE). (a) Cyclic 
voltammetry before and after the two experiments, recorded in a 0.5 M H2SO4 solution at 0.05 V/s. The 
voltammograms show only the reduction peaks of the platinum oxide layer from which the ECSA can 
be determined. (b) Potentiograms obtained in 0.1 M PBS, from which the OCP was determined. 
 
The areas within the troughs of the cyclic voltammograms in Fig. 4.18 (a) are associated 
with the quantity of charge needed to reduce a platinum oxide (PtO) layer to platinum (Pt), 
and this is proportionally related to the ECSA of the electrode [44]. The CVs [Fig. 4.18 
(a)] therefore show that the sensor post-extraction (blue curve) underwent a substantial 
reduction in ECSA compared to the control (black curve); the poisoned sensor (red curve), 
in contrast, showed little change. Fig. 4.18 (b) demonstrates a marked decrease in OCP 
after extraction, and a much smaller reduction after poisoning. Generally, a decrease in 
OCP can be attributed either to dissolution of the metal (in this case, the PtNPs decorating 
the screen-printed film support), or to passivation of the electrode via film formation.  
Samples examined by HPLC-MS showed that the biological species extracted from ISF 
in vivo comprised mostly amino acids and other small molecules (Table 4.7). Small and 
highly polar (such as zwitterions) compounds are essentially extracted in the same 
concentration in both the cathodic and anodic collection chambers by cyclically reverting 
the extraction polarity. However, fully ionized species including arginine, histidine, 
lysine, ornithine, aspartic acid, glutamic acid and urocanic acid are preferentially extracted 
and accumulated in the chamber of opposite polarity, in accord with electrostatics. This 
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preference was apparent even when the electrode polarity was alternated throughout the 
experiment due to the accumulation of the analyte during the last extraction cycle. The 
quantitative analysis of the content of the ISF-extraction is summarised in Table 4.7. 
 
Table 4.7: Quantification of the chemical species extracted by reverse iontophoresis (N=4; mean 
± S.D.); NP =  not present, NQ  =  not quantifiable.  
Compound Extraction chamber concentration (µM) 
Cystathionine NP 
Glycine 13.5 ± 1.82 
Homocysteine dimer NP 
Alanine 9.16 ± 1.02 
Anserine NP 
Carnosine 0.46 ± 0.08 
Citrulline 25.1 ± 2.46 
Creatinine 0.08 ± 0.01 
Cystine NQ 
Cystine dimer NQ 
Homocysteine NP 
Isoleucine 2.62 ± 0.56 
Leucine 2.22 ± 0.54 
Methionine 0.61 ± 0.15 
Phenylalanine 0.94 ± 0.25 
Proline 7.41 ± 1.18 
Serine 65.2 ± 5.91 
Threonine 22.3 ± 1.69 
Tryptophan 0.22 ± 0.19 
Tyrosine 3.26 ±0.43 
Valine 7.19 ± 1.12 
Taurine 0.85 ± 0.22 
Urea 160 ± 38.5 
Ethanolamine 14.6 ± 1.72 
Hydroxylysine NP 
Hydroxyproline NP 
Methyl histidine NP 
Pyrrolidone carboxylic acid NP 




Arginine 8.14 ± 1.61 2.93 ± 1.2 
Histidine 21.6 ± 3.02 8.39 ± 2.70 
Lysine 6.89 ± 1.04 2.89 ± 0.67 
Ornithine 3.41 ± 0.79 1.17 ± 0.42 
Aspartic acid 3.47 ± 0.63 9.21 ± 5.2 
Glutamic acid 8.86 ± 0.45 21.5 ± 8.1 
Urocanic acid 279 ± 31.6 337 ± 49.4 
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4.4.3.2 Drift in the reference electrode potential 
Although the primary cause of read-out signal decay is attributed to loss of sensitivity in 
the WE during operation, the reference electrode (RE) performance is also important. The 
RE defines the voltage applied to the WE during detection and maintaining a constant RE 
potential is therefore essential to the acquisition of reliable glucose measurements. During 
detection, each pixel works as a two-electrode system with the RE also acting as an 
auxiliary electrode receiving or providing electric current to balance the charge passing 
through the WE. Although this arrangement is commonly employed in low-current 
electrochemical systems [16], [23], current flow through the RE might affect its structural 
integrity and surface electrochemistry.  
To test RE stability after its use in a pilot volunteer experiment (as detailed above), 
potentiometric measurements were performed at open circuit potential in two-electrode 
mode; the electrode under examination was connected to the WE terminal and a 
commercial Ag/AgCl DriRef2 RE to the short-circuited counter/reference terminal.  Both 
electrodes were then immersed in a saturated KCl solution for an hour. Figure 4.19 shows 
the resulting potentiograms of the four REs of a 2×2 pixel array.  
 
 
Figure 4.19| Stability of the reference electrodes (RE) of the four devices in a 2x2 array following 
six hours of in-vivo operation. Potential differences at OCP between the screen-printed Ag/AgCl REs 




The variation in time reflects the progressive approach to the electrochemical equilibrium 
between the chloride ions in solution and the Ag/AgCl RE but, overall, the potentiograms 
show negligible voltage variation over time. 
In principle, since the materials involved are the same both for the device REs and for the 
DriRef2 (i.e., Ag/AgCl), the measured voltage difference between them should have been 
0 V. However, small mV voltage differences, as seen in Figure 4.19, are reasonable, and 
likely reflect variations in the electrochemical double layer at the electrode-solution 
interface. Such differences depend on both the physical structure of the screen-printed 
electrodes and the adsorption of biochemical species at the electrode surface after the in-
vivo experiment. The results from Figure 4.19 demonstrate the stability of the REs, and 
show that their performance was not affected by the operation of the devices in real-life 
conditions.  Furthermore, the standard potential of the screen-printed Ag/AgCl REs 
depends on the Cl- concentration in the geland this would be expected to be constant, i.e., 
0.64 M in each gel reservoir. However, during the extraction process, the chloride ion 
concentration fluctuates in the cathodic and anodic chambers due to the electrochemistry 
at the extraction electrodes’ surface (see Figure 4.11). Fortunately, though, the extraction 
polarity reversal at each operational half cycle restores the Cl- level to its initial value, 
thus preventing either accumulation or consumption. Even if the effects shown in Figure 
4.19 are not large, future sensor improvements may involve sharing a reference electrode 
among several pixels and placing it in a stand-alone saturated KCl gel outside the 
individual pixels, thus avoiding any detrimental effect due to Cl- fluctuations. 
 
 
4.4.3.3 Extraction electrode stability and recoverability 
Lastly, the extraction electrode (EE) pair may indirectly affect the sensor response to 
glucose. It is plausible to envisage that alteration of the EEs structure may decrease the 
efficiency of electroosmotic glucose extraction and promote uncontrolled and detrimental 
reactions at the electrode surface.  
Figure 4.20 presents chronopotentiograms acquired from three volunteers during glucose 
extraction in the pilot trial. In each set, the voltage across the skin gradually decreased and 
usually stabilized after a few extraction cycles in the process of establishing an optimal 
electromigration current. The data identify three distinct voltage ‘regimes’: (I) above 4.5 
V, the electroosmotic glucose extraction was generally poor and the high resistance of the 
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system was attributed to either poor contacts at the interface between gel and skin or 
reduced skin transport due primarily to low skin hydration; (II) between 2 and 4.5 V, 
although the resistance across the skin was lower, there was still impaired glucose 
extraction despite the fact that, overall, the sensor operation was feasible; and (III) below 
2 V, glucose transport across the skin was optimum. Furthermore, low voltage across the 
skin and in the gel greatly avoided the risk of unwanted chemical reactions occurring at 
the extraction electrode surface, such water electrolysis, and those involving chloride and 
silver species  
 
 
Figure 4.20| Extraction voltages measured during the in vivo pilot test. Potentiometric curves of the 
voltage across the skin illustrating three distinct behaviours as described in the text.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
It is noted that all the potentiograms in Figure 4.20 demonstrated full resiliency until the 
5th  extraction cycle when, after application of direct current for 200 s, nearly all of the 
curves began to distort.  This phenomenon was attributed to the molecular rearrangement 
of the material comprising the extraction electrodes and the likely loss of structural 
integrity. In conclusion, due to concurrent electrochemical reactions at the electrode 
surface, the EE material is not entirely recoverable suggesting that, in the next prototype 
iteration, an increase in the mass/thickness should be examined. 
Parenthetically, it should be mentioned that the direct application of current to the EE can 
cause release of Ag which, via diffusion in the gel, then deposits onto and passivates the 
WE (after its electrochemical conversion into silver oxide, AgO during the detection 
phase) [45]. Placing a polymeric membrane on the WE should allow this effect to be 




A second generation of 2  2 pixel arrays were realised. They incorporate a circular design 
which maintains the original pixel area but where the working electrode is central and of 
larger area. This design boosts both the sensor’s response, and the detection response time 
by accelerating glucose diffusion and consumption kinetics.  
The establishment of a novel surface pre-treatment protocol for the PtNPs-decorated 
screen-printed graphene electrodes led to both an increase of their electrochemical active 
surface area and faster electron transfer kinetic, showing efficient sensing for glucose 
determination.  
The range of in-vivo experiments performed was expanded in order to test various 
relationships at work during the process of transdermal glucose extraction – detection. 
Firstly, we decoupled extraction from detection and unequivocally demonstrated that at 
fixed extraction current (through the same probing area) the concentration of glucose 
extracted is “quantized”, scaling with the number of follicular pathways probed. Secondly, 
we extended the number of in-vivo glucose tracking experiments to a mini pilot trial 
involving ten non-diabetic volunteers. Tracking profiles were presented in the form of a 
Clarke Error Grid, showing that majority of data points fall within 20% of the median line 
of the grid (region A), with other points falling in the B region. These results are very 
encouraging, despite the study also having revealed a number of outstanding technical 
issues (as summarised below) that need solving in a further iteration of the technology. 
The volunteers also had no precedent history of skin disease, and the study was able to 
demonstrate that after six hours of continuous testing no skin irritation was induced, and 
neither was this present 24 hours after the test period. This is also very encouraging 
because skin irritation after operation, with exacerbation 24 hours later, was the main 
reason for failure of a related technology, the GlucoWatch. 
The in-vivo pilot study also highlighted technical limitations of the current implementation 
of the pixel array that need to be overcome for achieving better consistency of the response 
of the sensors in the arrays. This is mainly directed to the fact that not all pixel devices in 
the array were functional simultaneously and, hence, able to track the blood glucose 
profile. Furthermore, the methods of interrogation of the array need to be fully automated 
so that manual operation does not interfere with data acquisition; and the methods chosen 
for the fabrication of some of the device elements need to be able to deliver a higher level 
of reproducibility and uniformity of the pixel devices within an array, and between arrays. 
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The long-term operation (i.e. over 6 hours) was found to affect the elements of a pixel 
device (ranging from gel reservoir to working, reference and extraction electrodes) in 
various ways. Different deactivation processes affecting both glucose extraction and 
detection were revealed, and various strategies to eliminate or decrease the impact of these 
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 Conclusions and 
Perspectives 
5.1 General conclusions 
Recent years have seen a growing interest in developing wearable devices in conjunction 
with Smartphone apps for personalized health monitoring. Such an approach will promote 
the concept of continuously gathering bio-relevant information to assess the health status 
of a patient and make a prompt and personalised therapeutic action feasible. In glucose 
monitoring, the “holy grail” is to achieve a non-invasive approach that eliminates the use 
of needles in any form and, eventually, becomes appealing to pre-diabetics, in an effort to 
shift emphasis from diabetes treatment to its prevention.  
This doctoral thesis introduces and fully demonstrates a novel non-invasive, transdermal 
glucose monitoring technology, based on an innovative concept that exploits existing 
preferential transdermal pathways (in the form of skin appendages, such as hair follicles) 
for extraction of interstitial fluid (ISF) glucose via electroosmosis. The implication of this 
is that a quantifiable amount of glucose, with the “quantum” being fixed by extraction via 
a single preferential pathway would be drawn into a well-defined, microliter sensor 
volume – thus, opening the possibility of performing quantified, continuous glucose 
monitoring without the need for calibration using an external method (such as “finger-
pricking”). Depending on the level of accuracy that can be eventually obtained, the 
technology would be suitable for both Type 1 and Type 2 diabetics, as well as for 
prevention/determination of the onset of Type 2 diabetes.  
A reverse iontophoresis-based glucose monitoring platform was proposed in the form of 
an array of miniaturised pixel devices with dual extraction/detection roles, each pixel 
being small enough to be able to address individual pathways through skin having a wide 
range of follicular densities. The array was fabricated in a patch-like form, fastened to 
human skin, to provide real-time transdermal monitoring of ISF-born glucose. Not least, 
an important consideration was to keep the production cost of the technology low, so as 
to offer a final product at a competitive price. Hence, the technology was implemented via 
inexpensive fabrication techniques, such as screen printing, and using flexible and 
inexpensive substrate materials (such as polyethylene terephthalate) and graphene-based 




Proof-of-principle of the technology was demonstrated by a combination of ex-vivo 
experiments using excised porcine skin, and in-vivo studies on healthy human volunteers. 
“Deconstructed” in-vivo experiments, where the extraction circuitry was not allowed to 
interfere in any way with the detection stage, were also performed to validate the ex-vivo 
and in-vivo results obtained in normal extraction/detection operation. All these results 
allowed the determination of a glucose extraction flux per hair follicle in certain 
standardised extraction conditions, and demonstrated that this path-selective approach 
enabled significant improvement over that via non-follicular skin. All experiments 
employed 22 pixel arrays. This is less than the calculated number of pixels that 
statistically guarantees the interrogation of, primarily, individual follicular pathways  
(which  was determined to be  44 pixels); however, the results from the 22 pixel arrays 
showed that the measured extraction could be rationalized based on multiple “quanta” and 
that larger pixel sizes can still represent a valid physical realization of the technology.  
The initial proof-of-concept study (published in Nature Nanotechnology) was followed 
by more in-depth in-vivo work involving, first, extraction at constant blood glucose, and 
then, within the framework of a pilot study on a small cohort (n = 10) of healthy human 
volunteers, when the extracted and detected glucose profile was tracked following an oral 
glucose tolerance test. Overall, the ability of the technology to track various blood glucose 
profiles was demonstrated, and a preliminary Clarke Error Grid analysis was performed. 
This analysis showed that for the pixel devices that operated correctly, glucose tracking 
over about 6 hours with accuracy within acceptable limits, i.e., with all data falling within 
zones A and B of the Clarke Error Grid, was obtained. The studies also highlighted some 
limitations of the current technological implementation (summarised below in 
“Challenges and Perspectives”) that will need to be addressed to advance the technology 
to commercialization. 
The in-vivo work also highlighted another successful aspect: the lack of significant skin 
irritation after 6 hours operation of the sensor (and the complete absence thereof after 24 
hours). This is in marked contrast with the irritation observed after use of the 
GlucoWatch® (a related technology that was briefly commercialised in 2001), which had 
a much large sensor area (of ~1 cm2) than the miniaturised (of several tens of mm2 area) 
pixel devices described in this thesis.  
Several circuit layouts were examined in the project. With respect to glucose response 
time and collection efficiency, those designs with the working electrode positioned 
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centrally within the pixel were superior to those in which the WE was placed externally 
(and the extraction electrode was central). The effect of the extraction process (where a 
relatively sizeable bias is applied across a pair of extraction electrodes) on the other 
electrodes present in the pixel device, and notably on the working electrode involved in 
glucose sensing, was thoroughly investigated. The working electrode also appears to be 
affected (by biofouling) by a range of other analytes that are present in the reverse-
iontophoretically extracted ISF. Taken together, these phenomena contributed to a 
decrease over time of the glucose detection efficiency of the working electrode; this issue 
is of great importance and needs to be addressed in a future embodiment of the array. 
Approaches to re-activate the working electrode were also investigated and procedures 
proposed. It is important to realise that, even if these negative issues cannot be resolved 
in full, the recommended full-size 44 array, in which the number of pixels enables a 
degree of redundancy, provides a solution for the different electrode problems to be 
circumvented: for example, each quarter of the array (i.e., a 22 sub-array, as used in our 
studies) can be used successively for a 6-hour period, thereby increasing the operation 
time to a more optimal, and ultimately more desirable, 24 hours.  
Finally, by studying the efficiency loss of the electrodes of the pixel devices due to 
extraction of analytes other than glucose present in the ISF, it was possible to identify 
other potentially interesting compounds that may provide other ‘targets’ for biosensing 
with this non-invasive method. It is therefore possible to envisage a multiplexed array 
design to sense simultaneously other subdermal biomarkers such as amino acids, small 
peptides, metabolites and electrolytes. Such multi-analyte sensing could enable a 
molecular-level view of the health status of a patient and be an invaluable tool with which 
to personalise therapeutic interventions. 
 
 
5.2 Challenges and Perspectives 
The results presented in Chapter 4 revealed a number of issues that need to be solved to 
progress the technology to commercialization: 
• Potentially, the most severe problem uncovered was the decline in sensitivity of 
the sensing part of the miniature pixel devices that was linked to changes in the 
condition of the working electrodes. This phenomenon has been primarily 
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attributed to passivation of the working electrode with both organic and inorganic 
chemical species that decrease its active catalytic surface and obstruct charge 
transfer. Future device embodiments may consider the use of electrocatalysts 
based on multi-component catalysts (i.e. random alloys, inter-metallic alloys, near 
surface alloys, and core/shell particles[1]–[3]), instead of pure Pt, which can 
provide very large catalytic activity and be less prone to amino acid adsorption. 
Another approach is to deposit a protective polymeric membrane onto the working 
electrode to stop the adsorption of biofouling species onto the active sites of the 
catalytic particles. 
It is important to note that the array-based concept proposed in this work is not 
bound to the use of first-generation biosensors. Instead, the incorporation of an 
electron transfer mediator (second generation biosensor) may be considered. In 
this respect, of particular interest are electrochemically active redox couples 
(including Prussian blue or analogues) which allow H2O2 or direct glucose 
detection to take place at an applied voltage substantially lower than 0.4 V (vs 
Ag/AgCl reference), and, therefore, attenuate the working electrode passivation 
by impeding the electrochemical oxidation of silver to silver oxide. Finally, 
mitigation may also be achieved by increasing the detection sensitivity beyond 
that attained so far, for example, by implementing effective electroanalytical pulse 
techniques (such as  differential pulse voltammetry (DPV), square wave 
voltammetry (SWV) or normal pulse voltammetry (NPV)), and/or incorporating 
new/hybrid nanomaterials. In this way, coupled with the implementation of a 
“compensation” algorithm (that would correct for any decrease in sensitivity), the 
operation time of the devices would be increased even if biofouling is not entirely 
eliminated.  
• The ability to provide accurate blood glucose tracking can be improved by fully 
automating the electrical addressing of extraction/detection circuitry across all the 
pixels of the array. As a result, switching between various circuit parts can be 
performed at exactly regular time intervals, enabling similar device states to be 
achieved in all extraction/detection cycles.  
• The pilot trial showed that not all 4 pixels were operational across all the 22 
arrays tested.  
Therefore, future development requires more robust fabrication procedures, with 
potentially fewer processing steps so that uniformity in performance is achieved 
both between the pixels of the same array, and between different arrays.  
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• The use of a biorecognition strategy makes the biosensor sensitive to external 
stimuli, such as environmental temperature and changes of the pH in the gel 
reservoir. The reaction rate of an enzyme is related exponentially to temperature 
and doubles every 10°C [4]. Glucose oxidase (from A. niger) displays maximal 
activity at 40-60°C [5], above which denaturation causes a progressive enzyme 
activity loss. Furthermore, temperature fluctuations alter the viscosity of the 
hydrogel used as collection chamber, thus, affecting the electroanalytic detection 
(which is based on analyte mass-transport towards the sensing electrode). pH 
regulates the activity and stability of enzymes by influencing the ionization state 
of the amino acids involved in the biocatalytic processes and maintenance of a 
proper enzyme conformation[4]. The pH optimum for GOD (from A. niger) is in 
the 5.0 to 6.0 range[5]. Both temperature and pH fluctuations may cause 
measurement errors; it follows that the incorporation of sensors for these 
parameters may improve glucose tracking accuracy.  
In the longer term, the glucose monitoring array (the hardware) must be integrated with 
wireless electronics to fulfil two tasks: (i) to deliver defined DC currents and voltages for 
the extraction circuitry of individual pixels of the array, as well as incorporate the 
potentiostat function to perform detection; and (ii) to transmit, via NFC or Bluetooth, the 
raw signals (e.g., from chronoamperometry or an alternative method) from each pixel of 
the array to a device (such as personal computer, smartphone, smartwatch, or tablet) that 
would then determine and store the final blood glucose tracking data. The challenge is to 
create multi-channel electronics that will replicate these functions for up to 8 channels, as 
required for the full size, 44 array, and to perform real-time comparison and analysis of 
all these multiple signals. The glucose monitoring array and the associated, miniaturised 
electronics will be packaged as a wearable smart-patch, of which the array will most likely 
be the disposable element.  
Data obtained from such a wearable smart patch (or multiples thereof) could then be 
uploaded to a specialised cloud server. Finally, the combination of big data and machine 
learning techniques will accelerate the analysis of clinically relevant parameters, and the 
resulting correlation with patient health will inevitably improve quality of life in the 
future.   
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Annex 1 – EIS Theory 
 
Equation 4.1 is derived from the combination of the expression of the charge transfer 





and the exchange current under equilibrium, i0, for small applied signal amplitudes, which 












Where COx and CRed are the bulk concentration of the oxidized and reduced form of the 
redox couple in solution ([Fe(CN)6]
3−/4-), Edc represents the equilibrium DC-potential of 
the electrode, E°′ is the formal potential of the redox couple, α is the transfer coefficient 
and the remaining terms have their typical significance. With the experimental settings 





The combination of equations A.1 and A.3 gives equation 4.1, from which the 
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Figure A II -1| Example of the evolution of raw chronoamperometric signals corresponding to extracted ISF glucose during 
an in vivo glucose tracking experiment. The progression is indicated by the arrows, showing first an increase in the blood glucose, 
then, a decrease. Curves showing response to glucose concentration are shown in red, while their respective baselines are in black. 
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Figure A II -2| Primary in vivo data used in the Clarke Error Grid Analysis in Figure 
4.16.  The 8 sets of data are presented as follows: measured (ISF glucose vs blood glucose) 
time-dependent tracking profiles, left panels; (amperometric current vs blood glucose) 
calibration curves, right panels; and (measured ISF glucose vs reference blood glucose) 
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Table A II -1| Pictures of the volunteers forearm skin at site of application of the sensor. 
Pictures were taken following the in-vivo testing and 24 hours later. 
 
